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Abstract 
The breast cancer resistance protein (BCRP, ABCG2) is a member of the ATP 
binding cassette transporters (ABC transporters) that functions as an efflux transporter 
alongside other family members such as MDR1 and MRP2 to remove foreign entities 
from the cell. These efflux transporters often have overlapping substrate specificity 
that together comprise a formidable barrier in preventing cell exposure to foreign 
compounds, but in doing so inevitably influence drug absorption, elimination and 
distribution of a significant number of prescribed drugs.  
This thesis has used established in vitro epithelial cell models such as 
MDCKII and Caco-2 cells to examine the function and regulation of the less 
characterised of the three main efflux transporters, BCRP, in the context of epithelial 
expression with particular focus on human intestinal cells. Several complementary 
techniques have been used including cellular accumulation of Hoechst 33342, a 
known MDR1/BCRP bi-substrate in the presence of selective pharmacological 
inhibitors, together with immunocytochemistry, immunoblotting and PCR techniques. 
Of most importance were functional assays of transepithelial substrate flux measured 
across reconstituted epithelial layers. 
BCRP substrates were identified by comparing bi-directional transport directly 
across native MDCKII monolayers to hBCRP/mBcrp and MDR1 transfected 
MDCKII cell layers in a high throughput assay. This technique identified several 
BCRP substrates including the selective BCRP agent nitrofurantoin. 
The human intestinal Caco-2 cell system was used as a model for BCRP 
mediated transport and induction of ABC transport activity. BCRP is expressed at 
differing levels in 2 cell-strains; saturable nitrofurantoin transport was evident in the 
high-expressing strain. Ko143, a specific BCRP inhibitor, inhibited nitrofurantoin 
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secretion by this Caco-2 cell strain and allowed partition of BCRP mediated secretory 
flux from MDR1 for bi-substrates. The aryl hydrocarbon receptor (AhR) agonist β-
naphthoflavone (BNF) and the peroxisome proliferator receptor gamma (PPARγ) 
agonist rosiglitazone increased the BCRP mediated net flux of the selective substrate, 
nitrofurantoin and this correlated with an increase in both BCRP mRNA and protein 
expression. BCRP regulation in Caco-2 cells is likely to be controlled by more than 
one pathway and it appears that in the human gut a complex network of distinct 
nuclear receptors regulate the expression of BCRP. The present work suggests that the 
Caco-2 cell model together with nitrofurantoin as a substrate could serve as a screen 
for potential inducers of BCRP.      
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Abbreviations 
Aa Cellular accumulation across the apical membrane 
Ab Cellular accumulation across the basal membrane  
ABC ATP-binding cassette  
ADME Absorption, distribution, metabolism and excretion 
ATP Adenosine triphosphate 
AhR Aryl hydrocarbon receptor 
ARNT Aryl hydrocarbon receptor nuclear translocator 
BBB Blood brain barrier 
BCRP Breast cancer resistance protein 
BNF β-naphthoflavone 
CAR Constitutive androstane receptor 
CsA Cyclosporin A 
CYP Cytochrome P450 
DBM Dibenzoylmethane 
DDI Drug-drug interaction 
DMEM Dulbecco‟s Modified Eagle‟s Medium 
DMSO Dimethyl sulphoxide 
DNA Dideoxyribonucleic acid 
E217βG Estradiol-17-[beta]-glucuronide 
EDTA Ethylene-diamintetraacetic acid 
EGTA Ethylene glycol-bis(β-aminoethyl ether)-N,N,N´,N´ –tetraacetic acid 
EMEM Minimum Essential Eagle‟s Medium 
ER Estrogen receptor 
FDA Food and Drug Administration 
FITC Fluoroscein isothiocyanate 
FTC Fumitremorgin C 
FXR Farnesoid x receptor 
GSH Glutathione 
HBSS Hank‟s buffered saline solution  
HEK Human Embryonic Kidney 293 cells  
HEPES N-[2-hydroxyethyl]piperazine-N´-[2-ethanesulphonic acid] 
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HPLC High-pressure liquid chromatography 
HRE Hormone response element 
HSP90 Heat shock protein 90 
HUGO Human Genome Organisation 
IAAP Iodoazidoaryl prazosin 
Ja-b Flux in the apical-to-basal direction 
Jb-a Flux in the basal-to-apical direction 
Jnet net flux (secretory, Jb-a – Ja-b) 
Km Michaelis-Menten constant (concentration at which reaction is half maximal) 
LXR Liver x receptor 
MpkDCT Mouse distal convoluted tubule cells  
MpkCCDc14 mouse cortical collecting duct principal cells (clone 14) 
MDCK Madin Darby Canine Kidney 
MDR1 Multidrug resistance 1 
MRP Multidrug resistance-associated protein 
MXR Mitoxantrone resistance 
NBD Nucleotide binding domain 
NCE New chemical entity 
NR Nuclear receptor 
PA Cell passage 
Papp Apparent permeability 
PBS Phosphate buffered saline 
PPARγ Peroxisome proliferator activated receptor gamma 
Pgp P-glycoprotein 
PgR Progesterone receptor 
PXR Pregnane x receptor 
RAR Retinoic acid receptor 
RNA Ribonucleic acid 
SNP Single nucleotide polymorphism 
TBHQ Tert-butylhydroquinone 
TBS Tris buffered saline 
TEER Transepithelial electrical resistance  
TMD Transmembrane domain 
WT Wild type 
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1. Introduction 
 
1.1 Introduction to the ATP-binding cassette (ABC) 
transporters 
In order for cells, or indeed whole organisms, to survive and proliferate they need to 
maintain tight control on what enters from the extracellular milieu or environment and 
also on what needs to be excreted or removed. In order to achieve this, cells and 
absorptive/secretory organs have a comprehensive catalogue of membrane transport 
proteins that undertake these functions. As far as we know examples of such transport 
proteins are expressed in all living organisms and certainly in all cell types of all 
phyla of the animal kingdom (Jones & George, 2004). Membrane transport proteins 
are essential to life by the transportation of small ions, nutrients such as peptides, 
amino acids and sugars, water and xenobiotics to name but a few examples. In human 
physiology membrane transporters play an essential role in absorption from the 
intestinal tract, distribution and disposition of nutrients to all the body‟s organs, and 
finally elimination of metabolic waste and removal of environmental toxins and drugs 
via the liver and kidneys (Klaassen & Aleksunes, 2010).  
The considerable pharmaceutical interest in drug transport has evolved in the 
past 20 years, as it is realised that specialised membrane transport mechanisms not 
passive models, determine drug absorption, distribution, metabolism and excretion 
(ADME). It is now a legal requirement or at least a strong recommendation from 
authorities such as the Food and Drug Administration (FDA, 2006; 
http://www.fda.gov) to ascertain whether new chemical entities (NCEs) are substrates 
of particular transporters, such as MDR1 (ABCB1) in order to predict 
pharmacokinetic profiles and potential adverse drug interactions. 
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The Human Genome Organisation (HUGO) (http://www.genenames.org/) 
developed a new system of classification of this extensive group of proteins in 1999 
and placed these proteins mostly into two basic groups: the solute carrier proteins 
(SLCs) and ATP-binding cassette (ABC) proteins. Other classified families include 
the aquaporins and ion channels. 
The solute carrier proteins are an extensive collection of proteins with over 
350 members grouped into 55 gene families and reside typically on the outer plasma 
cell membrane, with some members residing intracellularly transporting across 
organelle membranes (He et al., 2009; Hediger et al., 2004). These transporters 
typically function on the plasma/organelle membrane by facilitating cellular uptake of 
an extensive list of nutrients and xenobiotics, see Klaassen and Aleksunes (2010) for 
xenobiotic substrates. Examples of SLC transporters expressed on the apical and 
basolateral surface of enterocytes that have an important role in oral drug absorption 
are shown in Figure 1.1. 
The primary active transporter family the ABC transporters are a protein super 
family that is comprised of 50 members which in turn comprise of further subfamilies 
such as: ABC1 (ABCA), MDR/TAP (ABCB), MRP/CFTR (ABCC), ALD (ABCD), 
OABP (ABCE), GCN20 (ABCF) and White (ABCG2) (Chan et al., 2004; Deeley et 
al., 2006; Klein et al., 1999). The focus of this thesis is with the ABC family 
members that are responsible for cellular efflux, especially of xenobiotics. The key 
members involved in enterocytes that limit intestinal absorption so producing an 
effective barrier are shown in Figure 1.1. An extended list of relevant drug efflux 
proteins expressed throughout the human body is given in Table 1.1.  
All of these ABC transporter proteins are composed of 6, 12 or more 
transmembrane domains (TMDs) with single or dual nucleotide binding domains 
17 
 
(NBDs), it is this NBD that is highly homologous between all family members, that 
gives rise to the protein family name ATP-binding cassette (ABC) proteins (Higgins, 
1992). 
Typical ABC transporters consist of twelve membrane spanning domains 
(TMD) and two cytosolic ATP binding motifs (NBDs), and this is usually comprised 
of two halves (a half unit being 6 TMDs and 1 NBD) (Chan et al., 2004; Higgins, 
1992). However, not all members follow this structure. For example, MRP1-3 and 
MRP6-7 possess an extra 5 trans-membrane domain (Deeley et al., 2006). The 
conserved region that gives rise to the family name is the ATP binding domain that 
utilises the energy from ATP hydrolysis to morphologically change transporter 
structure so allowing transport of its substrate. The two ATP binding regions are 
between 200-250 amino acid conserved regions with particularly important motifs 
called Walker A and Walker B (units responsible for the adherence of ATP) (Deeley 
et al., 2006). MDR1 (ABCB1) is an example of a typical ATP binding cassette 
protein and is expressed as one polypeptide. The enormous interest in this protein has 
arisen due to its role in chemotherapy-resistance in cancer, but this has lead to studies 
of the function of many other family members structurally related to MDR1.  
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Figure 1.1. Schematic diagram of a human enterocyte showing uptake and efflux 
transporters involved in xenobiotic transport  
 
Polarised expression of uptake (SLC) and efflux (ABC) transporters (adapted from 
Giacomini et al., 2010). In the apical (lumen) membrane uptake transporters (shown 
in blue) the organic anion transporting polypeptides (OATPs, SLCOs) such as 
OATP2B1 (SLC02B1); the peptide transporter 1 (PEPT1; SLC15A1); the ileal apical 
sodium/bile acid co-transporter (ASBT; SLC10A2); and the monocarboxylic acid 
transporter 1 (MCT1; SLC16A1). Expressed alongside the uptake transporters on the 
apical surface are the main efflux transporters shown in white; BCRP (ABCG2), 
MDR1 (ABCB1) and MRP2 (ABCC2). On the basolateral (blood) membrane the 
organic cation transporter 1 in blue (OCT1: SLC22A1); heteromeric organic solute 
transporter in green (OSTα–OSTβ) and the efflux transporter MRP3 in white 
(ABCC3) mediate exit from the cytosol or uptake from plasma. 
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Table 1.1. Human efflux transporter gene, mRNA and protein nomenclature 
 
Table is adapted from Klaassen and Aleksunes (2010) showing the gene names, the 
chromosomal loci, the mRNA nucleotide accession number and protein names for the 
efflux transporters typically expressed in humans. Data were originally taken from 
The National Centre of Biotechnology Information (NCBI). 
 
 
 
 
 
 
 
 
 
Human ABC efflux 
transporters isoforms
Gene mRNA Protein
Name Locus Accession number Name Other name
ABCA1 9q31.1 NM_005502 ABCA1
ABCB1 7q21.1 NM_000927 MDR1 Pgp
ABCB4 7q21.1 NM_000443 MDR3 PFIC3, PGY3
ABCB11 2q24 NM_003742 BSEP SPGP, PFIC2
ABCC1 16p13.1 NM_004996 MRP1 MRP, GS-X
ABCC2 10q24 NM_000392 MRP2 cMOAT, DJS
ABCC3 17q22 NM_003786 MRP3 MOAT-D, cMOAT2
ABCC4 13q32 NM_005845 MRP4 MOAT-B
ABCC5 3q27 NM_005688 MRP5 MOAT-C, ABC11
ABCC6 16p13.1 NM_001171 MRP6 MOAT-E, PXE, ARA
ABCC10 6p21.1 NM_033450 MRP7
ABCC11 16q12. NM_032583 MRP8
ABCC12 16q12. NM_033226 MRP9
ABCG2 4q22 NM_004827 BCRP
ABCG5 2p21 NM_022436 ABCG5 Sterolin-1
ABCG8 2p21 NM_022437 ABCG8 Sterolin-2
ATP7B 13q14.3 NM_000053 ATP7B WD
ATP8B1 18q21-22 NM_005603 ATP8B 1 PFIC1, FIC1, BRIC
OSTα q29 NM_152672 OSTα
OSTβ 5q22.31 NM_178859 OSTβ
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1.2 Multidrug resistance protein 1 (MDR1) 
 
The first member of the ABC protein family to be discovered in 1976 by Juliano and 
Ling was the permeability-glycoprotein (also known as Pgp/MDR1/ABCB1).  The 
term MDR1 will be used in this study for consistency (Juliano & Ling, 1976). A drug 
resistance phenotype was witnessed in the Chinese hamster ovary cell lines they were 
studying at the time and this phenotype was revealed to be due to the expression of 
the cell surface glycoprotein MDR1- hence the term “multidrug resistance” (MDR).  
It was this interest in chemotherapy-resistance that drove the field forward to discover 
functionally and structurally related protein family members of MDR1.  
1.2.1 MDR1 structure 
The human MDR1 gene on chromosome 7 encodes for a 1280 amino acid polypeptide 
unit comprising of the typical ATP binding cassette protein structure of two 
homologous halves (each comprising of a 6 transmembrane domain and one ATP 
NBD).  
The transmembrane domains form the pathway by which solutes cross the 
membrane, whilst the ATP-binding domains likely use the energy inherent in the 
hydrolysis of the high-energy phosphates to make conformational changes to the 
protein. The simplest idea is that the substrate binding sites are in an internal 
(cytosolic-facing) site, which may become occluded and then transformed into an 
outward-facing (external) binding site on conformational change. However, both 
MDR1 and other ABC transporters have been hypothesised to show multiple distinct 
binding sites. Substrates present in the inner bimolecular leaflet of the membrane may 
access a binding site within the protein through direct interactions from the 
hydrophobic membrane interior. 
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A 3-dimensional X-ray structure of a bacterial ABC transporter, MsbA (Ward 
et al., 2007), in different conformations may provide a proto-typical structure for all 
ABC transporters. MsbA is found in Gram-negative bacteria and transports 
lipopolysaccharide (LPS) from the cytoplasmic leaflet (inward-facing) to the 
periplasmic leaflet (outward-facing) of the inner membrane. However MsbA transport 
is not restricted to LPS, in fact it may transport multiple substrates and can actually 
transport a wide range of drug molecules. This combined with a great sequence 
similarity with mammalian/human ABC transporters such as MDR1 and even BCRP 
provides a working model for ABC transporter operation. Figure 1.2 shows the 
sequential changes in protein structure of MsbA during xenobiotic efflux; whereby 
the binding and hydrolysis of high-energy phosphates causes a change in structure 
from an inward facing to an outward facing confirmation.   
An X-ray structure of mouse MDR1 at 3.5Å has been reported by Aller et al. 
(2009) without ATP (apo-PgP) (Aller et al., 2009). This structure is very similar to 
MsbA and for the inner-facing conformation it shows an internal binding site/cavity 
of 6000
 
cubic Å with a wide 30Å separation of the two nucleotide-binding
 
domains. 
By placing cyclic peptide
 
inhibitors in the internal
 
cavity, 2 distinct binding sites 
showing stereo-selectivity due to hydrophobic
 
and aromatic interactions were 
identified. A very important feature of this open inner-facing conformation is that the 
binding sites are open to the cytoplasm to large molecules up to the size of the pocket, 
but also open to the inner leaflet of
 
the lipid bilayer. Therefore, MDR1 can “scan” the 
inner leaflet for drug molecules dissolved within the membrane phase. Substrates may 
not necessarily even enter the transporter from the cytoplasm but are expelled directly 
from the membrane phase. 
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1.2.2 Distribution of MDR1 within the body 
MDR1 protein is found in normal and tumour tissues throughout the body (Cordon-
Cardo et al., 1990; Thiebaut et al., 1987), expressed on the apical or luminal facing 
cellular membranes depending on cell type. Particularly high concentrations are found 
in intestinal epithelia, kidney proximal tubule epithelia, hepatocytes and the blood-
brain barrier (brain capillary endothelial cells) (Gatmaitan & Arias, 1993; Hunter et 
al., 1993; Tatsuta et al., 1992). This localisation suggests a protective excretory role 
of removing xenobiotics out of the body (Chan et al., 2004). 
 
1.2.3 MDR1 function 
The substrate profile of MDR1 is extensive; a list of known MDR1 substrates and 
inhibitors is given by Mattson et al. (2009), substrates being typically hydrophobic 
and cationic (Matsson et al., 2009). Substrates are known to bind to at least four 
separate binding sites on the MDR1 protein (Carrier et al., 2003; Martin et al., 2000; 
Safa, 2004).  
MDR1 has a great effect on the absorption, distribution and excretion of these 
compounds in the human body and is a great consideration in drug design (Fromm, 
2004; Polli et al., 2001; Raub, 2006; Schinkel, 1999). For example, MDR1 is 
responsible for limiting the oral bioavailability of the drugs cyclosporin (Lown et al., 
1997; Raub, 2006), digoxin (Cavet et al., 1996), quinidine (Su & Huang, 1996) and 
paclitaxel (Sparreboom et al., 1997), to name but a few.  
Due to the large number of clinically used drugs being MDR1 substrates or 
inhibitors, this has important implications for drug-drug interactions (DDIs) 
(Giacomini et al., 2010). These DDIs can have hazardous consequences if the drugs 
administered have a narrow therapeutic index and a low bioavailability; such as many 
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of the drugs in cancer treatment. Many cancer agents are potent MDR1 substrates 
(irinotecan, doxorubicin, vinblastine, paclitaxel). Thus in cancer regimens any change 
in ADME of the drug via inhibition or induction of MDR1 can affect cancer response 
and potentially patient survival.  
Digoxin is another example of a drug with a narrow therapeutic index, and it is 
one of the most commonly prescribed drugs in congestive heart failure. Digoxin is 
also a very good MDR1 substrate and, therefore, agents that affect MDR1 activity 
through induction or inhibition can lead to digoxin intoxication (Su & Huang, 1996). 
Agents such as cyclosporin A, quinidine and verapamil are known to be inhibitors of 
MDR1 in vivo and affect digoxin pharmacokinetics, efficacy and safety (Lown et al., 
1997; Su & Huang, 1996; Verschraagen et al., 1999). The interaction between digoxin 
and verapamil is well documented in medicine and this co-administration is often 
used to increase digoxin plasma concentration levels to anything between 60-90% 
(Verschraagen et al., 1999).  
However, MDR1 does not operate alone. The MDR1 gene is known to be 
tightly regulated in conjunction with the metabolising enzyme CYP3A4 and there is 
also considerable overlap with substrate specificity (Giacomini et al., 2010; Wacher et 
al., 1998; Zhang et al., 1998). This has led to the hypothesis that MDR1 has a further 
indirect role of increasing the rate of metabolism of xenobiotics. By limiting the 
concentration of xenobiotic in the cell via pumping it back out across the apical 
membrane it reduces the amount of substrate reaching the metabolising enzymes such 
as CYP3A4, reducing the possibility of CYP3A4 saturation. This xenobiotic cycling 
across the apical membrane allows progressive access to metabolic capacity and 
limits parent compound reaching the systemic circulation (Giacomini et al., 2010; 
Gomez et al., 1995; Lown et al., 1997). This interaction with the metabolising 
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enzymes adds another dimension in predicting the pharmacokinetics and safety of 
MDR1 substrates. 
Given the diverse effects MDR1 has on xenobiotic ADME the FDA has 
guidelines to identify any new drugs that are MDR1 substrates (Giacomini et al., 
2010). Currently there are many methods in vitro and in vivo that are used for 
studying MDR1 activity in drug development, including membrane-based assay 
systems (ATPase assays and vesicle transport assays), cell-based assay systems (using 
transfected cell lines, primary cells), in vivo models (animal and human) and even 
computational models. 
 
1.3 Multidrug resistance-associated protein (MRP) 
Following identification of MDR1, many functionally and structurally related ABC 
protein family members started to be discovered. 1992 saw the discovery of the next 
drug efflux pump, the multidrug resistance-associated protein (MRP). This MRP 
efflux pump is classified into the ABCC gene subfamily. This ABCC subfamily 
consists of 13 members, 9 members belonging to the MRPs (MRP1-6/ABCC1-6 and 
MRP7-9/ABCC10-12), with the remaining proteins being the cystic fibrosis 
conductance regulator protein (CFTR/ABCC7) and the sulfonyl urea receptors 
(SUR1/ABCC8 and SUR2/ABCC9) (Borst et al., 2000, 2007; Toyoda et al., 2008). 
Like MDR1 all the MRPs contain two membrane spanning domains each with 
an ATP-binding domain. However, MRP1, MRP2, MRP3, MRP6 and MRP7 contain 
an extra N-terminal domain (TMD0), which is absent in P-glycoprotein (Toyoda et al., 
2008). 
MRP1 (also known as ABCC1 or GS-X) is a highly characterised member of 
the MRP family. This transporter expressed on the cell plasma membrane is found in 
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nearly all tissue types of the human body (Toyoda et al., 2008) and initially it was 
shown to have a remarkably similar function to MDR1. Further work has shown that 
its substrates are often different from MDR1, with MRP1 preferring organic anions 
(such as entities conjugated with glutathione, glucuronide or sulphate) (Ishikawa et 
al., 1998; Jedlitschky et al., 1994), whereas MDR1 has a low affinity for these 
negatively charged conjugates (Borst et al., 2000). MRP1 is also thought to play a 
role in glutathione (GSH) homeostasis and it is this ability to pump GSH out of the 
cell that explains why it is so efficient at removing drug conjugates such as 
methotrexate.   
MRP2 (ABCC2) also known as the canalicular multispecific organic anion 
transporter (cMOAT), as the name suggests, is predominantly found in the liver and is 
involved in the expulsion of metabolites into bile. However, MRP2 is also an 
important efflux pump in the apical membrane of kidney proximal tubule cells in 
transporting conjugates into urine and on the apical surface of intestinal epithelia 
where it cycles agents back into the intestinal lumen (Giacomini et al., 2010). 
  A mutant Wistar rat strain lacking functional mrp-2 (TR
-
/GY) was used to 
characterise many substrates of this transporter. It turned out that these rats were also 
shown to be deficient in bilirubin-glucuronide secretion due to the mutation in the 
MRP2 gene (Buchler et al., 1996); this gene defect was matched with the human 
condition Dubin-Johnson syndrome (Kartenbeck et al., 1996; Paulusma et al., 1997).  
Over expression of MRP2 in vesicles and transfected cells has further 
characterised this transporter showing it to be responsible for the resistance seen with 
many cancer agents, such as resistance to doxorubicin, etoposide, methotrexate and 
vincristine (Cui et al., 1999; Hooijberg et al., 1999) to name but a few.  
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MRP3 (ABCC3) also functions as an organic acid transporter that transports 
many cancer agents similar to MRP1 and MRP2 (Borst et al., 2000; Hirohashi et al., 
1999; Kool et al., 1999). MRP3 localisation is also predominantly in the liver. 
However unlike its family counterpart MRP2, in which it shares 48% amino acid 
homology (Borst et al., 2000), it resides on the basolateral blood facing membrane of 
hepatocytes, where it transports organic acids into the bloodstream (Konig et al., 
1999), in complete opposition to the protective role of MRP2 which deposits 
substrates into the bile. Animals deficient in MRP3 have problems in transporting 
morphine from the liver into the blood stream, suggesting MRP3 to be the major 
transporter expressed on the basolateral membrane of hepatocytes (Toyoda et al., 
2008; Zelcer et al., 2005). MRP3 is also found basolaterally in the intestine and is 
thought to have a similar function of disposition of organic acids into the blood stream 
(Giacomini et al., 2010).  
The next MRP family member is MRP4 (ABCC4). MRP4 lacks the extra N-
terminal domain that the first three members of the MRP family contain. This 
apparent difference in structure stands it apart and may explain some of the unique 
characteristics of this transporter compared with MRP1-3.   
The localisation of this transporter is tissue dependent. It is found on the 
basolateral membrane of choroid plexus epithelia, hepatocytes, and prostate 
tubuloacinar cells, yet it is found on the apical membrane of proximal tubule cells and 
the luminal side of brain capillary endothelium (Russel et al., 2008). In the colon it 
has further been found to be localised on both apical and basolateral membranes 
(Russel et al., 2008). MRP4 is also expressed in the adrenal glands, ovaries, testis, 
various blood cells and neurons (Ritter et al., 2005). 
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Due to its variable localisation its function is also not typical for an MRP 
family member. In vitro, the substrate profile of MRP4, as for other ABC transporters, 
has been showed to be extensive (Chen et al., 2002; Rius et al., 2003; Russel et al., 
2008), transporting pharmaceuticals including antivirals (adefovir), antibiotics 
(cephalosporins), cardiovascular agents (loop diuretics and thiazides) and cancer 
agents (methotrexate, 6-mercatopurine and topotecan). However, aside from a role in 
drug disposition, it has been shown to have a specialist physiological role in 
transporting endogenous molecules such as; cyclic nucleotides, ADP, eicosanoids, 
urate and conjugated steroid hormones (Ritter et al., 2005; Zelcer et al., 2003); some 
of these substrates being distinct from MRP1-3. 
MRP5 (ABCC5) similarly to MRP4 also lacks the extra N-terminal domain 
and too has a role in disposition of cyclic nucleotides (Wijnholds et al., 2000). MRP5 
also functions like the other MRPs as a typical organic anion pump, transporting GSH 
conjugates (Borst et al., 2000, 2007). MRP5, unlike MRP4, is found at relatively low 
levels ubiquitously in the human body (Borst et al., 2000, 2007). In transfected cells it 
is found to be expressed on the basolateral surface (Borst et al., 2007).  
MRP6 (ABCC6) is found predominantly in the liver and kidneys (Kool et al., 
1999).  Its physiological function is not well characterised but it is known to transport 
GSH conjugates, with a lower affinity for glucuronic acid conjugates, such as E217βG 
(Belinsky et al., 2002). What is interesting about this transporter is that ABCC6 
knockout animal models were shown to have a skin defect that resembled the human 
condition pseudoxanthoma elasticum (Klement et al., 2005). It has since been 
confirmed that an ABCC6 mutation results in the condition, although why this 
mutation results in this phenotype remains unclear (Pfendner et al., 2007). 
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MRP7 (ABCC10) is known to be expressed ubiquitously but with a higher 
expression in the pancreas (Hopper et al., 2001). Unlike MRP6 it has a low affinity 
for glutathione conjugates and a greater affinity for glucuronic acid conjugates. Like 
most of the MRP family members it has been associated with cancer drug resistance 
(Toyoda et al., 2008). 
MRP8 (ABCC11) and MRP9 (ABCC12) were initially discovered by database 
search and then cloned from liver cells (Bera et al., 2001; Tammur et al., 2001; 
Yabuuchi et al., 2001). These two transporters have a predicted structure similar to 
that of MRP4 and 5, both lacking the extra N-terminal domain (Kruh et al., 2007). 
The substrate profiles of MRP8 and MRP9 are thought to be very similar to MRP4 
and MRP5 also (Toyoda et al., 2008). MRP8 has been shown to transport glutathione 
and glucuronic acid conjugates like most of the MRP family members, but it also 
transports cyclic nucleotides like members MRP4 and MRP5 (Chen et al., 2005; Kruh 
et al., 2007; Toyoda et al., 2008). It seems to have a role in multidrug resistance to 5-
Fluorouracil (5-FU) and possibly methotrexate (Guo et al., 2003; Kruh et al., 2007). 
MRP9 substrates are predicted to be very similar to that of MRP8 but this still needs 
to be elucidated (Toyoda et al., 2008).  
 
1.4 Breast cancer resistance protein (BCRP) 
The focus of this project will be a particular member of the White subfamily called 
BCRP (ABGG2). BCRP (ABCG2) was discovered in 1998 in the MCF-7 breast 
cancer cell line, where the phenomenon of multidrug resistance was displayed but in 
the absence of MDR1 expression (Doyle et al., 1998). RNA fingerprinting revealed a 
2.4-kb mRNA; this mRNA encoded a sequence not matching existing members of the 
ABC transporter family. Due to its initial discovery in an anthracyclin-resistant breast 
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cancer cell line it was coined BCRP (breast cancer resistance protein). However, this 
protein name is misleading as it is expressed in a far more ubiquitous fashion, with a 
background level of the protein found in every tissue examined (Maliepaard et al., 
2001). Two other groups (Allikmets et al., 1998; Miyake et al., 1999) cloned the gene 
denoting it MXR (mitoxantrone resistance) and ABCP (an ABC transporter expressed 
in the placenta). Honjo et al. (2001) showed a functional difference between “BCRP 
and MXR” due to a mutation at amino acid position 482 (Honjo et al., 2001). The 
wild type BCRP that has an arginine at position 482 does not actually transport the 
anthracyclin doxorubicin yet the BCRP
R482G
 mutant does transport doxorubicin 
(arginine is replaced with a glycine or threonine), this is actually a gain of function 
mutation only found in drug selected cell lines. For consistency the term BCRP will 
be used henceforth. 
1.4.1 BCRP structure 
Although detailed structural information is lacking, it is likely that the 3-dimensional 
arrangement of BCRP within the membrane will be similar to MsbA (Figure 1.2).  
BCRP is an example of a ½ ABC transporter that is expressed as more than one 
peptide forming a dimer or even a multimeric complex. The dimer is thought to 
possess a structure similar to that of typical ABC transporters.  Each polypeptide 
consists of one membrane spanning region (6 transmembrane helices) and one ATP 
binding domain (Bates et al., 2001; Chan et al., 2004), (shown in Figure 1.3). There 
are mixed reports whether BCRP functions as a homodimer bridged by disulphide 
bonds (Kage et al., 2002; Litman et al., 2002; Ozvegy et al., 2001), heterodimer or 
even a homotetramer complex (Xu et al., 2004). Several groups have since proved 
that cysteine residues residing on the extracellular loop between TM5 and TM6 are 
important for dimer formation, specifically residue Cys603 (Henriksen et al., 2005; 
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Kage et al., 2005; Wakabayashi et al., 2006). Taken together, this suggests that BCRP 
functions at least as a homodimer, however, a homotetramer is also possible. 
The predicted topology of the 655 amino acid primary sequence of BCRP is 
shown in Figure 1.3 displaying the 6 predicted transmembrane domains. Amino acids 
at key sites known to affect BCRP function are highlighted by Hazai and Bikadi (such 
as the mutations K86M which makes the transporter inactive whilst F431L gives rise 
to defective methotrexate transport) (Hazai & Bikadi, 2008). As mentioned 
previously, the mutation at amino acid position 482 on the BCRP polypeptide is 
thought to be functionally relevant in vitro, giving rise to the anthracyclin resistance 
phenotype. As seen in Figure 1.3 this residue is present adjacent to the 3rd 
transmembrane domain in an area that is thought to make up the interior cavity of the 
transporter. An amino acid change at this site is thought to disrupt shape and size of 
the cavity which in turn would affect substrate specificity (Hazai & Bikadi, 2008). 
Like MDR1, substrates are thought to interact with more than one binding site 
on BCRP giving rise to a complexity in identifying substrate and inhibitor molecules 
(Giri et al., 2009). Using the BCRP
R482G
 mutant isoform Clark et al. (2006) report 3 
distinct pharmacological binding sites using the anthracyclin daunorubicin (a 
substrate not transported by the wild type variant of BCRP), showing complete, 
partial or no binding (Clark et al., 2006). Two sites are thought to provide allosteric 
communication whilst no communication is seen for the third site (Clark et al., 2006). 
Hazai and Bikadi (2008) published an atomic model of BCRP predicted from the 
bacterial multidrug transporter Sav-1866 (which is also structurally related to MsbA 
shown in Figure 1.3) and suggests BCRP to have multiple binding sites. A recent 
study (Rosenberg et al., 2010), has gone a stage further, using heterologous bacterial 
expression of BCRP combined with electron crystallography of membranes. 2-D 
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crystals of BCRP were resolved and a low resolution structure (at 5Å) was obtained. 
Combining this with homology modelling using the high-resolution MsbA and Pgp 
structures, inward-facing and outward facing binding sites in combination with the 
substrate MTX were modelled. It should be noted that the nucleotide-binding sites in 
the NBDs are separate from the substrate sites. Thus there are 4 and possibly 6 sites if 
2 internal sites accessing the hydrophobic membrane phase are present. 
Giri et al. (2009) predict that the mouse Bcrp protein also has multiple binding 
sites, showing that the Bcrp substrates prazosin and imatinib bind to sites distinct 
from the nucleoside analogues abacavir and zidovudine (Giri et al., 2009). Other 
studies find similar discrepancies in BCRP functional data which are likely due to the 
multiple binding site phenomenon (Muenster et al., 2008; Xia et al., 2007b). Until a 
3-D crystal structure of human BCRP exists this cannot be confirmed but these 
publications address the need of careful choice of substrate and inhibitor pairs when 
looking at BCRP function. 
 
1.4.2 BCRP function 
BCRP function is atypical in that most “half transporters” associate with organelle 
membranes instead of residing in the plasma membrane. BCRP is localized on the 
apical side of the plasma membrane of epithelial cells (Scheffer et al., 2000). It is 
proposed that substrates bind to BCRP inside the plasma membrane where they are 
subsequently removed into the extracellular space. Constant cycling between the 
extracellular space and within the plasma membrane compartment restricts compound 
entering the cell and further restricts compound reaching the basolateral membrane 
(Matsson et al., 2007). 
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BCRP transports an extensive range of structurally diverse ligands. 
Sophisticated methods of high-speed screening and quantitative structure-activity 
relationship (QSAR) analysis suggest certain chemical properties required for BCRP 
binding. An amine group bonded to one carbon of a heterocyclic ring(s) is thought to 
be important (Giacomini et al., 2010). Furthermore, a fused heterocyclic ring structure 
with two additional side groups is also an important chemical feature for BCRP 
binding (Matsson et al., 2007; Nicolle et al., 2009; Saito et al., 2006). An example of 
a BCRP substrate with this structure is the protein kinase inhibitor gefitinib (Iressa; 
AstraZeneca). The structure of gefitinib is shown in Figure 1.4 alongside other 
examples of known BCRP substrates. 
 
1.4.3 BCRP: a detoxification pathway 
Many compounds with this heterocyclic ring structure are known to be genotoxic and 
associated with cancers. Benzo[a]pyrene (BP) is an environmental genotoxin with this 
heterocyclic structure and it so happens to be a BCRP ligand (Ebert et al., 2007). 
BCRP expressed on the apical membrane of epithelia (such as enterocytes), actively 
pumps its substrate from inside the cell back out across the plasma membrane into the 
surrounding extracellular space (Chan et al., 2004). In this circumstance BCRP has a 
role in preventing extensive absorption of BP at epithelial barriers and subsequently 
reduces entry into the systemic circulation.  
In the blood-brain barrier (BBB), BCRP is thought to act in conjunction with 
MDR1 in preventing xenobiotic entry into the brain (Cooray et al., 2002), whilst in 
the placenta it serves to protect the developing foetus from xenobiotics in the maternal 
circulation (Jonker et al., 2000) by acting as the rate-limiting barrier. BCRP is also 
localised in the blood-testis barrier and bile canalicular membrane. 
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BCRP is up regulated in response to chemotherapy and, unfortunately, 
protects these cells from chemotherapeutic agents, such as anthracyclins, 
daunorubicin and doxorubicin, camptothecans such as topotecan/SN-38, and finally 
mitoxantrone (Doyle & Ross, 2003; Doyle et al., 1998; Hardwick et al., 2007; Litman 
et al., 2000; Ozvegy et al., 2001; Scheffer et al., 2000). 
It is this function and localisation of BCRP that leads us to believe its chief 
function is to be a protective transporter that removes potentially toxic or otherwise 
deleterious compounds that have entered the mucosal cells. In human evolution this 
may explain why the presence of high levels of efflux transporters such as BCRP in 
the epithelial barriers may have given a survival advantage.  
 
1.4.4 BCRP: a transporter of endogenous compounds 
In apparent contradiction to its protective role, BCRP is also expressed in the 
secretory tissue in the breast of mice, cows and humans (Maliepaard et al., 2001; van 
Herwaarden & Schinkel, 2006). BCRP in the breast allows the passage of lipophilic 
xenobiotics into milk and hence will expose suckling neonates. Van Herwaarden et al. 
demonstrated in mice that BCRP substrates such as aflatoxin are actively pumped into 
milk (van Herwaarden & Schinkel, 2006). However, later work has revealed that the 
presence of BCRP in the lactating mammary gland is to actually pump a 
physiologically relevant substrate, riboflavin (Vitamin B2) into milk (van Herwaarden 
et al., 2007), and it seems unfortunate that other non-therapeutic BCRP substrates 
might access milk as well as these vitamin components.  
It has been hypothesised by Krishnamurthy et al. (2005) that the primary role 
of mouse Bcrp is not necessarily to protect cells from xenobiotics but to transport and 
regulate porphyrins such as heme (Krishnamurthy & Schuetz, 2005). Porphyrins have 
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a profound effect on gene expression; therefore, a transporter designated for its 
transport seems possible. They suggest that the transport of other Bcrp substrates may 
be infact coincidental and so acts as an advantage that it is able to remove potentially 
harmful compounds. This, however, has not been supported in human studies. 
Aside from this there is accumulating evidence that BCRP has a key role in 
lipid/sterol transport like other ABCG subfamily members (Klucken et al., 2000; 
Schmitz et al., 2001). It is known to transport conjugated bile acids, steroids (Imai et 
al., 2003; Suzuki et al., 2003), and there are reports of interactions with steroidal 
drugs (Pavek et al., 2005). Furthermore, there are findings from a BCRP over-
expressing stomach cell line that this transporter might have a function in cholesterol 
transport (Woehlecke et al., 2003). 
The BCRP transporter is also known to have a role in immature hematopoietic 
stem cells, giving rise to the defining feature of the “side population” phenotype, with 
its low BCRP substrate accumulation of Hoechst 33342 (Scharenberg et al., 2002; 
Zhou et al., 2001). Even though the transporter identifies the side population 
phenotype, the role of BCRP in stem cells is not well defined. 
Taken together, these studies highlight the diverse roles played by BCRP 
throughout the body; it looks likely that physiological function may depend on the 
context of its expression. 
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Figure 1.2. Conformational changes in MsbA 
 
Model of inward and outward-facing conformations of MsbA (adapted from Ward et 
al. 2007). Conformational changes of the MsbA dimer in the plasma membrane are a 
model for the human efflux transporters, especially the half transporter BCRP. Only 
transmembrane domains (TMDs) 1-6 of one monomer are shown for ease of viewing 
(shown in blue). In the open state, inward facing confirmation (part A) TMDs 4&5 are 
separated from TMDs 1&2 and 3&6  rendering a binding pocket available for 
substrate binding (substrate shown in red). Substrates are thought to bind to BCRP at 
multiple sites; this figure illustrates substrates gaining access from the lipid bilayer 
inner membrane leaflet. On nucleotide binding to the NBDs MsbA harnesses the 
energy inherent in ATP binding and hydrolysis to change protein confirmation 
causing TMDs 4&5 to shift causing TMDs 3&6 to pull apart from TMDs 1&2 (part 
B). This change shifts the structure from an inward to outward facing confirmation 
resulting in the substrate being expelled to the extracellular space. 
TMDs
A) Open, inward-facing conformation
NBDs
Out
In
B) Nucleotide bound outward-facing conformation
Out
In
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Figure 1.3. Schematic representation of the structure of the ABC efflux 
transporter BCRP 
 
Figure adapted from Allen and Schinkel (2002a) showing the topological (two-
dimensional) structure of the half-transporter BCRP in the plasma membrane, 
showing the conserved nucleotide binding domain (NBD). N and C denote the NH2- 
and COOH- termini. The polymorphism that gives rise to the anthracycline resistance 
is indicated at position 482, as is the proposed glycosylation site of hBCRP.  BCRP is 
thought to act as a homodimer, in a similar manner to MsbA. 
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Figure 1.4. Structures of known BCRP substrates 
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1.5 Implications of the efflux transporters on oral drug delivery 
The main efflux transporters expressed on the apical surface of human intestinal cells 
are BCRP, MDR1 and MRP2 (Dietrich et al., 2003), shown in Figure 1.1. These 
transporters are distributed along the whole length of the intestine (Dietrich et al., 
2003; Doyle & Ross, 2003; Englund et al., 2006; Maliepaard et al., 2001). Studies of 
relative transporter mRNA expression along the human gastro-intestinal tract have 
shown that each of the 3 transporters shows segmental differences in expression; 
BCRP expression is highest in the duodenum and decreases gradually towards the 
colon (Gutmann et al., 2005; Seithel et al., 2006). Englund et al. (Englund et al., 
2006) have compared relative mRNA expression levels (normalized to villin) of  both 
ABC and selected SLC transporters and  report levels of BCRP > MDR1 and > MRP2 
in duodenum, jejunum and colon with comparable levels of BCRP and MDR1 in the 
ileum and very low levels of MRP2 in colon samples. 
All 3 ABC-transporters are highly expressed in intestinal regions that mediates 
rates of high absorption, so that the site of highest absorption for a particular drug 
may overlap a region with highest efflux transporter expression (Maliepaard et al., 
2001); (Doyle & Ross, 2003). Therefore xenobiotic entering the portal vein and 
systemic circulation is reduced. 
Furthermore, all 3 transporters are present in the liver, or more specifically on 
the bile canalicular membrane. In this location xenobiotics that have gained entry via 
the intestine are then metabolised in the liver and cleared into the bile or are cleared as 
the parent molecule. The expression and function of these efflux transporters in the 
intestine and liver reduces the body content of potentially harmful compounds from 
the diet (Dietrich et al., 2003) but consequently provides a potential barrier for oral 
drug delivery. Factors that can influence transporter expression in the intestine are 
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likely to account for the variability in the expression data seen in the literature 
(Berggren et al., 2007; Englund et al., 2006; Gutmann et al., 2005; Taipalensuu et al., 
2001). Such factors include gender, ethnic group, genetics, diet, disease state, and 
multiple medications. Inter-individual variation in the bioavailability of orally 
delivered drugs which are ABC substrates is, therefore, inherently complex (Chan et 
al., 2004).  
The MDR1 polymorphism C3435T was found in 25% of a Caucasian 
population and is known to affect the oral bioavailability of the MDR1 substrate 
digoxin and reduce expression in the duodenum by 2-fold (Dietrich et al., 2003; 
Hoffmeyer et al., 2000). Many single nucleotide polymorphisms in BCRP have been 
shown to affect expression and function these being: the polymorphism C421A, 
C376T, G34A, T1291C and T623C (Adkison et al., 2008; Imai et al., 2002; 
Kobayashi et al., 2005; Kondo et al., 2004; Mizuarai et al., 2004; Tamura et al., 2007; 
Yoshioka et al., 2007). Probably the most characterised and frequently occurring 
polymorphism in the population is the C421A allele. This single nucleotide 
polymorphism (C421A) was shown to reduce topotecan and rosuvastatin efflux in 
certain individuals (Sparreboom et al., 1997; Zhang et al., 2006), giving a 1.34 fold 
increase in topotecan plasma levels. The C421A allele frequency is known to vary 
with ethnicity. 46% of East Asians, 16-19% of Whites and <2% sub-Saharan Africans 
are homo- or heterozygous carriers of the variant allele (Adkison et al., 2008; Imai et 
al., 2002; Lee et al., 2007; Yanase et al., 2006). Thus ethnicity may determine 
pharmacokinetic profiles following oral drug delivery. 
Nonetheless some studies that show that these polymorphisms do not appear 
to affect function in vivo; Zamber et al. looked at the natural variation of BCRP in the 
human intestine identifying BCRP mRNA and protein variants between patients but 
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could not detect functional differences, perhaps due to other confounding factors 
(Zamber et al., 2003). 
The polymorphism found in vitro in cell lines occurring at amino acid position 
482 and known to affect substrate binding of anthracylines, camptothecans, 
mitoxantrone and rhodamine 123 (Miwa et al., 2003) has no SNP counterpart (Honjo 
et al., 2001) and is not found in population studies suggesting it is only found after 
drug selection in vitro (Kobayashi et al., 2005). 
Dubin Johnson syndrome is known to result from a nonsense mutation of the 
MRP2 gene (Kartenbeck et al., 1996; Paulusma et al., 1997), thus patients with this 
condition lack functional MRP2.  
Mutations/SNPs in the main efflux transporters suggest a patient‟s genotype is 
important in predicting outcome to oral drug therapy, leading to the proposition that 
testing for these mutations before therapy would be advantageous (Ishikawa et al., 
2005). 
Disease, itself, may alter ABC transporter expression. All 3 transporters 
(BCRP, MDR1 and MRP2) are expressed highly on the villus-tip of enterocytes 
(Fromm, 2004; Krishnamurthy & Schuetz, 2005). The autoimmune disorders Crohn‟s 
disease and Coeliac disease are known to cause a blunting of intestinal villi (known as 
villous atrophy) which results in a reduction in expression of these efflux transporters 
(Fromm, 2004).  
A major factor influencing the oral availability of drugs is an individual‟s diet. 
Flavonoids are plant secondary metabolites, primarily natural in origin, which are 
present in most diets. They are found in chocolate, citrus fruits, liquorice, red wine, 
tea and vegetables, to name but a few sources, and an average intake of flavonoids 
have been approximated to be 1g per day (Formica & Regelson, 1995). They are 
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heavily metabolised by the gut flora and thus active concentrations will be reduced 
considerably. However, these compounds have been recognised to have beneficial 
health effects with anti-carcinogenic actions (Havsteen, 2002). Thus foods with high 
flavonoid content are becoming more popular and even flavonoid supplements, such 
as quercetin and genistein are available. Many studies link the modulating effects of 
these flavonoids with the ABC-efflux proteins; they have diverse structures and are 
known to be substrates, inhibitors and inducers of the ABC-efflux proteins (Alvarez et 
al., 2009; Ebert et al., 2007; Wang, 2007). 
Polypharmacy, where multiple drugs are prescribed for multiple conditions is 
increasingly common. It is also often the case that drugs are administered orally 
together to achieve an additive pharmacological effect, such as the two antibiotics 
amoxicillin and metronidazole, in combination with a proton pump inhibitor such as 
pantoprazole to treat gastric ulcers.  Drug interactions can occur as a result of being 
substrates of the ABC efflux proteins. Digoxin is a cardiac glycoside used in heart 
failure that has a narrow therapeutic index that is a good MDR1 substrate (Haslam et 
al., 2008). Agents such as verapamil and quinidine used in heart conditions, act as 
potent inhibitors to MDR1 and thus coadministration with digoxin would lead to 
elevated drug plasma levels and toxicity (Fromm et al., 1999; Klein et al., 1982). 
Drug-drug or herb-drug interactions can involve inhibition of the efflux activity by 
one compound, resulting in the increased absorption of a second drug (Haslam et al., 
2008). A classic example of a herb-drug interaction is with the herbal supplement St. 
John‟s wort, whereby the active component hyperforin is known to induce expression 
and function of MDR1 and CYP3A4 (Durr et al., 2000). The oral bioavailability of 
MDR1 substrates such as digoxin will be subsequently reduced resulting in a lack of 
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drug efficacy or even fatality especially when the absorbed drug has a low therapeutic 
window (such as digoxin). 
Anti-cancer agents often have narrow therapeutic indices and are often 
substrates of the ABC transporters. These drugs are normally administered in a 
regimen together and unfortunately drug-drug interactions occur because of the efflux 
transporters. For example, irinotecan bioavailability is found to increase in the 
presence of the tyrosine kinase inhibitor (TKI) gefitinib in mice (Stewart et al., 2004). 
Another report of this interaction showed that the TKI, imatinib mesylate (Gleevec), 
reversed topotecan resistance (Houghton et al., 2004). This interaction occurs because 
many of these TKIs, such as gefitinib and imatinib mesylate are potent BCRP 
inhibitors (Nakamura et al., 2005; Ozvegy-Laczka et al., 2004).  
Furthermore, certain anti-viral drugs are shown to be potent MDR1 and BCRP 
inhibitors (Wang et al., 2003; Weiss et al., 2007), such as lopinavir and nelfinavir. 
This inhibition can elucidate a drug-drug interaction especially when they are taken 
often in a HAART (highly active antiretroviral therapy) regimen. 
It is often the case that ABC efflux proteins have overlapping substrate 
specificity and it is quite rare to find substrates specific to a single ABC transporter. 
By having this system of multiple transporters removing a substrate it probably serves 
as a survival advantage, as one transporter becomes compromised the other 
transporter is still operational to remove the xenobiotic. This means the oral 
bioavailability of drugs can be affected by multiple efflux transporters. For example, 
the sympatholytic drug prazosin commonly prescribed to treat high blood pressure is 
known to be transported by both MDR1 and BCRP. In order to understand  how the 
oral availability of drugs is dependent on ABC-transporter action not only is it 
recommended that all drugs in development are tested as substrates for BCRP and 
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MDR1, but it is also important to test these directly in an appropriate context e.g. 
Caco-2 cells or in an intact epithelium. 
 
1.6 Systems for predicting oral bioavailability 
Medication is preferentially administered by the oral route for convenience and for 
patient compliance. In order to predict likely bioavailability and to understand the 
mechanistic basis of poor oral availability a number of different assays have been 
developed. It was originally thought that the majority of orally administered drugs 
were subject to passive absorption (Artursson & Karlsson, 1991), where the 
physiochemical properties of the drug were the main determinant. Relatively 
hydrophobic drugs combined with the principal of non-ionic diffusion (where the 
relative pKa or pKb and the relative concentration of the non-ionic hydrophobic 
moiety determined permeability) gave adequate oral availability. The role of specific 
drug transporters was considered to be minimal. Quantitative structure-activity 
relationship (QSAR) modelling, looking at the physiochemical properties of 
compounds such as hydrophobicity at a certain pH, pK and hydrogen 
accepting/donating ability, often give a predictive indication of the permeability of 
compounds and whether they are likely to interact with efflux transporters (Fujikawa 
et al., 2007; Ren et al., 1996). To measure permeability the parallel artificial 
membrane permeability assay (PAMPA) is used as a low cost measure of 
permeability in the early stages of development of compounds (Avdeef, 2005).  
It is now apparent, however, that a decent proportion of drugs taken orally are 
affected by active and facilitated transporter mechanisms. Typically, hydrophobic 
drug candidates are often poorly absorbed from the gut lumen. The recognition of the 
impact of the ABC-family of efflux transporters on the oral absorption of new and 
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existing xenobiotics has led to the development of new assays incorporating ABC-
transporter interaction. 2 such systems are isolated membrane vesicles or tissue 
cultured human intestinal cells derived from colonic adenocarcinomas e.g. Caco-2 
cells. 
Inside-out membrane vesicles from heterologously-expressing cells may be 
used to study the nature of ABC transport; they are relatively cheap and can be used 
in high throughput (Hegedus et al., 2009; Ozvegy et al., 2001). Transport assays or 
ATP hydrolysis stimulated by substrate are both utilised. However, these vesicle 
models are limited when applied to oral drug delivery. Firstly, BCRP is expressed on 
the extracellular facing membrane in the intestine (Maliepaard et al., 2001) thus cell 
lines with apical BCRP expression provide us with more physiological data. It is also 
known that compounds with high passive permeabilities will pass straight through 
these vesicles and will not be accumulated, giving false positive results (Hegedus et 
al., 2009). Moreover, this system of looking at one transporter in isolation is not a true 
representation of what is happening to a compound in a complex cell system such as 
an enterocyte. 
Today the use of polarized cell lines is the first choice when wanting to 
understand cellular membrane transport in the intestine.  The canine kidney cell line 
MDCKII has a low basal expression of transporters and its formation of a 
characteristic polarized epithelium has enabled it to be a popular choice in studying 
the ABC efflux transporters. The low endogenous expression of transporter proteins 
in these cells provides a good system to look at individual transporters in isolation, 
even though there are some reports of endogenous transport of drugs, such as digoxin 
and vinblastine in the native MDCKII cells (Haslam et al., 2008; Lowes et al., 2003). 
Stable vectorial transfection of MDCKII cells with ABC transporters such as MDR1 
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(Horio et al., 1989), MRP1 (Bakos et al., 1998), MRP2 (Evers et al., 1998) and the 
human and mouse BCRP homologues (Jonker et al., 2000; Pavek et al., 2005), have 
become routine tools in screening for candidate substrates, especially in drug 
development for the pharmaceutical industry.  
Over-expressing MDCKII cells are useful tools for researching ABC-
transporters in isolation. However, they do not always give a reliable measure of 
function in a complex cell system in vivo. Cell lines such as the human colon 
adenoma carcinoma cell lines Caco-2 and T84 provide much more useful tools when 
looking at complex cell systems such as the intestine.  
The use of the Caco-2 cell line serves today as probably the most popular in 
vitro tool to study intestinal processes; such as small peptide transport (Ganapathy et 
al., 1995; Thwaites et al., 1994) and drug transport (Artursson, 1990; Collett et al., 
1996; Englund et al., 2006; Hilgers et al., 1990). Early characterization with Caco-2 
cells showed extensive transporter expression and due to their expression of the ATP 
binding cassette transporters MDR1, MRP2, MRP3, MRP5 and BCRP they have been 
utilized routinely to model these transporters (Ebert et al., 2007; Lowes et al., 2003; 
Lowes & Simmons, 2002; Prime-Chapman et al., 2004; Xia et al., 2005). Caco-2 cells 
are frequently used in the pharmaceutical industry in drug permeability assays to 
model the human intestine (Artursson, 1990; Collett et al., 1996; Hidalgo et al., 1989; 
Hilgers et al., 1990). Many studies have compared the expression of these transporters 
in Caco-2 cells to human tissue (Englund et al., 2006; Gutmann et al., 2005; Seithel et 
al., 2006; Taipalensuu et al., 2001). Reports show that the expression profile of these 
transporters in Caco-2 cells is very similar to human jejunum (Gutmann et al., 2005; 
Seithel et al., 2006). On the other hand Taipalensuu et al. (2001) conversely show that 
particular transporters such as BCRP have a 100-fold lower transcript level in Caco-2 
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cells compared to that of human jejunum (Taipalensuu et al., 2001). These 
discrepancies and differences show that extrapolation from in vitro cell models to an 
in vivo situation also is by no means perfect but they are currently the best thing from 
using human tissue. 
To understand the ABC-transporter mediated secretion of compounds in a 
complex cell system in which multiple ABC transporters exist, such as Caco-2 cells, 
inhibitors can be used to distinguish between transporter family members. Many 
agents have been developed or existing agents recognized as BCRP inhibitors. As 
discussed previously these agents can affect the oral bioavailability of drugs and, 
therefore, in the clinic could be useful tools to improve oral bioavailability and 
reverse drug resistance to antibiotics and cancer agents. In the clinic tyrosine kinase 
inhibitors have been recognized as BCRP inhibitors and so can be used alongside 
other cancer agents to improve drug efficacy. Nonetheless there are relatively few 
examples of ABC inhibitors in clinical use.  
In vitro specific inhibitors of the ABC transporters are excellent research tools 
for studying ABC transport. Generating specific inhibitors of particular family 
members is difficult due to the overlap in substrate specificity, for example, 
GF120918 (elacridar), a third generation BCRP inhibitor is effective at inhibiting both 
MDR1 and BCRP in vitro (de Bruin et al., 1999). It often depends on the 
concentration of an inhibitor to achieve selective inhibition. For example, CsA is 
known to be an inhibitor of both MDR1 and BCRP and it depends on the 
concentration as to which family of transporters is inhibited (Ejendal & Hrycyna, 
2005; Xia et al., 2007b). Fumitremorgin C, a mycotoxin of Aspergillus fumigatus, is 
an ideal pharmacological research tool, as it is a specific inhibitor of BCRP 
(Rabindran et al., 1998). However, it possesses neurotoxic effects, which limit its use. 
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The analogue of FTC, Ko143, is a less toxic and even more effective selective BCRP 
inhibitor (Allen et al., 2002). A screen by Matsson et al. (2007) screened 123 
compounds to see whether or not they are BCRP inhibitors and stated that a logD7.4 
(octanol/water partition coefficient at pH7.4) of at least 0.5 was required for a 
compound to be a BCRP inhibitor (Matsson et al., 2007).    
As already noted, in vitro isolated intestinal segments mounted in Ussing 
chambers from both animal and human sources provide definitive data as to 
absorption but do not allow high-throughput capability. In vivo animal/human 
experiments are yet more expensive but probably serve as the most informative 
measure of likely oral absorption.  
Molecular specificity with respect to ABC-transport proteins may be 
combined with animal models using both in vivo and in vitro approaches with gene 
knock-out. This is illustrated by the use of mdr1a or mdr1b knockouts, double knock-
outs of mdr1a/b and Bcrp knockout mice in determination of the pharmacokinetics of 
candidate substrates of ABC transporters in a whole animal system rather than a 
particular tissue type (Jonker et al., 2005; Marchetti et al., 2008; Zhang et al., 2005). 
The knock down of a specific ABC transporter clearly shows the contribution of these 
efflux proteins on the ADME profile of individual drugs. This provides a 
physiological model that can be extrapolated to man. However, it is not economical to 
use these animals for all new drugs under development. The use of knockout animals 
is relatively expensive, is low throughput compared with in vitro methods that are 
available and, therefore, are only used were necessary. 
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1.7 ABC protein nuclear receptor modulation 
The expression of the ABC efflux transporters is thought to be tightly regulated by a 
complex network of interacting nuclear receptors (also known as xenosensors), such 
as constitutive androstane receptor (CAR), farnesoid X receptor (FXR), liver X 
receptor (LXR), pregnane X receptor (PXR) and vitamin D receptor (VDR). 
Approximately 50 nuclear receptors working alongside an even greater number of 
coactivators (which often occur in multiprotein complexes) have been identified, all 
of which have not been well characterised (Pascussi et al., 2008). These receptors in 
turn are regulated by a vast array of endogenous and exogenous ligands and it is 
estimated that approximately 10% of commonly prescribed drugs activate these 
nuclear receptors. The main structural features of the nuclear receptors are the ligand 
binding domain at the C-terminal and the more conserved DNA-binding domain 
(Gibson et al., 2006; Handschin & Meyer, 2003). Nuclear receptors regulate more 
than the ABC transporter proteins, for example PXR is known to regulate 
approximately 40 genes (Maglich et al., 2002), such as MDR1, MRP2 and CYP3A4, 
whilst CAR, 69 genes (Ueda et al., 2002) and LXR regulates approximately 319 
genes (Stulnig et al., 2002). Thus nuclear receptors co-ordinate a complex cellular 
adaptation to xenobiotic exposure by up/down regulation of an array of genes to rid 
the body of xenobiotics. Expression of cytochrome P450s, conjugation enzymes and 
ABC transporter proteins show co-ordinate regulation to name but a few (Pascussi et 
al., 2008). Furthermore, nuclear receptors are thought to work co-operatively in an 
interacting network of nuclear receptors controlling gene expression (Gibson et al., 
2006). 
Nuclear receptors are expressed at high concentrations in areas in which there 
is large ABC transporter expression (Chan et al., 2004). PXR is known to be 
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expressed in the small intestine and is known to regulate not only MDR1 (Geick et 
al., 2001) and MRP2 (Kast et al., 2002) but also the drug metabolising enzyme 
CY3A4 (Greiner et al., 1999). Nuclear receptors when activated by ligands are known 
to bind to conserved DNA sequences known as hormone response elements (HRE) 
which are found in the promoter regions of target genes. For example, when PXR is 
activated by rifampicin it dimerizes with a partner, RXR, to form a heterodimeric 
complex. This complex then binds to a response element known as PXRE on target 
genes such as MDR1. The location of these response elements are gene specific and 
activation also tissue specific, combining this with the multiple endogenous and 
exogenous ligands that may bind to different binding sites on the same gene, results in 
a highly complex dynamic method of regulation. 
Given the complex nature of nuclear receptor mediated regulation it is 
unsurprising to find that multiple nuclear receptors have been linked with MDR1 
regulation. In the intestinal cell line T84 it has been shown that MDR1 is regulated 
through PXR activation  (Haslam et al., 2008). Whilst there are reports that intestinal 
regulation of MDR1 is also regulated via the CAR receptor (Burk et al., 2005). 
The regulation of MRP2 is also reported to be regulated by PXR activation but 
also  by FXR and CAR (Kast et al., 2002), with reports showing that regulation is 
dissimilar to that of MDR1 (Haslam et al., 2008). 
BCRP has been shown to be regulated via many pathways in different 
epithelial tissues but no generic pathway of induction has been identified for BCRP 
between different tissue types. Findings by Albermann et al. (2005) correlated PXR 
with the regulation of BCRP mRNA but no further evidence for the involvement of 
this nuclear receptor has emerged (Albermann et al., 2005). Perhaps this difference in 
regulation between MDR1 and MRP2 serves to act as a survival advantage. Providing 
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alternative gene regulatory pathways for separate efflux transporters will allow one 
transporter to compensate for the others if any are compromised in any way. 
 
1.8 Objectives of the thesis 
Although most work on ABC-transporter function within the intestinal tract has been 
carried out on MDR1 and MRP2, it is quite clear from expression studies that BCRP 
is likely to be at least as important to limiting xenobiotic uptake from the diet as 
MDR1. The primary objective of this thesis is, therefore, to examine the function and 
regulation of the less characterised of the three main efflux transporters, BCRP in the 
context of epithelial expression with particular focus on human intestinal cells.   
Madin Darby Canine Kidney II (MDCKII) cells transfected with human 
BCRP and the mouse homologue Bcrp have been characterised for the extent and 
stability of BCRP/Bcrp expression. In order to identify organ-specific cell-lines in 
which endogenous BCRP expression occurred, the intestinal Caco-2 cell line, together 
with several renal epithelial cell lines were assayed for BCRP expression. In order to 
determine the functional activity of BCRP the fluorescent Hoechst 33342 dye was 
assessed as an appropriate substrate. Hoechst 33342 was then used as an indirect 
method of identifying BCRP substrates in the MDCKII cells (Chapter 3). 
Since Hoechst 33342 accumulation is only an indirect measure of substrate 
flux, MDCKII cell models and Caco-2 cells were reconstituted as functional epithelial 
layers grown upon filter supports to provide an unambiguous assay of BCRP 
mediated transport function by measurement of net substrate flux. The objectives 
were to assess the relative contribution of BCRP to ABC-transporter mediated 
secretion but also to identify a BCRP specific substrate that could be used in isolation 
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to assess BCRP function despite the existence of multiple ABC transport activities 
(Chapter 4). 
Despite several years of attempting to identify the molecular basis of the 
fluoroquinolone (ciprofloxacin) secretion, the basis of this secretion in Caco-2 
epithelia remained uncertain. The objective of Chapter 5 was, therefore, to determine 
whether BCRP alone or in conjunction with other ABC transporters mediates this 
secretion. 
Given the existence of a specific BCRP substrate (nitrofurantoin), the final 
objective addressed in Chapter 6 was to determine whether dynamic regulation of the 
BCRP pathway occurred in Caco-2 epithelia in response to potential stimuli arising 
from factors such as dietary components. Such regulation may be used to predict 
unwanted drug-drug interactions but also may provide insight into methods to 
improve oral drug delivery. 
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2. Materials and methods 
 
 
2.1 Materials 
Cell culture media and supplements were purchased from Sigma (Poole, Dorset, UK), 
and tissue culture plastic flasks and culture plates were supplied by Costar (High 
Wycombe, UK) and Millipore (Watford, UK). All chemicals were obtained from 
Sigma (Poole, Dorset, UK), at the highest purity available, unless otherwise stated. 
Ko143 was given as a gift from the Netherlands Cancer Institute to be used in Chapter 
5 only, the remaining work with Ko143 was sourced from AstraZeneca (Alderley 
Park, Cheshire). 
 
2.2 Methods 
2.2.1 Routine cell culture  
All cell culture was performed in a class II laminar flow hood (Safeflow1.2, Bio Air 
Instruments, Italy) under aseptic conditions.  Cells were grown in flasks of 175cm
2
 
surface area and maintained in a sterile incubator at 37ºC with 5% CO2 in air.  
In this study two Caco-2 cell-strains were used; a high-passage (PA) strain 
(passage 115-120) originating from Dr. I Hassan, as described previously (Cavet et 
al., 1997) and a low PA strain (passage 34-45) originating from AstraZeneca 
displaying rapid growth and higher values of transepithelial resistance (American 
Type Culture Collection, Manassas, VA, 20108, USA). All Caco-2 cells were 
maintained in high-glucose (4500mg.ml
-1 
D-glucose) Dulbecco‟s Modified Eagle‟s 
Medium (DMEM) supplemented with foetal calf serum (10% v/v), 1mM L-glutamine 
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(1% v/v), non-essential amino acids (1% v/v) and 30μg.ml-1 gentamicin (0.06% v/v). 
Media was replaced every 3-4 days and cells were passaged every 7-14 days.  
MDCKII native, human MDR1-MDCKII, human BCRP-MDCKII and mouse 
Bcrp1-MDCKII cells were gifts from the Netherlands Cancer Institute. MDCKII cell 
lines were cultured in Minimum Essential Eagle‟s Medium (EMEM) supplemented 
with foetal calf serum (10% v/v), non-essential amino acids (1% v/v), 1mM L-
glutamine (1% v/v) and a Penicillin Streptomycin mix (1% v/v). Media was replaced 
every 3-4 days. MDCKII native cells were used for 15 passages from frozen whilst 
transfected cells were used for 10 passages.   
Native HEK (293/4.59) and MRP4-transfected HEK cells (293/4.63) were a 
gift from Prof. P. Borst of the Netherlands Cancer Institute (Reid et al., 2003b). HEK 
293 cell lines were maintained in high-glucose (4500mg.ml
-1 
D-glucose) Dulbecco‟s 
Modified Eagle‟s Medium (DMEM) supplemented with foetal calf serum (10% v/v) 
and a Penicillin Streptomycin mix (1% v/v). 
The mouse cortical collecting duct principal cell line (mpkCCDc14) and 
mouse distal convoluted tubule cells (mpkDCT) were kindly provided by Dr. A. 
Vandewalle (INSERM, Paris). Both cell lines were cultured in a 1:1 (v/v) ratio of 
low-glucose (1000mg.ml
-1 
D-glucose) Dulbecco‟s Modified Eagle‟s Medium 
(DMEM) and HAMS-F12 nutrient mixture. The mixture was supplemented with 
20mM D-glucose (0.0224% v/v), 50nM dexamethasone (0.005% v/v), 10ng.ml
-1
 
epidermal growth factor (0.01% v/v), foetal calf serum (2% v/v), 20mM HEPES 
(0.002%v/v), 2mM L-glutamine (1% v/v), 5µg.ml
-1
 insulin (0.05% v/v), 
Penicillin/Streptomycin mix (1% v/v), selenium (0.02% v/v), 5µg.ml
-1
 transferrin 
(0.11% v/v) and 1nM triiodothyronine (0.0014% v/v) (Hasler et al., 2003). 
54 
 
MCF-10A cells were obtained from ATCC (Middlesex, UK) and cultured in a 
1:1 (v/v) ratio of low-glucose Dulbecco‟s Modified Eagle‟s Medium (DMEM) and 
HAMS-F12 nutrient. The mixture was supplemented with 20ng.ml
-1
 cholera toxin 
(0.5% v/v), 20ng.ml
-1
 EGF (0.2% v/v), foetal calf serum (5% v/v), 1µg.ml
-1
 
hydrocortisone (0.33% v/v), 10µg.ml
-1
 insulin (0.1% v/v) and a Penicillin and 
Streptomycin mix (1% v/v). Cholera toxin was added to increase the intracellular 
levels of cyclic AMP which is thought to promote growth and increase the number of 
times these cells could be subcultured (Stampfer, 1982). 
 
2.2.2 Functional transport assays 
2.2.2.1 Hoechst 33342 cellular accumulation assay  
Cell monolayers of all cell types used were seeded at a low density of 5 X 10
4
 cells 
per well onto 24-well plates or 3 X 10
4 
cells per well onto 96-well plates and grown 
for 5-7 days. Caco-2 cells were grown for 7-10 days. The cell monolayers were 
washed 2 times with warm Krebs‟ solution then incubated at 37ºC for 30 minutes in 
1ml (24-well plates) or 200μl (96-well plates) Krebs‟ solution (pH 7.4) containing +/- 
inhibitor. The bathing medium was then aspirated and monolayers were incubated for 
a further 60 minutes with 1ml (24-well plates) or 200μl (96-well plates) 3µM Hoechst 
33342 +/- inhibitor Krebs‟ solution. At 60 minutes cell medium was again aspirated 
and monolayers washed 2 times in Krebs‟ buffer. The 24-well plate‟s cells were 
subsequently lysed for between 15-30 minutes with 0.5ml (0.01% Triton X-100 lysis 
buffer). Typically 40ml of lysis buffer was made for each assay comprising of 1mM 
EDTA pH 8, 1mM EGTA pH 8, 640µM sucrose, 1mM Tris pH 7.6, 0.05 % Triton X-
100, and made up to 40ml with distilled water.  Following cell lysis an aliquot of 
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solution was kept to measure protein levels per well whilst the remainder was 
transferred to UV-grade cuvettes for Hoechst 33342 fluorescence to be measured on a 
Perkin Elmer fluorimeter (excitation wavelength 350nm and emission 480nm).  
Fluorescence was then corrected for protein levels in individual wells using the 
Bradford Assay for protein concentrations (Thermo). Assays conducted on 96-well 
plates were not lysed but read straight away on a fluorimetric plate reader (FLUOstar 
Omega, BMG Labtech), each well was read by a 5x5 well-scan grid system to ensure 
all areas of the well was read, giving an average fluorescence for each well. 
The Bradford assay for protein correction (Bradford, 1976) was performed by 
producing a bovine serum albumin (BSA) standard curve (0-20µg protein). 50µl of 
standards were prepared in Eppendorf tubes (1.5ml) and diluted using the lysis buffer 
used in the assay to remove cells. 10µl of the standards and samples were transferred 
in triplicate to a 96-well clear round bottomed plate (Fisher Scientific) and to all wells 
200µl of Coomassie Brilliant Blue (Thermo) was then added. Any bubbles were 
removed from the wells by briefly waving over a Bunsen burner flame. Plates were 
then measured at absorbance 595nm on the fluorimetric plate reader (FLUOstar 
Omega, BMG Labtech). A BSA standard curve was produced from the standard 
values and subsequently sample protein concentrations were determined by 
extrapolation from the curve and correcting for any dilutions (if sample dilutions were 
made). 
 
2.2.2.2 Measurement of bi-directional transport across epithelial layers grown on 
12-well filter plates 
Cells were seeded at high density (5 X 10
5
 cells per well) onto 12-well permeable 
polycarbonate membrane filters (Corning, Transwell, 3401, 12mm diameter, 0.4μm 
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pore size, 1.14cm
2
 growth area). Both Caco-2 and MDCKII cells were left until 
confluency (14 days and 5-7 days post seeding respectively); cells had media changed 
every 3 days. 
Transepithelial electrical resistance (RT) values were determined for each well 
as a quality control measure for both MDCKII and Caco-2 monolayer integrity, using 
a World Precision Instruments EVOM voltohmmeter.  Epithelial layers were only 
accepted if the data were above 200 Ω.cm2 for Caco-2 epithelia. For MDCKII layers 
values of < ~100 Ω.cm2 were more typical. The initial resistance values were 
corrected
 
for the resistance of the filter alone by subtracting its resistance (81.75 ± 
1.68 Ω in Krebs‟ buffer, n = 8) and adjusting for filter area (1.14 cm2). 
Since transepithelial resistance values for MDCKII monolayers were low an 
additional quality control measurement was employed to check for confluence. 
Transepithelial potential differences (PD, mV) were measured after replacement of 
the basolateral NaCl buffer with D-mannitol (basolateral solution electropositive). 
Dilution potentials typically greater than 30mV (basolateral solution electropositive) 
were considered acceptable for confluent monolayers (Carr et al., 2010). Normal PD 
values ranged between between 40-70mV. 
Cell monolayers were washed with warm Krebs‟ buffer (37°C) and were 
maintained at this temperature on a hot plate throughout the experiment. 
Radiolabelled drug was dispensed into the donor solutions. After the addition of the 
radiolabel-containing donor solutions to either apical or basal compartments, warm 
Krebs‟ buffer was added to the opposite compartment (the acceptor solution). The 
flux of the radiolabelled drug was determined from donor to acceptor compartments 
(apical or basal), giving a measure of apical to basal or basal to apical flux. 
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Transport inhibitors included in the experiment were added to both apical and 
basolateral compartments. Radiolabelled mannitol was included where possible as a 
measure of paracellular permeability, a mannitol flux greater than 5% into the 
opposite compartment at the end of the incubation time resulted in these results being 
discarded (due to poor monolayer integrity).  
At 60, 120 and 180 minutes incubation, 50µl samples were removed from both 
apical and basal compartments of each well. This sample was added to 2.5ml of 
scintillation cocktail (OptiPhase “Hisafe” 2 Liquid Scintillation Cocktail). After the 
samples were collected at the end of the 180 minutes, Transwells were washed 
thoroughly (4 times in ice cold Krebs‟ buffer), this reduced extracellular isotope to a 
negligible concentration still remaining on the filter. The filters were then cut out and 
also added directly to scintillation cocktail. Sample activity was measured using a 
liquid scintillation counter (Beckman LS 5000 Liquid Scintillation System). 
Flux calculations were made as follows and are expressed in moles.cm
-2
.hr
-1
: 
             Db x M 
 Ja-b =  -----------         
             Dt x S 
 
             Da x M 
 Jb-a = ----------- 
             Dt x S 
 
Jnet = Jb-a – Ja-b 
 
From the formulas Ja-b is the apical to basal flux, Jb-a is the basal to apical flux 
whilst Jnet is the net flux. Dt is the total dpm (disintegrations per minute) added to the 
donor compartment (apical and basal) at the start of the experiment. Da and Db are 
the activities (in dpm) transported to the apical and basal receiver compartments per 
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hour, respectively. M is the number of moles of the substrate present and S is the 
growth area of the filter (1.14cm
2 
for 12-well, 0.7cm
2 
for 24-well or 0.11cm
2 
for 96-
well plates). 
The accumulation of radiolabelled substrate within the cells was determined 
using these equations: 
        Ta x M 
Aa = ------------ 
       Dt x V 
 
        Tb x M 
Ab = ------------ 
      Dt x V 
 
From the formulas Aa represents accumulation from the apical compartment 
and Ab accumulation from the basal. Ta is the activity (dpm) of the cell layer exposed 
to the apical donor solution and Tb the layer exposed to the basal donor solution, V 
represents the volume of cells on the filter. Cell volumes for Caco-2 and MDCKII 
grown on 12mm Transwells were approximately 1.98µl and 2µl respectively, 
calculated previously by using confocal imaging to measure cell height (h) and radius 
(r) of the filter (πr2.h) (Griffiths et al., 1994; Lowes et al., 2003). 
 
 
 
 
2.2.2.3 Bi-directional transport across epithelial layers grown on 24 or 96-well 
filter plates 
Caco-2 and MDCKII cell-lines were seeded onto 24 or 96-well permeable culture 
inserts (Millipore, Millicell®-24 and 96 well plates, 0.4μm pore size) at high density. 
Caco-2 cells were seeded at 2.25 X 10
5
 cells per well
 
and 3 X 10
4
 cells per well for 24 
and 96-wells, respectively. MDCKII cells were seeded at 5 X 10
5
 cells per well
 
and 3 
X 10
4
 cells per well for 24 and 96-well, respectively. Caco-2 and MDCKII cells were 
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cultured until confluency (14 days and 3-5 days post seeding respectively). Cells had 
media changed every 3 days. 
Caco-2 and MDCKII cell confluence was determined by measurement of 
transepithelial electrical resistance (RT) using an automated TEER reader using the 
REMS system for 96-well plates, the WPI EVOM voltohmmeter (World Precision 
Instruments, Stevenage, Hertfordshire, UK) was used for the 24-well format.  
Resistance values for confluent cell monolayers layers on 96-well permeable supports 
gave TEER values of approx 2500Ω and 450Ω for Caco-2 and MDCKII, respectively 
without correcting for filter resistance and growth area. Resistance values for 
confluent cell monolayers layers on 24-well permeable supports gave TEER values of 
approx 500Ω and 120Ω for Caco-2 and MDCKII, respectively without correcting for 
filter resistance and growth area. Prior to experimentation MDCKII and Caco-2 cell 
confluency were determined by the magnitude of the Na
+
/choline bi-ionic potential 
difference (p.d.) (with basal bathing solution replacement), as described previously.  
Transport assays measured the compound of interest as the unidirectional 
(apical to basal, Ja-b and basal to apical, Jb-a) flux from a donor solution of 10μM 
unless otherwise stated. Sampling was either performed manually for 24-well assays 
or for the 96-well format using the Hamilton Starplus robot. Two automated scripts 
were used for the 96-well format, including a 24 compound substrate assay and a 6 
compound substrate assay including ABC transporter inhibitors. Lucifer Yellow 
(100μM) was included were possible in the transport buffer to allow post-assay 
determination of paracellular permeability, measured by spectrofluorometry (485-
535nm). 
Epithelial layers were first washed (3 times) in Hank‟s Buffered Saline 
Solution (HBSS) and placed in a fresh base-plate containing HBSS supplemented 
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with 10mM HEPES. Monolayers were allowed a 15 minute equilibration period at 
37ºC. For flux experiments, the buffer composition was identical for apical and basal 
compartments (HBSS + 10mM HEPES) with the addition of compound of interest to 
either the donor apical or basal compartments.  Samples were taken and at 2 hours 
incubation at 37°C to determine absorptive (apical to basal, Ja-b) and secretory (basal 
to apical, Jb-a) flux. All compounds were made up from solid in DMSO and 
experimentation volume never exceeded 0.1% DMSO. All assay plates were then 
prepared for measurement via mass spectroscopy by protein precipitation (“crashing”) 
with MeOH, followed by centrifugation and transferral of supernatants to new sample 
plates. Samples were optimized and compound analysed by high pressure liquid 
chromatography-mass spectroscopy (HPLC-MS). Samples were analysed via single 
or parallel chromatography, using a Phenomenex Gemini 5µ 50 x 2.0 column, in 
column ovens set at 50°C. The rest of the HPLC unit comprised of: a HP1100 series 
binary pump, column heater, Diode Array Detector, CTC HTS PAL autosampler. The 
HPLC stationary phase used was non polar with a polar mobile phase comprising of 
water and ammonium acetate. The gradient switched from 5% water and 95% 
ammonium acetate at time 0 to 95% water and 5% ammonium acetate at 3 minutes. 
Formic acid was added to adjust pH depending on the compound retention. Detection 
by mass spectroscopy (Waters® Quattro Ultima™) was done by switching between 
positive or negative ionization modes depending on the individual compound being 
used. An internal standard was included in samples to ensure injections onto the 
HPLC-MS system were standardized. C0 samples (concentration at the start of the 
assay) were also included in the samples to assess the recovery of the compound from 
the Transwell assay (recoveries were acceptable between 40-120%). Chromatogram 
data were processed using QuanLynx V4.1 software (Waters Inc. 2008) and flux 
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values were determined on adjacent layers using the calculations determined in 
(2.2.2.2). 
 
 
2.2.3 Induction pre-treatments of Caco-2 cell monolayers 
Cell monolayers were incubated between 24-72 hours with different agents, DMSO 
concentration never exceeding 0.1%. All inducing agents were made up in DMSO and 
then diluted to the required final concentration using phenol red free Dulbecco‟s 
Minimum Essential Media. Cell monolayers were incubated between 24-72 hours 
depending on the experiment. The washout period consisted of 2 initial washes with 
pre-warmed media at 37°C and incubated for 60 minutes. 60 minutes washout being 
long enough to ensure any inducing agent has had adequate dilution and transit time 
from the cell. The washout duration was not too long as to prevent a reversal of the 
induction. The protocol was then followed as described in (2.2.2.3). 
 
2.2.4 Cellular ciprofloxacin accumulation in HEK 293 cells 
HEK 293 cells were seeded 5 x 10
4 
onto 12 well plates (Corning). Cells were grown 
for 4 days. Media was aspirated and replaced with transport buffer (Krebs‟ buffer with 
additional radiolabel and inhibiting agents). Cells were incubated at 37°C for 1 hour 
and were then washed with ice cold Krebs‟. Cells were then treated with 500µl lysis 
buffer (0.05% Triton X-100) and samples were collected for measurement and protein 
correction via a Bradford Assay. Cellular accumulation of [
14
C]-ciprofloxacin (made 
up to 10μM with unlabelled ciprofloxacin) was determined by scintillation counting. 
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2.2.3 Molecular biology 
2.2.3.1 RNA isolation and quantitative PCR 
RNA was isolated from confluent flasks of epithelial cells, using the Qiagen RNeasy 
mini-kit following the manufacturer‟s standard protocol. Any contaminating DNA 
was digested using a DNAse treatment according to the manufacturer‟s protocol 
(Promega).  RNA was quantified using a NanoDrop ND-1000 spectrophotometer 
(NanoDrop Technologies Inc., Wilmington, DE, USA) and integrity checked by 
measurement of the A260/280 nm ratio, which was routinely in the range of 1.8-2.0. 
 
2.2.3.2 Reverse transcription 
To synthesise cDNA to be used in the polymerase chain reaction, reverse transcription 
(RT) was performed using 1µg total purified RNA. Using components from Promega, 
a 20µl reaction was set up on ice, the final tube contained: 5 X RT reaction buffer (20 
% v/v), 2mM dNTP mix (25% v/v), 0.5µg/ml random hexamer primers (5% v/v), 
RNase inhibitor (1.25% v/v), reverse transcriptase (2.5% v/v) and 1µg template RNA, 
RNase-free water (to 20µl). Negative controls were also made up at the same time 
which involved replacing the reverse transcriptase enzyme with an equal volume of 
RNase-free water. 
Note that before all components were added, the RNA template and random 
hexamer primers were mixed in tubes and then quickly denatured for 5 minutes at 
65ºC on a thermal cycler (Px2 thermal cycler, Thermo). The tubes were then 
transferred to ice for 2 minutes before adding the remaining components. The tubes 
were then subsequently incubated at 42ºC for 2 hours to allow cDNA synthesis and 
finally denatured for 3minutes at 95ºC. 
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2.2.3.3 Standard polymerase chain reaction 
Using the cDNA product synthesized from the RT reaction the product was then 
amplified by standard polymerase chain reaction. The gene region to be amplified was 
defined by primers that were designed by OligoPerfect™ designer software 
(Invitrogen). These forward and reverse primers were verified for specificity by 
BLAST (basic local alignment search tool) and these gene-specific primers were 
purchased from VH Bio Limited (Gateshead, UK). The primer pairs used in this study 
are shown in Table 2.1 of methods. 
PCR reactions were made up using HotStartaq PCR kits (Qiagen). A 25µl 
PCR master mix was made on ice, containing: 10 X PCR buffer (10% v/v), 10mM 
dNTP mix (1% v/v), 10µM forward primer (5% v/v), 10µM reverse primer (5% v/v), 
HotStarTaq DNA polymerase (0.5% v/v), cDNA sample (8% v/v) and distilled H20 
(to 25µl). Negative controls were again set up for each sample; an RT negative 
control (described in section) and a second negative in which the cDNA template is 
replaced with an equal volume of distilled water (this was to confirm the lack of 
genomic DNA contamination). 
The PCR reaction was incubated in a Px2 thermal cycler (Thermo) according 
to a specific protocol of repeated DNA denaturation, hybridization and extension. The 
protocol involved 15-minute incubation at 95ºC to activate the Taq Polymerase 
enzyme. The reaction mix was then cycled between 30-35 times with these 3 steps in 
sequence; 30 seconds at 94ºC to denature the DNA strands, 30 seconds at a particular 
cooling temperature depending on the primer pair (shown in Table 2.1 of methods) 
and then 60 seconds at 72ºC to allow DNA extension. After the cycles were complete 
the tubes were held for a further 10 minutes at 72ºC and then held at 4ºC until stored 
in the -20ºC freezer. 
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PCR products were then separated on a 2% agarose gel containing 0.005% 
Safeview, whilst a 100 base pair ladder (GeneRuler 100 base pair DNA Ladder plus, 
Fermentas, Thermo Fisher Scientific) was used to obtain the size of the PCR product. 
The electrophoresis was run for 70V for 1 hour and viewed using a UV 
transilluminator (Uvitec, Cambridge). 
 
2.2.3.4 Real-time polymerase chain reaction 
Real-time PCR was performed with the same principal as standard PCR, however, as 
the product can be visualized whilst the reaction is occurring to give a quantitative 
measure of mRNA when compared with a standard curve. The SYBR green I 
fluorescence dye is the simplest detection method for RT-PCR; whereby the dye 
fluoresces when bound to DNA specifically to the minor groove of double stranded 
DNA (Morrison et al., 1998). 
A 10µl reaction mixture was added to a 96-well white PCR analysis plate 
(Roche) and comprised of: SYBR green (Roche) Master Mix (50%v/v), 10µM 
forward primer (5% v/v), 10µM reverse primer (5% v/v), 1:4 diluted cDNA sample 
(20% v/v) and distilled H20 (to 10µl). Note the cDNA sample was diluted 1:4 to allow 
samples to go further and to be quantified from the standard curve. Negative controls 
were again set up for each sample; an RT negative control (described in section 
2.2.3.2) and a second negative in which the cDNA template is replaced with an equal 
volume of distilled water. This was to confirm the lack of genomic DNA 
contamination. 
Amplification was performed over 45 cycles using the Roche Light Cycler 
480.  Quantification of mRNA was done via two methods. For the MDCKII, Caco-2 
and HEK mRNA characterisation, levels were quantified using the Pffafl method of 
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quantification. This is a mathematical approach that requires no calibration curve 
(Pfaffl, 2001). The relative expression ratio is calculated only from the real-time PCR 
efficiencies and the deviation in crossing point of an unknown sample versus a 
control. The crossing point (CP) is defined as the point at which fluorescence rises 
appreciably above the background level of florescence. The relative expression ratio 
of a target gene is calculated using this equation: 
 
                         (Etarget)
ΔCPtarget (control-sample) 
 
                 Ratio(R) =    ______________________________ 
 
                         (Eref)
ΔCref (control-sample) 
  
Etarget is the real-time PCR efficiency of a target gene transcript (such as hBCRP). Eref 
is the real-time PCR efficiency of a reference gene transcript (the stable housekeeping 
gene GAPDH was used). The efficiency was determined from the given slope on the 
LightCycler software, calculated from the equation E= 10
[-1/slope]
 (Pfaffl, 2001; 
Tichopad et al., 2003). The ΔCPtarget is the CP deviation of control-sample of the 
target gene. 
The second method used to quantify changes in BCRP expression in Caco-2 
cells shown in Chapter 6 was done via the conventional method of using positive 
control mRNA to generate standard curves from each primer set, allowing relative 
quantification (using hBCRP-MDCKII cDNA to generate the standard curve). Sample 
values were extrapolated from the standard curve and then data were normalised to 
the expression of the house keeping gene GAPDH and then in turn expressed as 
relative arbitrary units. Products were verified by electrophoresis on a 2% agarose gel, 
cut out under UV light, and purified using a Qiagen QIAquick PCR purification kit. 
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Then 15µl of > 2ng/µl of product was sent off for sequencing (Eurofins MWG DNA 
Sequencing). 
 
2.2.4 Immunoblotting 
Cells were cultured and grown in 75cm
2
 flasks as described in Routine Materials and 
Methods (section 2.2.1). Whole cell extract was lysed using a buffer comprising of 
1mM EDTA pH 8, 1mM EGTA pH 8, 640µM sucrose, 1mM Tris pH 7.6, 0.05 % 
Triton X-100 and ½ a protease inhibitor tablet (Roche), made up to 5ml with distilled 
water. Cells were washed twice with 1% Phosphate Buffered Saline (PBS) and 1ml of 
lysis buffer was added to the 75cm
2
 flask. Cells were scraped off using a rubber 
policeman and pippetted into a 15ml Falcon tube. Homogenisation with a needle and 
syringe was followed by centrifugation at 10,000 x g for 10 minutes. Whole cell 
lysate was protein quantified using the Bradford Assay (Thermo). Proteins were 
loaded between 5-40µg onto graded 4% SDS-polyacrylamide (stacking) + 10% SDS-
polyacrylamide (running) gels. The Precision Plus Protein
TM
 Dual Colour Standards 
(Invitrogen) were loaded to allow protein molecular weight to be estimated. Samples 
were separated by electrophoresis for 1 hour (40mA). Gel transfer onto PVDF 
membranes (Millipore) was then conducted overnight at 50mA, or for 180 minutes at 
250mA. Membranes were blotted in 5% non-fat dry milk in 0.1% Tween 20 
phosphate buffered saline (PBS-T) for 1 hour. The membranes were mixed either with 
the rat-monoclonal anti human/mouse BCRP antibody BXP-53 (Santa Cruz) or BXP-
9 (Kamiya), diluted 1:50 and 1:500 respectively in milk PBS-T (both raised against 
the amino sequence of 221-394 of mouse Bcrp). The mouse-monoclonal antibody 
BXP-21 (Santa Cruz) was diluted 1:100 in non-fat dry milk PBS-T (raised against the 
amino sequence 291-396 of human BCRP).  Primary incubations were conducted on a 
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roller mixer at 4°C overnight or for 2 hours at room temperature. Membranes were 
then washed with PBS and incubated with the appropriate secondary HRP-labelled 
IgG (Santa Cruz), an anti-rat HRP for BXP-53 and BXP-9, and anti-mouse HRP for 
BXP-21, diluted 1:10,000. The membrane was then developed using the pico-
chemiluminescence substrate (Thermo) and developed using an automatic developer 
in a dark room. Equal protein loading was confirmed by re-probing membranes for α-
tubulin, but before which membranes were stripped with stripping buffer (Thermo) 
using the manufacturer‟s guidelines. The primary rabbit anti-human α-tubulin 
antibody (Abcam) diluted 1:100 in 5% milk was used. Secondary staining was 
performed with an anti-rabbit HRP-conjugated secondary diluted 1:10,000 (Abcam). 
Finally the PVDF membranes were copper stained. 
 
2.2.5 Immunocytochemistry 
MDCKII and Caco-2 cell monolayers were grown on permeable polycarbonate 
membrane filters (Transwell, Corning, 3401) for 7 and 14 days respectively. Layers 
were fixed, prior to staining, with ice cold MeOH for 15minutes. Transwells were 
then flooded with PBS and blocked in 3% horse serum (HS).  
Primary block was followed by the application of a primary antibody either 
rat-monoclonal anti human/mouse BCRP antibody BXP-53 (Santa Cruz), used at 1:50 
dilution in 3% horse serum or mouse-monoclonal anti human BCRP antibody BXP-
21 (Santa Cruz) diluted 1:50 and subsequently left in the fridge overnight. Secondary 
block was done with 3% donkey serum and followed by the secondary antibody; goat 
anti-rat Alexa Fluor
TM
 488 (FITC) was diluted 1:100 and used for staining with BXP-
53 primary. Secondary block for use with BXP-21 was done with 3% horse serum and 
followed by the secondary antibody; donkey anti-mouse Alexa Fluor
TM
 488 (FITC) 
68 
 
and diluted 1:100. Layers were stained with propidium iodide (TRITC) diluted 1:1000 
for nuclear staining. Layers were finally mounted onto slides using Vecta Shield and 
images were taken with a Leica confocal microscope. 
 
2.2.6 Statistical Methods 
Results are expressed as mean ± standard error of mean (SEM). Individual 
experiments were conducted with at least 3 replicates per condition, whilst 
experiments were repeated at the very least once. Statistical analysis was performed 
using Student‟s unpaired t-tests or one-way analysis of variance (ANOVA) with 
Bonferroni‟s or Dunnett‟s post-test for multiple comparisons. Kinetic constants for 
Michaelis-Menten kinetics and IC50 were calculated by non-linear regression with the 
method of least squares (GraphPad Instat, SanDiego, USA). 
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Figure 2.1. Schematic diagram of an epithelial layer grown on a Transwell filter  
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Table 2.1. Primer sequences used in standard and real-time qPCR reactions 
 
Gene F  Sequence R Sequence Product size (bp) TA(°C) 
        
 hBCRP 5`-AGCTGCAAGGAAAGATCCAA-3` 5`-TCCAGACACACCACGGATAA-3` 289 55 
mBcrp 5`-GCATTCTCTGATATGGCTTCA-3` 5`-TTAACACAAGTGCTGTTGTCCG-3` 100 56 
hMRP4 5`-CTTGGAGAGGAGTTGCAAGG-3` 5`-GCTGTGTTCAAAGCCACAGA-3` 236 57 
hPPAR γ 5`-GACCACTCCCACTCCTTTGA-3` 5`-CGACATTCAATTGCCATGAG-3` 257 55 
Ah receptor 5`-CTTCCAAGCGGCATAGAGAC-3` 5`-AGTTATCCTGGCCTCCGTTT-3` 204 56 
GAPDH PrimerDesign Ltd- sequence or product size not given   60 
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3. Functional expression of BCRP in epithelial 
cell-lines 
 
3.1 Introduction 
Since the discovery of the efflux pump BCRP, in the breast cancer cell line MCF-7 in 
1998 (Doyle et al., 1998), many cell models and techniques have been derived and 
used to model BCRP function in different tissues.  
Before ABC transporter function can be assessed in vitro the need to 
characterise the cell type being used is essential; variations in culture techniques 
between laboratories has led to differential selection of cells with differing strains 
arising between laboratories, so resulting in discrepancies in data. For example, the 
MDCK cell line which was originally derived from a kidney of a female adult cocker 
spaniel (Madin & Darby, 1972) was shown to have a characteristic low resistance 
phenotype of 100 Ω.cm2 (Cereijido et al., 1978, 1980). However, Barker and 
Simmons (1981) demonstrated that with passage two distinct strains of high and low 
resistive strains had emerged, displaying differences in size, morphology and 
expression of Na-K pumps (essentially two distinct cell types) (Barker & Simmons, 
1981). 
Caco-2 cells are known to be a heterogeneous population of cells, and it is not 
surprising to find that variant strains of Caco-2 cells have emerged over the years 
from the original cells, showing inter-laboratory variation in transporter expression 
and function (Sambuy et al., 2005). This variation highlights the need to characterize 
protein expression in Caco-2 and other epithelial studies to ensure comparability 
between laboratories.   
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In this study two Caco-2 cell-strains were used; a high-passage (PA) strain 
(115-120 passages) originating from Dr. I Hassan, described previously (Cavet et al., 
1997) and a low PA strain (passage 34-45) originating from AstraZeneca displaying 
rapid growth and higher values of transepithelial resistance (American Type Culture 
Collection, Manassas, VA, 20108, USA). Caco-2 cells were selected over T84 cells 
based on the principle they have been shown to express all three main efflux 
transporters (MDR1, MRP2 and BCRP), whilst expressing multiple nuclear receptors, 
unlike T84 cells which have been shown to not express MRP2 (Lowes & Simmons, 
2002) and BCRP (Haslam, 2007). 
The objective of the work in this chapter was to characterise native MDCKII 
cells, transfected MDCKII cells, Caco-2 cells and other epithelial cell models with 
respect to BCRP expression and function to ensure their suitability as cell models for 
the remainder of the project. In order to assess function of BCRP in the chosen 
epithelial cell lines, the fluorescent dye Hoechst 33342 was used as a substrate. 
Hoechst 33342 is a dye that is only fluorescent when bound to DNA. Cellular efflux 
of Hoechst 33342 was initially demonstrated when small populations of bone marrow 
and peripheral blood cells in mice gave a reduced staining with the dye Hoechst 
33342; these cells were then named as side population cells (Goodell et al., 1996). 
Further investigation by transfecting MDR1 into the murine bone marrow cells 
increased the number of cells with the side population cell phenotype (Bunting et al., 
1999), suggesting Hoechst 33342 to be a substrate of MDR1. However, on closer 
inspection more than just MDR1 was responsible for Hoechst 33342 efflux and the 
side population phenotype. Other studies have now shown that both human BCRP and 
murine Bcrp are responsible for the efflux of Hoechst 33342 dye and the side 
population phenotype (Kim et al., 2002; Zhou et al., 2001).  
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Hoechst 33342 is a relatively lipophilic compound displaying an octanol-water 
coefficient (LogP) of 3.1, it is likely that Hoechst 33342 will partition into the plasma 
membrane prior to entry into the cell to access  BCRP and MDR1 (Matsson et al., 
2007). This mechanism of substrate binding to BCRP from the membrane phase as 
proposed by Matsson et al. (2007), and the competition between Hoechst 33342 and 
substrate can be harnessed to identify potential BCRP substrates. In epithelial cells 
BCRP is expressed in a polarized manner within the apical plasma membrane whilst 
for bone-marrow cells and blood cells no such polarity exists. Whether Hoechst 
33342 is suitable under all conditions (density of growth, time of growth, etc…) to 
assay BCRP is unclear.  
Thus the secondary aim of this chapter is to determine whether or not the 
fluorescent Hoechst 33342 dye can be used to assess BCRP function in epithelial cells 
and furthermore whether it can be used to identify BCRP substrates. 
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3.2 Methods 
3.2.1 Deglycosylation 
Cells were cultured and grown in 75cm
2
 flasks as described in Materials and Methods 
(section 2.2.1). Extraction and treatments were done on the same day as instructed by 
the manufacturer‟s protocol from the peptide N-glycosidase F kit (PNGase F kit, New 
England Biolabs). Whole cell extracts were lysed using a buffer comprising of 1mM 
EDTA pH 8, 1mM EGTA pH 8, 640µM sucrose, 1mM Tris pH 7.6, 0.05 % Triton X-
100 and ½ a protease inhibitor tablet (Roche), made up to 5ml with distilled water. 
Cells were washed twice with 1% PBS and 1ml of lysis buffer was added to the 
75cm
2
 flask. Cells were scraped off using a rubber policeman and pippetted into a 
15ml Falcon tube. Homogenisation with a needle and syringe was followed by 
centrifugation at 10,000 x g for 10 minutes. Whole cell lysate was protein quantified 
using the Bradford Assay (Thermo). To the tube 25µg of protein lysate was added to 
2µl of denaturing buffer and made up to 20µl with distilled water. Samples were then 
vortexed and boiled at 100°C for 10 minutes. Samples were then cooled on ice for 1 
minute before adding the remaining components (4µl 10x G7 reaction buffer, 4µl 
10% NP40, 5µl PNGase F and made up to 40µl with distilled water). Finally samples 
were incubated at 37°C for 1 hour; samples were then ready for immunoblotting or 
were frozen at -20°C. 
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3.3 Results 
3.3.1 hBCRP/mBcrp mRNA expression in epithelial cell models 
Human BCRP mRNA was analysed in native and hBCRP-transfected MDCKII cells.  
Measured by real time PCR analysis and adjusted relative to GAPDH levels we found 
the results were as expected; native cells showed no human BCRP product, with 
levels no different from the negative controls (RT negative and water control). Human 
BCRP mRNA was significantly greater in the transfected MDCKII compared with the 
native cells (Figure 3.1, n = 3 extractions, P < 0.05). The other transfect looked at in 
great detail in this project was the mouse Bcrp protein, the mouse homologue to the 
human variant. Figure 3.2 shows a significantly higher concentration of murine Bcrp 
mRNA compared with the native MDCKII (n = 3 extractions, P < 0.05), which in turn 
showed levels no different to the negative controls (RT negatives and water controls).  
After confirming hBCRP/mBcrp expression in the MDCKII over-expressing cell 
lines, human intestinal Caco-2 cells were analysed to confirm BCRP expression.  
Given the heterogeneous nature of Caco-2 cells and the reported variation of BCRP 
expression it is unsurprising that differences exist between cell strains arising from 
different laboratories. This study used two Caco-2 cell strains (high and low passage 
strains derived from two laboratories, see Materials and Methods). The BCRP levels 
established by real time PCR (Figure 3.1) showed a dramatic and significant 
difference in BCRP expression between the two strains of Caco-2 cell (n = 3 
extractions, P < 0.05). The high passage Caco-2 cell line showing no significant 
difference in BCRP expression compared with the negative controls (RT negatives 
and water controls). Whilst BCRP was readily detected in the lower passage Caco-2 
cells that was significantly elevated compared with negative controls (n = 3 
extractions, P < 0.05). The high PA Caco-2 cells expressed little to no BCRP mRNA. 
76 
 
The human small intestine has been shown to express BCRP mRNA (Englund et al., 
2006; Gutmann et al., 2005; Maliepaard et al., 2001), thus high PA Caco-2 are an 
inappropriate model for studying BCRP activity alone, however they could be used as 
a negative control for BCRP expression. In contrast, the low PA Caco-2 cells, 
although the BCRP mRNA was not quantified and cannot be compared directly with 
human intestinal tissue, show a greater BCRP mRNA expression and looked to be a 
more suitable cell line for studying intestinal BCRP activity.  
 
3.3.2. BCRP/Bcrp protein expression in epithelial cell models 
Using antibodies against an internal epitope of hBCRP/mBcrp protein (residues 221-
394 of mouse protein); expression was investigated by immunoblotting and 
immunocytochemistry. Initially BXP-53 (Santa Cruz) which is a rat-monoclonal anti 
hBCRP/mBcrp antibody was utilised for immunocytochemistry to detect both human 
and mouse proteins. This antibody was effective for immunohistochemistry of 
hBCRP/mBcrp but was unable to identify BCRP in Caco-2 cells by immunoblot. 
BXP-9 which is a rat-monoclonal anti mouse antibody raised against the same epitope 
as BXP-53 was found to be more effective at detecting both mouse and human 
BCRP/Bcrp in immunoblotting compared to BXP-53 and was used instead. Figure 3.3 
shows that no BCRP band at 72kDa was visible in the native MDCKII cells but a 
strongly defined band was seen in the human BCRP transfected MDCKII cells at 
10μg of protein loaded at 72kDa (n = 3 extractions), with a possible band at lower 
molecular size. A less intense band was seen at approximately 100kDa. For mBcrp1-
MDCKII cells protein loading was reduced (shown with the reduced α-tublin band) 
together with that of the antibody concentration from 1:50 to 1:500. The band 
recognised for mBcrp1-MDCKII had an apparent molecular size of approximately 
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100kDa not 72kD (Figure 3.3.C). Treatment with the deglycosylating enzyme 
PNGase F reduced the mBcrp apparent molecular size from approximately 100kDa to 
the expected molecular size of the core mouse Bcrp protein of 72kDa (Figure 3.4). 
This suggests that the mouse and human proteins are subject to different patterns of 
glycosylation when expressed in MDCKII cells. According to the literature there are 
three predicted putative N-linked glycosylation sites at Asn418, Asn557 and Asn596 
of human BCRP (Allen & Schinkel, 2002; Mao & Unadkat, 2005), whilst Diop et al. 
(2005) further showed that only Asn 596 is subject to N-linked glycosylation (Diop & 
Hrycyna, 2005). For mouse Bcrp, two predicted sites for N-glycosylation exist: 
Asn596 and Asn600 (Allen & Schinkel, 2002). N-glycosylation prediction software 
(ExPAsy) shows the predicted sites for human BCRP and mouse Bcrp N-
glycosylation below. 
Predicted N-glycosylation sites on the amino acid sequence of human BCRP and mouse Bcrp 
(ExPAsy software)  
N-linked 
glycosylation
hBCRP mBcrp
Position Potential Position Potential
338 NSSF 0.5136 316 NKTE 0.5413
418 NDST 0.3618 331 NLSE 0.6974
557 NLTT 0.6748 596 NVTD 0.5798
596 NATG 0.4693 600 NSTC 0.6029
 
The human BCRP has predicted sites of N-linked glycosylation at positions 418, 557 
and 596 (Asn338 is intracellular and is unlikely to be N-glycosylated); these data 
taken with what is known in the literature shows that Asn596 is likely to be the only 
N-linked amino acid on the human BCRP sequence. Mouse predictions highlight 
Asn596 and Asn600 as N-linked glycosylation sites. Asparagines in positions 316 and 
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331 are located intracellularly and are unlikely to be glycosylated. Thus two closely 
spaced N-linked glycosylation sites are present on the mouse Bcrp sequence, therefore 
this predictive data taken with the immunoblotting shows that a greater degree of 
glycosylation occurs in the mouse protein expressed in MDCKII cells. It is not known 
whether N-glycosylation of hBCRP\mBcrp affects expression or function (Diop & 
Hrycyna, 2005) but it is possible it may affect substrate binding. 
 In agreement with BCRP mRNA expression, in the two Caco-2 cell strains no 
BCRP protein was detectable in the high passage Caco-2 cells but a band of the 
apparent correct molecular size for BCRP of ~72kDa was detected in the lower 
passage Caco-2 cells (Figure 3.3). As expected the expression of BCRP protein was 
found to be much lower in the Caco-2 cells compared with that of the over-expressing 
hBCRP-MDCKII cell line (although not quantified, it is clearly shown in Figure 3.3). 
Note that the hBCRP-MDCKII cells were loaded at 10μg whilst the Caco-2 cells at 
40μg (shown visually by the band intensity of α-tubulin). Taken together this result 
suggests that native hBCRP expressed in Caco-2 cells is not subject to N-
glycosylation. 
 Finally BCRP protein expression at the cell surface was investigated with 
immunocytochemistry using 2° immunofluorescence with BXP-53 as the primary 
antibody (Figure 3.5), whilst cell nuclei were stained with propidium iodide (red). No 
hBCRP/mBcrp immunofluorescence was seen on either XY or XZ sections of native 
MDCKII cells. In positions 221-394 of the BCRP protein sequence only 15/173 
amino acids are not conserved between dog and the human/mouse protein epitopes 
(shown below). As this is a small difference it would be expected the antibody would 
detect dog BCRP. It is likely, as no staining is seen, that no dog endogenous BCRP is 
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expressed in native MDCKII cells. A similar argument applies to the immunoblots 
with BXP-53 (above). 
 The MDCKII cells transfected with human BCRP show strong BCRP 
immunofluorescence localized to the apical cell surface of MDCKII cells (shown on 
XY and XZ sections Figure 3.5). MDCKII cells transfected with mouse Bcrp cDNA 
also show localisation of mouse Bcrp to the apical surface of these epithelial cells 
(shown on XY and XZ sections, Figure 3.5). Caco-2 cell immunocytochemistry with 
BXP-53 was unsuccessful, but was shown with the human BCRP specific antibody 
BXP-21 in the low passage Caco-2 cells (Figure 3.6). 
 
The BCRP protein sequence (positions 221-394) showing sequence homology between (A) 
Mouse/Dog and (B) Mouse/Human/Dog 
 
(A) Epitope area: Mouse/Dog  
 
ANAVLLLLKRMSKQGRTIIFSIHQPRYSIFKLFDSLTLLASGKLVFHGPAQKALEYFASA 59  Mouse            
ANAVLLLLKRMSEQGRTIIFSIHQPRYSIFKLFDSLTLLAAGKLMFHGPAQEALGFFASV 60  Dog 
                 
***********:***************************:***:******:** :***. 
 
           
GYHCEPYNNPADFFLDVINGDSSAVMLNREEQDNEANKTEEPSKGEKPVIENLSEFYINS 119 Mouse            
GYHCEPYNNPADFFLDVINGDSSAVVLNREDQEGEVKVTEEPSKRGTPFIERIAEFYANS 120 Dog 
*************************:****:*:.*.: ******  .*.**.::*** ** 
 
          
AIYGETKAELDQLPGAQEKKGTSAFKEPVYVTSFCHQLRWIARRSFKNLLGNPQASVAQL 178 Mouse            
DFCRKTKEELDQLSKSQKRK-SSAFKEITYATSFCQQLKWISKRSFKNLLGNPQASIAQI 179 Dog 
 :  :** *****. :*::* :***** .*.****:**:**::*************:**: 
 
IVTVI 184 Mouse 
IVTVI 184 Dog 
***** 
 
 
42/184 dissimilar 142/184 identical 
 
 
(B) Epitope area: Mouse/Human/Dog 
 
          
ANAVLLLLKRMSKQGRTIIFSIHQPRYSIFKLFDSLTLLASGKLVFHGPAQKALEYFASA 59 Mouse          
ANAVLLLLKRMSKQGRTIIFSIHQPRYSIFKLFDSLTLLASGRLMFHGPAQEALGYFESA 60 Human            
ANAVLLLLKRMSEQGRTIIFSIHQPRYSIFKLFDSLTLLAAGKLMFHGPAQEALGFFASV 60 Dog 
                 
***********:***************************:*:*:******:** :* *. 
 
GYHCEPYNNPADFFLDVINGDSSAVMLNREEQDNEANKTEEPSKGEKPVIENLSEFYINS 119 Mouse 
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GYHCEAYNNPADFFLDIINGDSTAVALNREE-DFKATEIIEPSKQDKPLIEKLAEIYVNS 119 Human            
GYHCEPYNNPADFFLDVINGDSSAVVLNREDQEGEVKVTEEPSKRGTPFIERIAEFYANS 120 Dog 
*****.**********:*****:** ****: : :..   ****  .*.**.::*:* ** 
 
           
AIYGETKAELDQLPGAQEKKGTSAFKEPVYVTSFCHQLRWIARRSFKNLLGNPQASVAQL 179 Mouse          
SFYKETKAELHQLSGGEKKKKITVFKEISYTTSFCHQLRWVSKRSFKNLLGNPQASIAQI 179 Human 
DFCRKTKEELDQLSKSQKRK-SSAFKEITYATSFCQQLKWISKRSFKNLLGNPQASIAQI 179 Dog 
 :  :** **.**. .:::*  :.***  *.****:**:*:::*************:**: 
 
IVTVI 184 Mouse 
IVTVV 184 Human 
IVTVI 184 Dog 
****: 
 
 
62/184 dissimilar 122/184 identical 
 
3.3.3 Cellular retention of Hoechst 33342 dye: an assay to assess 
hBCRP/mBcrp function 
 
The Hoechst 33342 retention assay, as fully described in the Materials and Methods, 
involved an incubation step without Hoechst 33342 in the presence and absence of a 
pharmacological inhibitor. This step was followed by incubation with Hoechst 33342 
also when appropriate plus inhibitor. During this incubation Hoechst 33342 dye 
permeates into the cell and binds to DNA whilst the remaining dye is removed from 
the cells by the efflux transporters BCRP and MDR1. Only DNA-bound Hoechst 
33342 shows fluorescence when excited at 350nm. Since both BCRP and MDR1 may 
transport Hoechst 33342 it was first necessary to optimise the uptake/retention assay.  
Figure 3.7 shows the effect of increasing exposure time to Hoechst 33342 in MDCKII 
cells on dye retention. In controls, increasing incubation time increases Hoechst 
33342 cellular retention in a non-linear fashion, the initial rate declines as incubation 
time increases. This may indicate both attainment of a steady state and saturation of 
nuclear binding sites. The presence of the ABC transporter inhibitor CsA increases 
cellular Hoechst 33342 at all time points. After prolonged incubation times it is 
predicted that curves representing Hoechst 33342 in the presence and absence of CsA 
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would converge as Hoechst 33342 is bound on all available DNA sites. CsA would 
increase the rate at which this equilibrium is attained. 
 Figure 3.8 shows how increasing the seeding density can affect cellular 
Hoechst 33342 retention. At lower cell numbers the difference in the presence and 
absence of CsA was not very apparent; for example at 5 x 10
3
 cells per well there was 
only a 6% difference between CsA and non CsA control. However, with higher cell 
densities, this difference was more marked; at the higher seeding density of 5 x 10
4
 
cells per well the difference went up to 45% in the presence of CsA compared to the 
control. An increase in cellular accumulation of Hoechst 33342 was to be expected as 
nuclear DNA increases. However, there was an apparent saturation with higher 
seeding density. This is most likely due to monolayer formation resulting in decreased 
access of dye from the basolateral surfaces, Hoechst 33342 moving into the cell via 
the apical membrane only. High cell densities were therefore preferable to optimize 
the effects of inhibition. 
 Figure 3.9 shows that with increasing Hoechst 33342 bathing concentration in 
native MDCKII the retention of Hoechst 33342 increases. At all Hoechst 33342 
concentrations there was a significant increase in accumulation in the presence of 
10μM CsA (n = 4 wells per point, P < 0.05). Subtracting control data from that in the 
presence of CsA gives an apparent saturation curve for the CsA-sensitive component 
(Figure 3.9B); the apparent Km was 0.3 ± 0.2 µM for Hoechst 33342. The effect of 
increasing Hoechst 33342 dose in the native cells was also compared to the human 
BCRP transfected MDCKII cells (Figure. 3.10). The presence of human BCRP 
significantly reduces the cellular accumulation of Hoechst 33342 dye compared to 
native MDCKII at all Hoechst 33342 concentrations (n = 4 wells per point, P < 0.05).  
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 Subtraction of the Hoechst 33342 accumulation from that seen in native cells 
allows the BCRP-dependent component to be plotted (Figure 3.10B). This component 
shows saturation with an apparent Km of 10.3 ± 2.6 µM, this value being substantially 
greater than the value in the native MDCKII cells (0.3 ± 0.2 µM). The apparent 
difference in Km between native and BCRP transfected MDCKII demonstrates that 
Hoechst 33342 interacts with transfected BCRP with a lower affinity compared to the 
native ABC transporter in MDCKII cells. Due to the observed saturation with 
Hoechst 33342, subsequent experiments used a Hoechst 33342 concentration lower 
than the Km value (3µM Hoechst 33342 was used). 
 The dose effect of pharmacological inhibitors was assessed in the BCRP 
transfected MDCKII cells.  Ko143 (Allen et al., 2002) is a known potent 
hBCRP/mBcrp inhibitor; Figure 3.11A shows that Ko143 increased Hoechst 33342 
accumulation in a saturable manner, with an IC50 value of 1.06 ± 1.58 µM. 
Cyclosporin A (CsA) also increased Hoechst 33342 accumulation, but with an IC50 of 
1.17 ± 1.12 µM (Figure 3.11B). Cyclosporin A is a known MDR1 substrate and 
inhibitor but also a BCRP inhibitor at higher concentrations (Ejendal & Hrycyna, 
2005; Xia et al., 2007a). The increase in Hoechst 33342 observed is therefore a 
mixture of inhibition of a native ABC-transporter and BCRP. For these reasons a low 
concentration of CsA (1μM) was used to selectively inhibit MDR1 in other 
experiments. 
 Interestingly Ko143 was more effective in the mouse Bcrp1-MDCKII cells 
than the human BCRP-MDCKII cells (Figure 3.11C), increasing Hoechst 33342  dye 
retention with an IC50 value of 0.15 ± 0.06 µM, a sub micro molar value similar to 
that previously reported (Allen et al., 2002).  
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 Hoechst 33342 accumulation was then used to assess the functional 
differences between ABC transporter expression in the different MDCKII cell models 
and Caco-2 cells (Figure 3.12). In native MDCKII cells Hoechst 33342 retention was 
significantly increased by 1µM CsA (Figure 3.12A), by 3.1 fold. In contrast no effect 
was seen with 0.8µM Ko143 treatment. This is consistent with MDR1-like native 
ABC expression and the absence of BCRP in MDCKII cells. The human BCRP 
transfected MDCKII cells gave a completely different pattern; unlike the native 
MDCKII cells no significant effect of CsA was seen in the hBCRP-MDCKII cells 
whilst Ko143 had a dramatic effect increasing Hoechst 33342 retention by 4.3 fold 
(Figure 3.12B). This shows that human BCRP is functional in the hBCRP-MDCKII 
cells and though CsA is effective at inhibition of the native ABC transporter, hBCRP 
action compensates for its loss. Clearly CsA does not inhibit BCRP at 1µM. The same 
pattern was seen in the murine Bcrp1-MDCKII with no effect of CsA but an even 
greater increase in Hoechst 33342 retention to 5.5 fold with Ko143 (Figure 3.12C). 
For MDR1-MDCKII cells, a 3.4 fold increase in Hoechst 33342 retention was seen 
with CsA compared with the 3.1 fold increase seen in the native cells (Figure 3.12D). 
Ko143 had no effect in the MDR1-MDCKII cells confirming that Ko143 (1μM) had 
no effect on MDR1 in this assay. 
 The two Caco-2 cell strains were also characterised using the Hoechst 33342 
retention assay. Figure 3.12E shows a significant effect of 1µM CsA on Hoechst 
33342 retention, increasing Hoechst 33342 fluorescence by 2.8 fold, consistent with 
an MDR1 component in the high passage Caco-2 cell strain. The absence of Ko143 
action on Hoechst 33342 retention shows that there is no functional BCRP activity in 
the high passage Caco-2 cells. The low passage Caco-2 cell strain shown in Figure 
3.12F whilst showing a 2.3 fold increase in fluorescence with CsA, showed a 2.52 
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fold increase in fluorescence with the selective BCRP agent Ko143. This is consistent 
with both functional MDR1 and BCRP expression responsible for Hoechst 33342 
transport in the low passage Caco-2 cell strain. 
 Other epithelial cell culture models were characterised using the Hoechst 
33342 retention assay to identify cell-lines showing an hBCRP/mBcrp functional 
component. Figure 3.13A shows a significant 2.6 fold increase in Hoechst 33342 
retention with 1μM CsA in the mouse cortical collecting duct principal cell line 
(mpkCCDc14). A significant 2.3 fold increase in fluorescence with 1μM Ko143 
demonstrated a BCRP mediated transport of Hoechst 33342. The mouse distal 
convoluted tubule cells (mpkDCT) gave a similar pattern of fluorescence retention to 
that observed with the mpkCCDc14 cells, showing a 1.6 and 1.9 fold increase in 
fluorescence with CsA and Ko143 respectively. Finally, the human breast cancer cell 
line MCF-10a, showed a 1.6 and 1.4 fold increase in fluorescence with CsA and 
Ko143 respectively, again confirming that this cell model could be utilised to further 
our understanding of BCRP in different tissue types. The MCF cell lines exposed to 
cytotoxics, such as MTX, have been shown previously to hyper-express BCRP 
(Robey et al., 2001). 
3.3.4 Screening for BCRP substrates using Hoechst 33342 in 
MDCKII cells 
 
The utility of the Hoechst 33342 retention assay with a high throughput 96-well 
format was tested to identify substrates or inhibitors of BCRP. In addition, data were 
compared to native cells and to MDR1-MDCKII cells to identify interaction with the 
ABC transporter native to MDCKII cells and to identify potential bi-substrates of 
BCRP/MDR1. All MDCKII cell lines were screened with the same compounds, 
shown in Table 3.1.  
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 In the native MDCKII cells several compounds increased Hoechst 33342 
retention (Figure 3.14A). 1μM Ko143 had no significant effect on accumulation as 
noted above, however with an increased concentration of 10µM Ko143 a significant  
increase in Hoechst 33342 retention of 1.36 fold from the control MDCKII cells was 
observed (n = 8 wells, P < 0.05). Significant changes were also seen with 
nitrofurantoin, novobiocin, prazosin, quinidine, risperidone and verapamil. These 
changes indicate that these compounds are acting as either competitive substrates or 
non-competitive inhibitors of an endogenous component in native MDCKII cells.  
 The human BCRP-MDCKII cells showed a more profound effect with the 
different compounds (Figure 3.14B). All compounds had a significant effect of 
increasing fluorescence apart from 10μM nitrofurantoin and 10μM risperidone (n = 8 
wells, P < 0.05). The anti-psychotic drug risperidone has been shown to be a BCRP 
inhibitor with an IC50 of 38.1µM in the BCRP over-expressing MCF-7 cell line 
(Wang et al., 2008b), yet no significant inhibition was seen in this study. This result 
most likely reflects the multiple binding sites on BCRP whereby substrate access may 
be via the membrane or from the aqueous cytoplasm (Giri et al., 2009); see 
Discussion. The greatest change in Hoechst 33342 retention was with Ko143, 
increasing retention by a 2.51 and 3.84 fold with a 1µM and 10µM dose respectively 
(Table 3.1).  
 For the mouse Bcrp1-MDCKII only Ko143, risperidone and verapamil 
increased Hoechst 33342 retention (Figure 3.14C). Ko143 increased fluorescence by 
2.79 and 3.35 fold with a 1µM and 10µM concentration respectively, whilst 10µM 
risperidone and 100µM verapamil increased arbitrary fluorescence by 1.34 and 1.66 
fold respectively (Table 3.1).  
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 In contrast to hBCRP and mBcrp1-MDCKII cells Figure 3.13D shows the 
MDR1-MDCKII cells did not show an increase in Hoechst 33342 retention with 1µM 
Ko143. However with 10µM Ko143 fluorescence was significantly increased from 
4.7 ± 0.07 to 7.27 ± 0.15 arbitrary units, a 1.54 fold increase (Table 3.1, n = 8 wells, P 
< 0.05). This data shows Ko143 used at 10µM concentration has an unspecific but 
minor inhibitory effect on MDR1. However, comparing data between cell lines (Table 
3.1), it can be seen that 10μM Ko143 had only a marginal effect in the MDR1-
MDCKII cells when compared to the increase seen in the human BCRP-MDCKII 
cells, indicating that even at 10µM Ko143 this agent is more selective to BCRP. 
Prazosin is a known MDR1 (Feng et al., 2008; Polli et al., 2001; Zhou et al., 2009) 
substrate and has a significant effect on increasing Hoechst 33342 retention (Figure 
3.14, n = 8 wells, P < 0.05). The known MDR1 substrate quinidine (Feng et al., 2008; 
Polli et al., 2001) dramatically increased fluorescence 2.46 fold from control values 
(Table 3.1). Risperidone has been shown to be a substrate of MDR1 (Feng et al., 
2008) and significantly increased fluorescence in this study (Figure 3.14, n = 8 wells, 
P < 0.05). However the greatest effect came from 100µM verapamil which increased 
fluorescence from 4.7 ± 0.07 to 12.91 ± 0.39 arbitrary units, a 2.74 fold increase 
(Table 3.1, n = 8 wells, P < 0.05). The effect of verapamil on human BCRP and 
mouse Bcrp at 100µM was minor compared to the dramatic effect seen in the MDR1-
MDCKII. Verapamil is therefore selective for MDR1.   
 In summary, known inhibitors of BCRP (eg. Ko143) and MDR1 (quinidine 
and verapamil) can be differentiated by the Hoechst 33342 retention assay. However 
limitations relate to the relative affinity of competitive inhibitors with relation to 
Hoechst 33342 affinity and to the presence of an endogenous ABC transporter in 
MDCKII cells. 
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Figure 3.1. Expression of hBCRP mRNA in MDCKII and Caco-2 cells 
 
(A)  An agarose gel image showing PCR product of BCRP mRNA from hBCRP-
MDCKII. Lane 1 shows the expected product size of approximately 289 base 
pairs for the reverse transcriptase positive sample, whilst lane 2 confirms no 
product in the reverse transcriptase negative sample. PCR product was 
confirmed by nucleotide sequencing by comparing to the published sequenced, 
giving 99% identity (see Materials and Methods section 2.2.3.4).  
 
(B)  Real time PCR analysis indicating expression of hBCRP mRNA in native 
MDCKII and human transfected BCRP-MDCKII. Data bars are adjusted 
relative to GAPDH expression. Quantification was performed using the Pfaffl 
method (bars represent mean of n = 3 extractions ± SD). Significant difference 
in hBCRP mRNA expression between native MDCKII and hBCRP-MDCKII 
cells denoted by * P < 0.05.   
 
(C)  Real time PCR analysis indicating expression of hBCRP mRNA in Caco-2 
epithelia. Data bars are adjusted relative to GAPDH expression. Quantification 
was done via the Pfaffl method (bars represent mean of n = 3 extractions, ± 
SD). Significant difference in hBCRP mRNA expression between low and 
high passage Caco-2 cells denoted by * P < 0.05.   
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Figure 3.1. Expression of hBCRP mRNA in MDCKII and Caco-2 cells 
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Figure 3.2. Expression of mouse Bcrp mRNA in transfected MDCKII cells 
 
(A)  An agarose gel image showing PCR products from mBcrp1-MDCKII. Lane 1 
shows the expected product size of approximately 100 base pairs for the 
reverse transcriptase positive sample, whilst lane 2 confirms no product in the 
reverse transcriptase negative sample. PCR product was confirmed by 
nucleotide sequencing by comparing to the published sequenced, giving 97% 
identity (see Materials and Methods section 2.2.3.4). 
 
(B)  Real time PCR analysis indicating expression of mBcrp mRNA in native and 
transfected MDCKII cells relative to GAPDH. Data bars are adjusted relative 
to GAPDH expression. Quantification was performed using the Pfaffl method 
(bars represent mean of n = 3 extractions, ± SD). Significant difference in 
mBcrp mRNA expression between native MDCKII and mBcrp-MDCKII cells 
denoted by * P < 0.05.   
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Figure 3.2. Expression of mouse Bcrp mRNA in transfected MDCKII cells 
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Figure 3.3. Western Blot analysis of BCRP protein expression in epithelial cell 
models  
 
Images (A) and (B) show BCRP protein and α-tubulin expression respectively. 
Lane 1 is native MDCKII cell protein (10µg loaded), lane 2 is human BCRP-
MDCKII cell protein (10µg loaded), lane 3 is mouse Bcrp1-MDCKII cell 
protein (5µg loaded), lane 4 is low PA Caco-2 cell protein (40µg loaded) and 
lane 5 is high PA Caco-2 cell protein (40µg loaded).  
 
(A) Membrane was probed initially with rat-monoclonal anti-mouse Bcrp antibody 
BXP-9 (Kamiya) at a dilution of 1 in 50 for (samples 1, 2, 4 and 5), whilst the 
dilution of 1 in 500 was used for sample 3. This image is representative of one 
gel and shows were the membrane was cut and treated separately (lane 3). 
BCRP yields bands at approximately 72kDa and 100kDa.  
 
(B)  Image shows the membrane from part A stripped and re-probed with a cross 
species polyclonal anti-α-tubulin antibody (Abcam). The α-tubulin band was 
visible at approximately 50kDa.  
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Figure 3.4. Western Blot analysis of deglycosylated mouse Bcrp protein  
Mouse Bcrp is predicted to be glycosylated at two sites within close proximity 
(Asn596 and Asn600). This image shows (A) Mouse Bcrp1-MDCKII protein lysate 
treated with the deglycosylating enzyme PNGase F (5µg protein loaded) and (B) 
Untreated mBcrp1-MDCKII cells (5µg protein loaded). Gel was probed initially with 
rat-monoclonal anti-mouse Bcrp antibody BXP-9 (Kamiya) at a dilution of 1 in 500. 
PNGase F treated mBcrp1-MDCKII yields a band of smaller molecular weight 
(approximately 72kDa) compared with the untreated sample (approximately 
100KDa). This Western blot image shown is one gel.  
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Figure 3.4. Western Blot analysis of deglycosylated mouse Bcrp protein 
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Figure 3.5. Immunocytochemical detection of BCRP in (A) Native MDCKII, (B) 
hBCRP-MDCKII and (C) mBcrp1-MDCKII epithelial cell monolayers 
 
Images (A), (B) and (C) display indirect fluorescence staining of (A) Native MDCKII, 
(B) hBCRP-MDCKII and (C) mBcrp1-MDCKII epithelial cell monolayers with the 
rat monoclonal primary (1°) antibody BXP-53 directed against human/mouse BCRP 
(shown in green). Cell nuclei were counterstained with propidium iodide (shown in 
red). No positive staining with the BXP 53 1° is shown for native MDCKII (A), 
whilst positive staining with the BXP 53 1° is shown for hBCRP-MDCKII (B) and 
mBcrp1-MDCKII (C). Negative controls (no BXP 53 1°) are shown alongside the 
positive staining for native MDCKII (A), hBCRP-MDCKII (B) and mBcrp1-MDCKII 
(C). Images were viewed using confocal laser scanning microscopy. XY sections 
were imaged at the apical pole of the cell, XZ images confirm the apical expression 
(XZ-B1C). Scale bars = 20µm.  
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Figure 3.6. Immunocytochemical detection of BCRP in low passage Caco-2 
epithelial cell monolayers 
 
Images display indirect fluorescence staining of the low passage (PA) Caco-2 
epithelial cell monolayers with the mouse monoclonal primary (1°) antibody BXP-21 
directed against human BCRP (shown in green). Cell nuclei were counterstained with 
propidium iodide (shown in red). Negative controls (no BXP 21 1°) are displayed 
alongside the positive staining for XY and XZ sections. Images were viewed using 
confocal laser scanning microscopy. XY sections were imaged at the apical pole of 
the cell. XZ images confirm the apical expression (XZ-B1C). Scale bars = 20µm.  
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Figure 3.6. Immunocytochemical detection of BCRP in low passage Caco-2 
epithelial cell monolayers 
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Figure 3.7. Effect of incubation time on Hoechst 33342 dye retention in native 
MDCKII cells 
 
Effect of incubation time (0 to 90 minutes) on Hoechst 33342 retention in native 
MDCKII cells ± Cyclosporin A (10µM). Cells were incubated in 3µM Hoechst. Data 
points are means of n = 7 wells, ± SEM. * P < 0.05, are significantly different from 
control values.  
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Figure 3.8. Effect of seeding density on Hoechst 33342 dye retention in native 
MDCKII cells 
 
Effect of seeding density on Hoechst 33342 retention in MDCKII cells ± Cyclosporin 
A (10µM). Cells were incubated in 3µM Hoechst. Data points are means of n = 4 
wells, ± SEM. * P < 0.05, are significantly different from control values.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
102 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.8. Effect of seeding density on Hoechst 33342 dye retention in native 
MDCKII cells 
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Figure 3.9. Effect of increasing extracellular Hoechst 33342 on cellular dye 
retention in native MDCKII cells 
 
(A)  Effect of increasing extracellular Hoechst 33342 dye on cellular retention in 
native MDCKII ± Cyclosporin A (10µM). Circles = control MDCKII cells and 
filled squares = CsA treated MDCKII cells. Solid lines represent Michaelis-
Menten fit of the data. Native control; Km = 35.5 ± 5.4 µM, Vmax = 890 ± 85.1 
(arb. units) and R
2 
= 0.98. CsA treated MDCKII; Km = 5.7 ± 0.9 µM, Vmax = 
664.5 ± 33.6 (arb. units) and R
2 
= 0.97. Data points are means of n = 4 wells, ± 
SEM. 
 
(B)  CsA sensitive component of Hoechst 33342 fluorescence with increasing 
concentration. Solid lines represent Michaelis-Menten fit of the data; Km = 0.3 
± 0.2 µM, Vmax = 198.4 ± 12.8 (arb. units) and R
2 
= 0.84. Data points are 
means of n = 4 wells, ± SEM.  
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Figure 3.9. Effect of increasing extracellular Hoechst 33342 on cellular dye 
retention in native MDCKII cells 
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Figure 3.10. Relationship between Hoeschst 33342 concentration and 
intracellular Hoeschst 33342 accumulation in human BCRP-transfected 
MDCKII cells 
 
(A) Effect of increasing extracellular Hoechst 33342 dye on cellular retention in 
native MDCKII and human transfected MDCKII cells. Solid lines represent 
Michaelis-Menten fit of the data. Data points are means of n = 4 wells, ± 
SEM. 
 
(B) Effect of transfection of human BCRP protein in MDCKII cells on Hoechst 
33342 dye retention with increasing extracellular Hoechst 33342 
concentration. Data points were deduced from subtracting hBCRP-MDCKII 
Hoechst 33342 retention from native MDCKII values. Solid line represent 
Michaelis-Menten fit of the data; Km =10.3 ± 2.6µM, Vmax = 962.9 ± 92 (arb. 
units) and R
2 
= 0.85. Data points are means of n = 4 wells, ± SEM.  
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Figure 3.10. Relationship between Hoeschst 33342 concentration and 
intracellular Hoeschst 33342 accumulation in human BCRP-transfected 
MDCKII cells 
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Figure 3.11. Concentration dependent effect of known ABC transporter 
inhibitors on cellular Hoechst 33342 dye retention in transfected MDCKII cells 
 
(A) Effect of increasing extracellular Ko143 on cellular Hoechst 33342 dye 
accumulation in human BCRP transfected MDCKII cells. Cells were 
incubated in 3µM Hoechst. Solid lines represent best-fit lines for Michaelis-
Menten kinetics. Data points are means of n = 6 wells, ± SEM. IC50 = 1.06 ± 
1.58 µM. 
 
(B) Effect of increasing extracellular CsA on cellular Hoechst 33342 dye 
accumulation in human BCRP transfected MDCKII cells. Cells were 
incubated in 3µM Hoechst. Solid lines represent best-fit lines for Michaelis-
Menten kinetics. Data points are means of n = 6 wells, ± SEM. IC50 = 1.17 ± 
1.12 µM. 
 
(C) Effect of increasing extracellular Ko143 on cellular Hoechst 33342 dye 
accumulation in mouse Bcrp transfected MDCKII cells. Cells were incubated 
in 3µM Hoechst. Solid lines represent best-fit lines for Michaelis-Menten 
kinetics. Data points are means of n = 6 wells, ± SEM. IC50 = 0.15 ± 0.06 µM. 
 
 
 
108 
 
2.5 5.0 7.5 10.0
-50
0
50
100
50 100
[Ko143] (M)F
lu
o
re
s
c
e
n
c
e
 (
E
M
4
8
0
)
 A
rb
it
ra
ry
 U
n
it
s
0.00 0.25 0.50 0.75 1.00
0
50
100
150
[Ko143] (M)
F
lu
o
re
s
c
e
n
c
e
 (
E
m
4
8
0
)
 A
rb
it
ra
ry
 U
n
it
s
0.0 2.5 5.0 7.5 10.0
0
20
40
60
80
50 100
[CsA] (M)
F
lu
o
re
s
c
e
n
c
e
 (
E
M
4
8
0
)
 A
rb
it
ra
ry
 U
n
it
s
B
C
A
 
 
 
 
 
 
 
 
 
Figure 3.11. Concentration dependent effect of known ABC transporter 
inhibitors on cellular Hoechst 33342 dye retention in transfected MDCKII cells 
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Figure 3.12. Assessment of functional ABC-transporter activity in MDCKII and 
Caco-2 cell-lines using Hoechst 33342 dye retention  
 
Figures (A)-(F) display Hoechst 33342 retention in (A) native MDCKII, (B) human 
BCRP-MDCKII, (C) mouse Bcrp1-MDCKII, (D) MDR1-MDCKII, (E) high PA 
Caco-2 and (F) low PA Caco-2 cell strains. Hoechst 33342 retention was assessed in 
the presence or absence of 1µM CsA (cross-hatched bars), 0.8µM Ko143 (black solid 
bars) and control bars (unfilled bars). Data bars are means of n = 12 wells, data pooled 
and normalised from 3 independent experiments ± SEM. * P < 0.05, are significantly 
different from control values. 
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Figure 3.12. Assessment of functional ABC-transporter activity in MDCKII and 
Caco-2 cell-lines using Hoechst 33342 dye retention  
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Figure 3.13. Assessment of functional ABC-transporter activity in diverse cell-
lines using Hoechst 33342 dye retention  
 
Figures (A)-(C) display Hoechst 33342 retention in (A) MPK CCD, (B) MPK DCT 
and (C) MCF-10 cells. Hoechst retention was assessed in the presence or absence of 
1µM CsA (cross-hatched bars) and 1µM Ko143 (black solid bars), control bars 
(unfilled bars). Data bars are means of n = 12 wells, data pooled and normalised from 
3 independent experiments ± SEM. * P < 0.05, are significantly different from control 
values.  
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Figure 3.13. Assessment of functional ABC-transporter activity in diverse cell-
lines using Hoechst 33342 dye retention  
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Figure 3.14. Identification of potential BCRP substrates using Hoechst 33342 
across A) native MDCKII, B) hBCRP-MDCKII, C) mBcrp1-MDCKII and D) 
MDR1-MDCKII cells  
 
Figure shows the effect of selected compounds on Hoechst 33342 retention in 96-well 
plates of (A) MDCKII cells, (B) hBCRP-MDCKII cells, (C) mBcrp1-MDCKII and 
(D) MDR1-MDCKII cells. All compounds were used at 10µM, Ko143 was used at 
both 1 and 10µM and verapamil at 100µM. Hoechst 33342 was used at 3µM. Data 
bars are means of n = 8 wells, data are representative of 2 individual experiments ± 
SEM. * P < 0.05, are significantly different from control (DMSO) values.  
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Figure 3.14. Identification of potential BCRP substrates using Hoechst 33342 
across A) native MDCKII, B) hBCRP-MDCKII, C) mBcrp1-MDCKII and D) 
MDR1-MDCKII cells  
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Table 3.1. Identification of potential BCRP substrates using Hoechst 33342 
retention in  (A) MDCKII cells, (B) hBCRP-MDCKII cells, (C) mBcrp1-
MDCKII and (D) MDR1-MDCKII  
 
Figure shows the effect of select compounds on Hoechst 33342 retention in 96-well 
plates of (A) MDCKII cells, (B) hBCRP-MDCKII cells, (C) mBcrp1-MDCKII and 
(D) MDR1-MDCKII cells. All compounds were used at 10µM, Ko143 was used at 
both 1 and 10µM and verapamil at 100µM. Hoechst 33342 was used at 3µM. Data 
bars are means of n = 8 wells, data are representative of 2 individual experiments ± 
SEM. * P < 0.05, are significantly different from native MDCKII values.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Native MDCKII hBCRP-MDCKII mBcrp1-MDCKII MDR1-MDCKII
DMSO 4.41 ± 0.44 3.83 ± 0.13* 2.72 ± 0.07* 4.7 ± 0.07
Cimetidine 5.03 ± 0.2 4.79 ± 0.21 2.99 ± 0.08* 4.99 ± 0.09
Diclofenac 5.21 ± 0.09 5.1 ± 0.1 2.82 ± 0.1* 4.67 ± 0.06*
Flavopiridol 5.37 ± 0.11 6.34 ± 0.2* 2.99 ± 0.1* 4.79 ± 0.09*
1µM Ko143 5.4 ± 0.35 9.63 ± 0.29* 7.16 ± 0.21* 4.79 ± 0.16
10µM Ko143 5.99 ± 0.07 14.72 ± 0.34* 9.13 ± 0.18* 7.27 ± 0.15*
Nitrofurantoin 5.62 ± 0.06 4.87 ± 0.13* 3.36 ± 0.16* 5 ± 0.07*
Novobiocin 5.63 ± 0.43 5.61 ± 0.52 3.33 ± 0.18* 5.32 ± 0.13
Prazosin 5.95 ± 0.2 6.1 ± 0.33 3.24 ± 0.19* 5.63 ± 0.59
Quinidine 6.2 ± 0.23 5.6 ± 0.26 3.3 ± 0.18* 11.6 ± 0.19*
Risperidone 5.74 ± 0.23 4.85 ± 0.15 3.65 ± 0.41* 6.08 ± 0.15
Verapamil 6.19 ± 0.16 6.21 ± 0.3 4.53 ± 0.33 12.91 ± 0.39*
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3.4 Discussion 
The primary aim of this chapter was to characterize available model systems (eg. 
MDCKII cells transfected with hBCRP/mBcrp) in relation to the stability and extent 
of BCRP expression and to establish a functional assay of BCRP to allow 
substrate/inhibitor specificity to be defined. Since data on the expression of BCRP in 
the human intestinal Caco-2 cultured line have been ambiguous (Sambuy et al., 
2005), BCRP expression and activity was determined in 2 separate strains of these 
cells to assess BCRP within an appropriate cellular context and as a prerequisite to the 
use of Caco-2 epithelia for transepithelial transport (Chapters 4 and 5) and as a 
suitable model to measure regulation of transport activity (Chapter 6). 
 It was confirmed that both MDCKII transfected cell lines express mRNA and 
protein of hBCRP/mBcrp whereas native MDCKII cells were negative.  
HBCRP/mBcrp was expressed at the apical membrane of these epithelial cells and no 
immunostaining was visible in the native MDCKII cells. The antibodies BXP-9 and 
BXP-53 used for immunoblotting and immunocytochemistry respectively were raised 
against an internal protein epitope that was similar between human, mouse and dog. 
The protein sequence alignment shown in the results indicates that both antibodies are 
likely to recognise dog protein, as is the case for the human and mouse BCRP protein 
(although this needs to be confirmed with a positive control). Therefore as no 
expression was seen with either technique it may be concluded that canine BCRP is 
not expressed in wild-type MDCKII cells. 
 Protein immunoblotting with BXP-9 pointed to varied levels of glycosylation 
in BCRP and Bcrp cDNA transfected MDCKII cells. Glycosylation was minimal in 
the hBCRP-MDCKII cells compared with mouse Bcrp1-MDCKII cells which 
revealed a strong band at the higher molecular size of 100kDa which was reduced to 
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the core protein size of ~72kDa after digestion with PNGase F. The apparent 
difference in glycosylation revealed by immunoblotting with BXP-9 agrees with what 
is predicted in the literature (Allen & Schinkel, 2002), showing the mouse Bcrp 
protein contains additional sites for glycosylation than that of the human protein. This 
difference in tertiary protein structure may give rise to a difference in transport 
characteristics between hBCRP-MDCKII cells and mBcrp1-MDCKII cells as the 
environment of the external facing binding site may be altered with greater 
glycosylation. 
 The existence of different Caco-2 cell strains with varied phenotype has been 
recognized for some years (Sambuy et al., 2005). In the present work it was found 
that Caco-2 cells which had been cultured for many passages in Newcastle did not 
express BCRP at neither the mRNA nor protein level. A lower passage strain from 
AstraZeneca laboratories clearly showed expression at both the RNA and protein 
level.  
 Notwithstanding evidence of BCRP expression in Caco-2 cells, the 
immunoblot in Figure 3.3 shows there is a visible difference in the amount of BCRP 
protein between the low passage Caco-2 cells and the over-expressing hBCRP-
MDCKII cells. This difference in expression may not result in differing levels of 
substrate flux compared to hBCRP-MDCKII cells if substrate availability is limited 
by access to the cytosol (e.g. across the basolateral membrane) or from the membrane 
phase. Nonetheless, the fact that expression appears relatively low in the Caco-2 cells 
may be an advantage in studies of up-regulation of BCRP where any difference may 
be more evident from a lower basal level. 
 After confirming expression of BCRP at the mRNA and protein level in the 
cell model systems the cell lines were characterised functionally using the 
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hBCRP/mBcrp substrate Hoechst 33342 (Kim et al., 2002; Zhou et al., 2001). 
Hoechst 33342 is a substrate that can be easily measured by fluorescence and scaled 
up to a high through-put assay format at a relatively low cost compared with 
counterpart assays, such as transepithelial flux and Ussing chamber techniques. 
However the main problem with Hoechst 33342 is that it is a known substrate of both 
BCRP and MDR1 (Bunting et al., 1999; Kim et al., 2002; Zhou et al., 2001), given 
the existence of an endogenous secretory capacity in wild-type MDCKII cells, 
characterization with selective pharmacological inhibitors to BCRP and MDR1 is 
essential. 
 In this study both hBCRP-MDCKII and mBcrp1-MDCKII significantly 
differed in the retention of Hoechst 33342 compared with the native MDCKII cells in 
response to Ko143 and verapamil (Figure 3.12). These data confirmed that both 
human BCRP-MDCKII and mouse Bcrp1-MDCKII express a functionally active 
transporter not seen in native MDCKII cells.   
 The endogenous secretory component in the MDCKII cells is inhibited by 
1µM CsA. Native MDCKII epithelial layers have been reported previously to secrete 
the MDR1 substrates digoxin and verapamil (Haslam et al., 2008; Lowes et al., 2003). 
In this study the effects of CsA were similar to that seen in the MDR1-MDCKII cells, 
which taken together leads to the conclusion that the endogenous component is 
MDR1. No effect of 1µM CsA on the endogenous component is seen in the 
hBCRP/mBcrp transfected cells. Here the lack of CsA effect likely results from the 
low concentration of CsA used and the compensatory capacity of the transfected 
hBCRP/mBcrp to transport Hoechst 33342 instead of MDR1. Used at higher 
concentrations, CsA may inhibit hBCRP/mBcrp as well as the endogenous dog 
protein. The apparent IC50 of 1.17μM in the hBCRP-MDCKII cells represents both 
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MDR1 and BCRP inhibition (Ejendal & Hrycyna, 2005; Xia et al., 2007a). In contrast 
100µM verapamil shown in Figure 3.14 was relatively selective for MDR1 compared 
with BCRP. 
 Ko143 used at a low concentration (0.8-1μM) was shown to be a selective 
inhibitor for hBCRP/mBcrp with little to no effect on the native and MDR1-MDCKII 
cells. Data from this study are confirmatory to that shown by Mattson et al. (2007). At 
a higher concentration of 10μM the selectivity of Ko143 seems to slightly deteriorate 
in that there is a slight inhibition seen in MDR1-MDCKII cells on Hoechst 33342 
accumulation. However given the affinity of Ko143 to BCRP, shown with the low 
IC50 values, this compound is a powerful tool that can be used to elucidate BCRP 
mediated secretion in a cell line with multiple transporter systems, such as the low 
passage Caco-2 cells.  
 Functional characterisation with Hoechst 33342 (using CsA and Ko143 as 
MDR1 and BCRP inhibitors respectively) show the low passage Caco-2 cells to have 
functional MDR1 and BCRP activities, whilst further showing the high passage Caco-
2 cells to display only MDR1 function. These functional data are in agreement with 
the expression data (above). 
 The concentration-dependent kinetics of Hoechst 33342 retention changed 
when BCRP was introduced into the parental MDCKII cells; this allows a BCRP-
dependent component to be identified with a Km of 10.3 ± 2.6 µM. This compares 
with the concentration dependence of the CsA sensitive endogenous Hoechst 33342 
retention (due to canine MDR1) of 0.3µM.  
 To identify a BCRP substrate using this assay a compound has to compete 
with Hoechst 33342 for the binding site on BCRP or MDR1, or act as a non-
competitive inhibitor. The choice of ~3µM for the screening assay should allow all but 
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the lowest affinity substrates to be able to compete with Hoechst 33342 at the 
substrate binding site. However it should be noted that multiple binding sites on the 
BCRP protein may exist (Clark et al., 2006; Hazai & Bikadi, 2008; Xia et al., 2007b) 
and that Hoechst 33342 may access BCRP from the membrane interior. Therefore the 
physiochemical properties of the substrate will determine binding to BCRP and 
whether it will be identified as a substrate/inhibitor in this competitive assay. It is 
thought that Hoechst 33342 binds to one binding site on the BCRP protein (Clark et 
al., 2006). The LogP value of Hoechst 33342 is 3.1 suggesting high lipophilicity. The 
data from this study show that in the hBCRP-MDCKII cells, nitrofurantoin does not 
affect Hoechst 33342 accumulation, yet nitrofurantoin is shown to be a BCRP 
substrate (Merino et al., 2005). The LogP value of nitrofurantoin is -0.6. As these 
compounds are lipophilic and non-lipophilic respectively it is likely that they partition 
in the plasma membrane differently and bind to distinct binding sites on BCRP. The 
results from this study fit with the Mattson et al. (2007) publication that fails to show 
that nitrofurantoin increases mitoxantrone accumulation (Matsson et al., 2007). 
Therefore, problems in BCRP substrate identification may arise when using a 
competitive assay such as Hoechst 33342 if the site and mode of transport within the 
BCRP protein differ. Even if this approach identifies a change in Hoechst 33342 
accumulation with a compound, this assay alone cannot distinguish between a 
competitive inhibitor and non competitive inhibitor (Hegedus et al., 2009). This is 
because it is not a direct measure of cellular transport across the apical surface. 
Therefore a more direct approach of measuring transport needs to be used. 
 Further limitations of the Hoechst 33342 assay may arise due to problems with 
cellular access and membrane leakage (Hegedus et al., 2009). Compounds that gain 
cell entry through the basal membrane are unlikely identified as substrates/inhibitors 
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using this method. This is because in a confluent layer of cells access to the basal 
membrane is limited and thus compound entry is restricted. A way to circumvent this 
would be to use the cells before reaching maximum confluency to allow better access 
to the cells; however Figure 3.8 demonstrates that at lower cell seeding density 
inhibition is difficult to measure. Furthermore as there is no control of cellular 
integrity, increased passive permeability resulting from toxicity may account for loss 
of Hoechst 33342 dye.  
 In summary this chapter states MDCKII cells transfected with the 
hBCRP/mBcrp cDNA, as well as the low PA Caco-2 cells (AstraZeneca variant 
shown in this study), all look suitable epithelial cell lines to achieve the aims of this 
project. The Hoechst 33342 cellular retention assay is an effective method of 
determining BCRP and MDR1 function and identifying inhibitors of these 
transporters, however it does not look suitable as an assay for screening for BCRP 
substrates or understanding BCRP regulation due to the indirect measure of transport 
having several limitations. Measurement of compounds via bi-directional transport 
across confluent cell monolayers is a more direct and sensitive method. 
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4. Transepithelial transport mediated by BCRP 
 
 
4.1 Introduction 
It is now clear that the ABC family of efflux transporters plays a major role in 
limiting the oral bioavailability, whole body distribution, and subsequent excretion of 
both potential and novel pharmaceutical agents. The focus of the present thesis is to 
understand the scope of BCRP with respect to individual agents, but more importantly 
to understand how the operation of BCRP, within the intestine, acts to limit 
absorption from the gut lumen to the blood. 
The data presented in Chapter 3 has introduced the use of MDCKII cells 
stably transfected with relevant ABC transporters to identify BCRP-mediated 
transport and also as a screen to identify compounds able to interact with BCRP (as 
inhibitors of Hoechst 33342 efflux). However, as already noted, Hoechst 33342 efflux 
only provides an indirect measure of BCRP function and may fail to distinguish 
between a competitive substrate and non-competitive inhibitor. Its use is also limited 
as a screen for novel substrates if the inhibitory potency of the compound being 
screened is low relative to Hoechst 33342 affinity for BCRP (Ki > Km for Hoechst 
33342). The data presented in Chapter 3 clearly allow high-affinity inhibitors such as 
Ko143 to be identified, but other potential substrate actions are less clear. In order to 
overcome such limitations, a direct assay of the transport activity of BCRP is required 
with respect to potential substrates. Use of excised animal or human intestinal tissue is 
the gold standard when looking directly at transport of xenobiotics. However the 
expense and ethical issues point to a more suitable in vitro method of looking at 
transport, especially in the pharmaceutical industry where throughput of new 
chemical entities (NCEs) to be tested is high. Cell based in vitro techniques have been 
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developed and are used for measuring BCRP function; these techniques are fast, high 
throughput and relatively low cost. The most widely used assay in this respect is the 
Transwell based monolayer assay. This technique requires epithelial cells to be grown 
to confluency thereby forming “tight” epithelial layers in which apical tight-junctions 
are formed and separate brush-border (apical) and basolateral (basal) membrane 
domains delimit the transcellular pathway for absorption/secretion. The tight junctions 
form a separate route for passive solute permeation. These epithelial layers therefore 
simulate the complex transcellular and paracellular barriers that need to be overcome 
in vivo (Hegedus et al., 2009) to attain oral absorption and therefore act as vital, 
physiologically appropriate tools in screening for xenobiotic transport. Transwell 
based assays consist of a porous polycarbonate membrane filter insert of varying size 
that fits directly into multiwell 6 to 96-well plates. Polarized cells are seeded directly 
onto the upper surface of the insert, adhere and then grow to confluency. The system 
has an apical and basolateral compartment representing lumen and interstitial/blood 
compartments found in vivo (shown in the Fig 2.1 of Materials and Methods).This 
simple geometry facilitates the investigation of transepithelial transcellular transport 
by the application of the compound of interest in either the apical or basolateral 
compartment as the donor compartment, with sampling in the opposite receiver 
compartment. 
As outlined in Chapter 3, MDCKII and ABC-transfected cell-lines provide a 
suitable means to test directly for substrates of BCRP and other ABC transporters. 
Caco-2 cells, in contrast, relate such ABC-mediated transport to the context of the 
human intestine in which multiple ABC-transporters, often with overlapping 
specificity are expressed. The primary aim, therefore, is to use the parental MDCKII 
cells alongside the ABC transfected MDCKII cells to determine selective BCRP 
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substrates from a diverse selection of compounds all associated with BCRP transport 
from the literature. Screening for ABC-transporter substrates in this way has allowed 
many studies to identify ABC-transporter substrates and is used frequently in the 
pharmaceutical industry (Matsson et al., 2007; Polli et al., 2001). 
The intestinal processing of such compounds will then be modelled by Caco-2 
epithelial cell monolayers. The BCRP mediated fraction of transport may be assessed 
using selective pharmacological inhibition (Ebert et al., 2007; Giacomini et al., 2010; 
Lemos et al., 2008). A secondary aim is the identification of a compound exclusively 
transported by BCRP so that the behaviour of this component can be determined 
directly in Caco-2 cell layers. 
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4.2 Methods 
4.2.1 Cell culture 
MDCKII and Caco-2 cells were cultured as previously described in Methods section 
2.2.1. 
 
4.2.2 Bi-directional transport across epithelial layers- 24 or 96-well 
filter plates 
Bi-directional transport across 24-well and 96-well cell monolayers was performed 
essentially as described in Materials and Methods (Section 2.2.2.3). 96-well transport 
assays were performed automatically on the Hamilton StarPlus robot. Two robotic 
scripts were written for the Hamilton StarPlus robot. The first was used in the 
transport assay for compounds at a selected donor concentration of 10µM. The second 
robot script allowed the transport assay to be conducted over a range of 
concentrations in the presence or absence of a pharmacological inhibitor(s). 
Alternatively transport assays were performed manually in a 24-well format. Donor 
and receiver concentrations of all compounds were determined by HPLC-MS. 
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4.3 Results 
4.3.1 Identification of BCRP substrates in ABC-transfected MDCKII 
monolayers 
Native MDCKII cell lines together with those stably transfected with human BCRP, 
mouse Bcrp and human MDR1 were used to identify drug BCRP substrates. The 96-
well Transwell format was used for determination of bi-directional flux of potential 
compounds using protocols implemented on the Hamilton Starplus robot allowing 
automated solution delivery, exchange and sampling. Initially 21 potential BCRP 
substrates were selected to include; cimetidine, clozapine, curcumin, diclofenac, 
estrone-3-sulphate, flavopiridol, gefitinib, methotrexate, mitoxantrone, nitrofurantoin, 
novobiocin, omeprazole, paclitaxel, pheophorbide A, prazosin, progesterone, 
quinidine, resveratrol, risperidone, sulphasalazine and zidovudine. However due to 
limited epithelial permeability and compound levels falling below the detection limit 
or failure of HPLC/ionisation to allow detection of appropriate m/z intensities, no data 
for curcumin, estrone-3-sulphate, methotrexate, mitoxantrone, omeprazole, paclitaxel, 
pheophorbide A, resveratrol,  sulphasalazine and zidovudine were obtained. Appendix 
tables 1-4 summarise the transepithelial flux in the apical to basal direction (Ja-b), 
basal to apical direction (Jb-a) and net secretory flux (Jnet = Jb-a - Ja-b) of those 11 
compounds on which data were obtained (appendix tables representative of n = 2 
experiments with 4-6 replicates per condition).  
Diclofenac has been reported to be a BCRP substrate (Lagas et al., 2009), 
Figure 4.1 illustrates the utility of native and transfected MDCKII cell layers in the 
identification of the mechanism of transport.  Bi-directional flux across the native 
(Figure 4.1.A), human BCRP (Figure 4.1.B), mouse Bcrp (Figure 4.1.C) and human 
MDR1 (Figure 4.1.D) show that whereas no endogenous significant net secretion of 
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diclofenac across native MDCKII epithelial monolayers is observed, hBCRP-
MDCKII, mBcrp1-MDCKII and MDR1-MDCKII cell monolayers all display a 
significant and elevated net secretory flux (P < 0.05, Figure 4.1 E, Table 4.1). The net 
secretory flux of 132 ± 137 pmol.cm
-2
.hr
-1
 for the parental cell line was increased to 
678.8 ± 57 pmol.cm
-2
.hr
-1
 for hBCRP transfected, 665.1 ± 37.2 pmol.cm
-2
.hr
-1
 for 
mBcrp transfected and 625.6 ± 144.7 pmol.cm
-2
.hr
-1
 for MDR1 transfected MDCKII 
cell layers (n = 2 experiments, P < 0.05). Therefore diclofenac is likely to be a 
substrate for mouse and human BCRP and for human MDR1 in agreement to the data 
of Lagas et al. (2008). 
Table 4.1 summarises the absorptive permeabilities (Pa-b = Ja-b / Ca) of all 
compounds for which transport data were obtained. A major determinant of epithelial 
permeability is its lipophilicity. Correlations of partition coefficient (e.g. 
octanol/water, LogP) have shown a high correlation with % drug absorption in man 
(Zhao et al., 2002). A high LogP value of 4.5 for diclofenac suggests that passive 
transcellular absorption across epithelial barriers would predominate and indeed the 
observed absorptive permeability for diclofenac in native MDCKII cells exceeds that 
seen for other compounds tested (Table 4.1). The operation of ABC transporters such 
as MDR1 is generally thought to limit the absorptive permeability (Hunter et al., 
1993). A reduction in the apical permeability is generally seen for mBcrp1-MDCKII 
whilst a modest reduction is generally seen for hBCRP-MDCKII cell layers; no 
reduction is seen for MDR1-MDCKII cell layers (Table 4.1). 
Table 4.2 shows a summary of the net secretory flux for all 11 compounds 
optimised for HPLC-MS analysis in all four MDCKII cell lines (native, hBCRP-
MDCKII, mBcrp1-MDCKII and MDR1-MDCKII). Bi-directional flux data displayed 
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in Table 4.2 was taken from Appendix Tables 1-4. Each compound may be defined to 
be either a substrate of hBCRP, mBcrp or MDR1.  
Cimetidine is a known hBCRP, mBcrp substrate (Pavek et al., 2005) and also 
an MDR1 substrate (Dahan & Amidon, 2009), yet only modest and non-significant 
increments in secretion were seen for mBcrp and hBCRP and MDR1-transfected 
MDCKII cell layers (Table 4.2). However the retention time for cimetidine in the 
HPLC system was atypical suggesting that quantification of this compound was in 
doubt. 
Clozapine is an example of an anti-psychotic drug that has been reported to be 
a BCRP inhibitor (Wang et al., 2008b). It was found not to be a substrate of hBCRP-
MDCKII cells. However, it was shown to be a substrate of MDR1-MDCKII cells 
increasing net secretory flux from 176.3 ± 29.5 pmol.cm
-2
.hr
-1
 across native MDCKII 
to 321.5± 26.5 pmol.cm
-2
.hr
-1
 in MDR1-MDCKII cell layers (P < 0.05, Table 4.2).  
Flavopiridol net secretion of 872.1± 50.2 pmol.cm
-2
.hr
-1
 in native MDCKII 
cell layers increased significantly to 1969.2 ± 315.1 pmol.cm
-2
.hr
-1
 in hBCRP-
MDCKII cells and 1625.2 ± 87.7 pmol.cm
-2
.hr
-1
 in mBcrp1-MDCKII cells (P < 0.05, 
Table 4.2). Flavopiridol is therefore a substrate of both human BCRP and mouse 
Bcrp. No significant increase was observed with MDR1-MDCKII cell layers in 
comparison to wild-type MDCKII cell layers, perhaps due to a very high basal 
secretion observed in the non-transfected MDCKII cell layers. These findings are 
similar to Robey et al. (2001), whilst Zhou et al. (2009) showed flavopiridol transport 
by human and mouse MDR1/Mdr1a but not to the same extent as human BCRP and 
mouse Bcrp (Robey et al., 2001; Zhou et al., 2009).  
Gefitinib (Iressa™, ZD1839) is an epidermal tyrosine kinase inhibitor used in 
cancer clinical trials and treatment of non-small cell lung cancers (NSCLC). This 
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compound has been reported to be an inhibitor of BCRP and MDR1 (Leggas et al., 
2006; Ozvegy-Laczka et al., 2004; Yanase et al., 2006), reverses resistance to agents 
such as topotecan in mice through its interaction with Bcrp (Stewart et al., 2004). Net 
secretion of gefitinib across all the MDCKII epithelial layers was observed with net 
flux increasing in the hBCRP, mBcrp and MDR1 transfected MDCKII cells. However 
only the murine Bcrp1-MDCKII cells showed a significant difference from the native 
cells with a profound increase in secretion of 1196.4 ± 418.6 pmol.cm
-2
.hr
-1
 compared 
to the parental secretion of 81.6 ± 29.4 pmol.cm
-2
.hr
-1
 (P < 0.05, Table 4.2). 
In contrast to the other compounds tested, nitrofurantoin is not subject to 
epithelial secretion in the parental MDCKII cells. In contrast there is a net absorption 
of nitrofurantoin (see Appendix Table 1 and Figure 4.6). In MDR1-MDCKII cells, no 
net secretion was observed and there was a similar net absorption compared to native 
MDCKII epithelial layers (Appendix Table 4, Figure 4.6). Nitrofurantoin is therefore 
not an MDR1 substrate. However net absorptive flux of -81.3 ± 25.4 pmol.cm
-2
.hr
-1
 in 
native layers is converted to substantial net secretions of 269.7 ± 31 pmol.cm
-2
.hr
-1
 
and 232.9 ± 93.7 pmol.cm
-2
.hr
-1 
in the human and mouse Bcrp1-MDCKII cell 
monolayers respectively (P < 0.05, Table 4.2), showing nitrofurantoin to be a good 
hBCRP/mBcrp substrate. Nitrofurantoin is a drug used commonly throughout the 
world to treat bacterial infections and these data confirm findings in previous studies 
(Merino et al., 2005). 
The coumermycin antibiotic novobiocin was included in the substrate screen 
because of its reported action as a BCRP inhibitor (Shiozawa et al., 2004; Su et al., 
2007). In this study no significant effect of hBCRP, mBcrp or MDR1 was seen on 
novobiocin net secretion, but as with clozapine, novobiocin was subject to epithelial 
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secretion by the intrinsic secretory transporter(s) present in native MDCKII cells 
(Table 4.2). 
Prazosin is a well known BCRP substrate and is often used with a BODIPY 
tag to quantify BCRP function (Cerveny et al., 2006; Matsson et al., 2009; Muenster 
et al., 2008; Staud et al., 2006). It is also reported to be a substrate of MDR1 also but 
to a lesser degree than BCRP (Feng et al., 2008; Polli et al., 2001; Zhou et al., 2009). 
Table 4.2 data confirmed these findings for prazosin. Secretion by hBCRP-MDCKII 
epithelial monolayers (1653.7 ± 117 pmol.cm
-2
.hr
-1
) was significantly elevated 
compared to that (1039.5 ± 92.1 pmol.cm
-2
.hr
-1
) seen across the native MDCKII cell 
monolayers (P < 0.05, Table 4.2). Net secretion seen with both mBcrp1-MDCKII and 
MDR1-MDCKII epithelial layers, (1426.5 ± 50.2 pmol.cm
-2
.hr
-1 
and 1538.6 ± 30.9 
pmol.cm
-2
.hr
-1
) were also significantly elevated compared with the parental MDCKII 
cells (P < 0.05, Table 4.2).  
Progesterone, though subject to epithelial secretion by native MDCKII cell 
layers, does not show any significant increase in secretion with mBcrp, hBCRP and 
MDR1 transfected MDCKII cell monolayers (Table 4.2). Progesterone has been 
suggested to possess a modulating/regulating role for BCRP in epithelial tissue (Vore 
& Leggas, 2008; Wang et al., 2008a).   
Despite quinidine having being shown to be a good substrate for MDR1 (Polli 
et al., 2001) Table 4.2 shows that there was no significant difference in secretion 
between MDR1 transfected and native MDCKII epithelial monolayers. A large net 
secretion of quinidine was however seen in the native MDCKII cell monolayers, with 
a ratio of bi-directional flux (Jb-a / Ja-b, the efflux ratio) of 15.5 (Appendix table 1). 
This large endogenous secretion observed in the parental MDCKII cells may act to 
mask secretion mediated by BCRP or MDR1 if flux across the basolateral membrane 
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is rate-limiting. A significant endogenous secretion is seen with all but one of the 
other compounds tested and highlights a potential problem with the MDCKII cell 
model for screening ABC transporter substrates. 
As described in Chapter 3 using Hoechst 33342 dye retention, risperidone was 
found to be a likely BCRP inhibitor at high concentrations (Wang et al., 2008b). The 
MDCKII substrate screen identified risperidone as a possible hBCRP substrate, this is 
because net flux significantly increased from 656.4 ± 19.0 pmol.cm
-2
.hr
-1 
in the native 
MDCKII cells to 1110.6 ± 218.1 pmol.cm
-2
.hr
-1 
in the hBCRP-MDCKII cells (n = 2, P 
< 0.05, Table 4.1). However it was not identified as a mouse Bcrp or MDR1 substrate. 
An additional feature of the present data set is the global comparison of absorptive 
permeabilities between the 11 compounds tested (Table 4.1). Artursson and Karlsson 
(1991) have found that such permeabilities broadly correlate with a measure of 
lipophilicity (the partition coefficient, LogP), as can be seen from Table 4.1 this is 
also fairly true for the compounds shown (Artursson & Karlsson, 1991). Diclofenac is 
a lipophilic compound displaying high apical to basal permeability whilst cimetidine 
is a fairly lipophobic compound displaying much lower absorptive values (data shown 
in Table 4.1) but with notable exceptions (e.g. nitrofurantoin and gefitinib). 
Nitrofurantoin shows a low LogP (0.5) but an elevated absorptive permeability 
suggesting that there is a specialised absorptive mechanism for this compound in 
MDCKII epithelial cells. Conversely the absorptive permeability for gefitinib is low 
despite a high LogP value (4.9) suggesting that the intrinsic ABC transporters present 
in the native MDCKII cell-line limit uptake.  
In summary the use of ABC transfected MDCKII cell layers as a substrate 
screen has identified 5 compounds as hBCRP substrates: diclofenac, flavopiridol, 
nitrofurantoin, prazosin and risperidone. It further identified 5 mouse Bcrp substrates: 
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diclofenac, flavopiridol, gefitinib, nitrofurantoin and prazosin. 3 compounds were 
identified as MDR1 substrates: clozapine, diclofenac and prazosin. Flavopiridol and 
nitrofurantoin are substrates for both human BCRP and mouse Bcrp and provide 
likely substrates for elucidating directly the functional properties of BCRP within an 
intact epithelial system. Compounds such as diclofenac and prazosin are secreted by 
all 3 transporters. 
 
4.3.2 Inhibition of BCRP mediated transport in MDCKII cell 
monolayers using Ko143 
 
Figure 4.2A shows that when measured over an extended concentration range of 1-
100µM flavopiridol was not secreted across the native MDCKII epithelial layers. 
These data contrast to the high basal level of secretion observed at a donor 
concentration of 10µM in the substrate screen script giving an efflux ratio of 3.9 
(Appendix table 1). However Figure 4.2B shows that for hBCRP-MDCKII cell 
monolayers a substantial net secretion over the concentration range 1-100µM of 
flavopiridol (P < 0.05) was evident. Flavopiridol net secretion showed non-linear 
kinetics and a Michaelis-Menten fit (Fig 4.3A) for hBCRP mediated secretion gave a 
Vmax of 5.1 ± 1.7 nmol.cm
-2
.hr
-1 
and apparent Km of 126 ± 70 µM. This net secretion 
was significantly reduced in the presence of 1µM Ko143 (P < 0.05, Figure 4.3A). 
Transepithelial flux of flavopiridol was also determined in the 24-well layers in the 
presence of a higher concentration of 10µM Ko143 (Figure 4.3B) in order to be sure 
that access did not limit Ko143 action. Flavopiridol net secretion was reduced from 
9.01 ± 0.92 nmol.cm
-2
.hr
-1 
to 4.19 ± 0.27 nmol.cm
-2
.hr
-1 
in the presence of 10µM 
Ko143. A Ko143 sensitive and insensitive component of flavopiridol secretion 
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therefore exists. The Ko143 insensitive component most probably represents 
endogenous secretion. 
Prazosin was shown to be a substrate for hBCRP/mBcrp and MDR1 from the 
substrate screen shown in Table 4.1. In the native MDCKII cell line at low prazosin 
concentrations, secretion was limited but a significant net secretion was observed at 
100µM (P < 0.05, Figure 4.4A). Figure 4.4B shows the concentration dependence of 
prazosin secretion by hBCRP-MDCKII epithelia; net secretion of prazosin was 
significantly greater in the hBCRP-MDCKII cells compared with the native MDCKII 
at all concentrations apart from 3µM (P < 0.05, Figure 4.5A, B). Prazosin secretion by 
hBCRP-MDCKII cell monolayers was also significantly reduced by the BCRP 
selective 1µM Ko143, reducing secretion at all concentrations (Figure 4.5). In the 
manual 24-well format (Figure 4.5B) prazosin net secretion by hBCRP-MDCKII cell 
monolayers was significantly reduced from 10.2 ± 0.62 nmol.cm
-2
.hr
-1 
to 3.24 ± 0.21 
nmol.cm
-2
.hr
-1 
in the presence of 10µM Ko143, but as with flavopiridol secretion was 
not completely abolished (P < 0.05, Figure 4.5B). 
Nitrofurantoin was selected from the MDCKII substrate screen because it was 
not secreted in the native MDCKII cells but was highly secreted in the human BCRP 
and mouse Bcrp cDNA transfected MDCKII cell monolayers (Table 4.2 and Figure 
4.6A-D). This net secretion of nitrofurantoin across the hBCRP-MDCKII cells was 
selectively reduced from 1.08 ± 0.12 nmol.cm
-2
.hr
-1 
in the untreated monolayers to 
0.23 ± 0.01 nmol.cm
-2
.hr
-1 
in the presence of 10µM Ko143 (P < 0.05, Figure 4.7). 
Taken together this MDCKII data confirms flavopiridol, prazosin and 
nitrofurantoin as suitable compounds to study functional BCRP activity in a complex 
cell system such as Caco-2 epithelia. 
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4.3.3 Determination of the BCRP mediated component of substrate 
flux across Caco-2 cell monolayers 
 
Data from Chapter 3 confirmed BCRP expression and functionality in the low passage 
(PA) Caco-2 cells. Table 4.3 summarises the data for transepithelial flux data across 
Caco-2 cell confluent monolayers. As for MDCKII data, only 12 compounds were 
amenable to HPLC-MS quantification. 
All 12 compounds were secreted across the Caco-2 cell monolayers (Table 
4.3). Sulphasalazine, whose low permeability in native MDCKII epithelia precluded 
measurement, was secreted by Caco-2 cell monolayers. It is known sulphasalazine has 
a poor absorptive passive permeability (LogP 3.8) (Jani et al., 2009) and this is 
replicated in the current data (Table 4.3). In contrast there is a high level of 
basolateral to apical transport and hence secretion of sulphasalazine in Caco-2 cells in 
agreement with the data of other workers (Dahan & Amidon, 2009; Jani et al., 2009).  
The dose dependence of flavopiridol, prazosin and nitrofurantoin were 
determined over a range of concentrations. Figure 4.8A shows the bi-directional flux 
of flavopiridol across Caco-2 cells. Secretion shows saturation (Figure 4.8B) and is 
sensitive to 10µM Ko143 inhibition (Figure 4.8B). Ko143 reduces the Vmax of 
flavopiridol secretion from 5.12 ± 0.99 nmol.cm
-2
.hr
-1
 in untreated cells to 1.59 ± 0.2 
nmol.cm
-2
.hr
-1
 in the presence of 10µM Ko143. The use of Ko143 shows the 
contribution of BCRP to its secretion in an intact intestinal epithelium and also shows 
that it is secreted by at least another component (perhaps an MRP family member). 
Figure 4.9A shows that prazosin secretion displays saturation kinetics across 
Caco-2 cell monolayers, with an apparent Km of 22.1 ± 2.9 µM and a Vmax of 3.57 ± 
0.17 nmol.cm
-2
.hr
-1
. In the presence of 10µM Ko143, there is a reduction in the Vmax 
of prazosin to 2.54 ± 0.41 nmol.cm
-2
.hr
-1
. A substantial Ko143 insensitive component 
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of prazosin net secretion may represent an MDR1 mediated component (Table 4.2). 
The effects of Ko143 or verapamil inhibition alone and combined on prazosin flux in 
the manual 24-well assay format showed that 10µM Ko143 reduced secretion from 
1.22 ± 0.06 nmol.cm
-2
.hr
-1
 to 0.51 ± 0.69 nmol.cm
-2
.hr
-1 
in the Ko143 treated cells (P 
< 0.05, Figure 4.9C). 100µM verapamil had a marginal but none significant effect at 
reducing prazosin secretion. However when combined with 10µM Ko143 it reduced 
net secretion to 0.21 ± 0.02 nmol.cm
-2
.hr
-1
. This data shows prazosin is secreted by 
BCRP in these Caco-2 cells but there is also an alternative route of secretion, likely to 
be MDR1 due to verapamil sensitivity. 
Figure 4.10A shows that nitrofurantoin is subject to saturable secretion by 
human intestinal Caco-2 cell monolayers. A Michaelis-Menten fit of the net secretion, 
shown in Figure 4.10B, shows an apparent Km = 69.4 ± 22.3 µM and a Vmax = 14.03 ± 
2.27 nmol.cm
-2
.hr
-1
. The Vmax of nitrofurantoin was also profoundly reduced by 
Ko143 to just 1.3 ± 0.19 nmol.cm
-2
.hr
-1 
across Ko143 treated layers. This effect of 
10µM Ko143 shows that the vast majority of nitrofurantoin secretion can be ascribed 
to BCRP in Caco-2 cells. In the manual 24-well assay format nitrofurantoin flux 
(donor concentration 10µM) was reduced from 2.28 ± 0.08 nmol.cm
-2
.hr
-1
 across 
untreated Caco-2 cell monolayers to 0.18 ± 0.02 nmol.cm
-2
.hr
-1
 across 10µM Ko143 
layers (P < 0.05 Figure 4.10B). In contrast to its action on prazosin flux, verapamil 
had no effect whatsoever on nitrofurantoin flux and did not affect flux even when 
combined with Ko143. 
Therefore nitrofurantoin may be regarded as a selective BCRP substrate and 
may be used to characterise the functional BCRP component in the context of 
multiple ABC-transporter expression.  
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Table 4.1. Absorptive permeabilities of potential BCRP substrates across 
MDCKII and Caco-2 cell monolayers  
 
Summary table of absorptive permeabilities (Pa-b = Ja-b / Ca) of potential BCRP 
substrates in native and transfected MDCKII cells and low passage Caco-2 cells. 
Partition coefficient at pH 7.4 (LogP) is also displayed for each compound. Cells were 
grown to confluency on 96-well permeable Transwell supports and assays were 
conducted via automation on a Hamilton StarPlus Robot. Compounds were used at a 
concentration of 10µM. Data points are means of n = 6 wells, data were pooled and 
normalised from 2 independent experiments ± SEM. * P < 0.05, are significantly 
different from control native values.  
 
Pa-b (10
-6cm.h-1)
LogPMDCKII hBCRP-MDCKII mBcrp1-MDCKII MDR1-MDCKII Caco-2 
Cimetidine 1.31  0.07 7.21  2.9 0.14  0.05 6.23  0.79 6.79  0.51 0.4
Clozapine 7.49  0.71 10.38  3.43 6  0.68 22.52  0.57 23.23  0.92 3.2
Diclofenac 33.23  19.72 41.14  3.54 35.66  2.3 80.9  8.04 46.25  14 4.5
Flavopiridol 29.66  1.01 16.57  4.32 0.05  0.01 40.82  4.81 36.54  1.17 3.3
Gefitinib 0.14  0.09 0.73  0.53 0.64  0.39 2.22  1 1.73  0.36 4.9
Nitrofurantoin 17.26  3.54 0.12  0.2 0.15  0.01 16.26  1.28 7.53  0.94 0.5
Novobiocin 1.74  0.54 1.09  0.07 0.06  0.01 2.85  0.6 6.64  0.38 2.5
Prazosin 24.2  2.27 11.01  1.71 0.18  0.05 29.14  0.88 20.93  1.08 1.3
Progesterone 39.0  1.06 33.32  4.88 5.24  0.86 24.33  2.85 21.18  0.38 3.9
Quinidine 11.22  0.93 6.89  1.37 144  11.54 9.93  0.47 35.78  1.57 3.4
3.5Risperidone 30.77  1.84 28.24  1.93 24.77  2.82 52.4  6.86 49.59  1.21
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Table 4.2. Elucidation of potential BCRP-substrates using MDCKII cell 
monolayers  
 
Summary table of net secretory flux (Jnet = Jb-a - Ja-b) of potential BCRP substrates in 
transfected MDCKII cells. Cells were grown to confluency on 96-well permeable 
Transwell supports and assays were conducted via automation on a Hamilton StarPlus 
Robot. Compounds were used at a concentration of 10µM. Data points are means of n 
= 6 wells, data were pooled and normalised from 2 independent experiments ± SEM. 
* P < 0.05, are significantly different from control native values.  
 
 
Net secretory flux (pmol.cm-2.hr-1)
Compound Native MDCKII (Jnet) BCRP-MDCKII (Jnet) Bcrp1-MDCKII (Jnet) MDR1-MDCKII (Jnet)
Cimetidine 128.8 ± 21.3 187.4 ± 48.1 220.8 ± 93.1 141.1 ± 71.7
Clozapine 176.3 ± 29.5 237.9 ± 51 226.7 ± 14.1 321.5 ± 26.4 *
Diclofenac 131.7 ± 137 678.8 ± 57 * 665.1 ± 37.2 * 625.6 ± 133.7 *
Flavopiridol 872.1 ± 50.2 1969.2 ± 315.1 * 1625.2 ± 87.7 * 1060.1 ± 145.3 
Gefitinib 81.6 ± 29.4 265.8 ± 45 1196.4 ± 418.6 * 268.6 ± 17.5 
Nitrofurantoin -81.3 ± 25.4 269.7 ± 31 * 232.9 ± 93.7 * -101.3 ± 2.98
Novobiocin 188.8 ± 24.7 236.1 ± 18 162.7 ± 23.1 69.9 ± 8.3
Prazosin 1039.5 ± 92.1 1653.7 ± 117* 1426.5 ± 50.2 * 1538.6 ± 30.9 *
Progesterone 455.4 ± 21.0 468.9 ± 131.1 337.3 ± 52.6 545.2 ± 45.3 
Quinidine 1849.1 ± 25.1 2423.1 ± 640 2390.0 ± 421.4 2064.9 ± 38.9 
Risperidone 656.4 ± 19.0 1110.6 ± 218.1 * 407.1 ± 75.5 906.1 ± 27.7 
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Figure 4.1. Use of ABC-transfected MDCKII cells to determine substrate 
specificity; transepithelial flux of diclofenac  
 
Figures (A)-(D) show the transepithelial flux of diclofenac in (A) native MDCKII, (B) 
human BCRP-MDCKII, (C) mouse Bcrp1-MDCKII and (D) MDR1-MDCKII. Cells 
were grown to confluency on 96-well permeable Transwell supports and assays were 
conducted via automation on a Hamilton StarPlus Robot. Total diclofenac 
concentration was 10µM. Horizontal striped bars show flux in the apical to basal 
direction (Ja-b), diagonal stripes represent flux in the basal to apical direction (Jb-a) and 
filled bars represent net flux (Jnet = Jb-a - Ja-b). Data bars are means of n = 6 wells, data 
pooled and normalised from 2 independent experiments ± SEM. * P < 0.05, are 
significantly different from control values. 
Figure (E) shows net transepithelial flux (Jnet) of diclofenac across confluent 
MDCKII monolayers. Black filled bar = native, dark grey = human BCRP-MDCKII, 
light grey = mouse Bcrp1-MDCKII and unfilled bar = MDR1-MDCKII diclofenac net 
secretion (Jnet) respectively. Data bars are means of n = 6 wells, data pooled and 
normalised from 2 independent experiments ± SEM. * P < 0.05 represent significant 
difference of transfected MDCKII net flux compared to native MDCKII.  
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Figure 4.1. Use of ABC-transfected MDCKII cells to determine substrate 
specificity; transepithelial flux of diclofenac  
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Figure 4.2. Dose-dependency of flavopiridol transepithelial flux across confluent 
native and human BCRP-MDCKII monolayers 
 
(A) Dose-dependency of flavopiridol flux in native MDCKII cells grown to 
confluency on permeable 96-well Transwell supports. Flux were determined in 
the apical-to-basal (Ja-b) and basal-to-apical (Jb-a) directions where secretory 
net flux (Jnet) = Jb-a – Ja-b.  Data points are means of n = 4 monolayers ± SEM.  
 
(B) Dose-dependency of flavopiridol flux in human BCRP-MDCKII cells grown 
to confluency on permeable 96-well Transwell supports. Flux were determined 
in the apical-to-basal (Ja-b) and basal-to-apical (Jb-a) directions where secretory 
net flux (Jnet) = Jb-a – Ja-b.  Data points are means of n = 4 monolayers ± SEM. 
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Figure 4.2. Dose-dependency of flavopiridol transepithelial flux across confluent 
native and human BCRP-MDCKII monolayers 
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Figure 4.3. Action of bi-directional transport of flavopiridol across native and 
human BCRP-MDCKII monolayers 
 
(A) Dose-dependency of flavopiridol net secretory flux (Jnet = Jb-a – Ja-b) across 
native MDCKII and hBCRP-MDCKII in the presence and absence of the 
BCRP inhibitor Ko143 (1µM). MDCKII cells were grown to confluency on 
96-well Transwell supports.  Data points are means of n = 4 monolayers ± 
SEM.  
 
(B) Transepithelial flux of flavopiridol in hBCRP-MDCKII grown to confluency 
on permeable 24-well Transwell supports. Donor flavopiridol concentration 
was 10µM. Flux were determined in the presence and absence of the ABC-
transporter inhibitors Ko143 (10μM) and verapamil (100μM). Data bars are 
means of n = 4 monolayers ± SEM. * P < 0.05, significantly different from 
control.  
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Figure 4.3. Action of bi-directional transport of flavopiridol across native and 
human BCRP-MDCKII monolayers 
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Figure 4.4. Dose-dependency of prazosin transepithelial flux across confluent 
native and human BCRP-MDCKII monolayers 
 
(A) Dose-dependency of prazosin flux across native MDCKII cells grown to 
confluency on permeable 96-well Transwell supports. Flux were determined in 
the apical-to-basal (Ja-b) and basal-to-apical (Jb-a) directions where secretory 
net flux (Jnet) = Jb-a – Ja-b. Data points are means of n = 4 monolayers ± SEM.  
 
(B) Dose-dependency of prazosin flux across human BCRP-MDCKII cells grown 
to confluency on permeable 96-well Transwell supports. Flux were determined 
in the apical-to-basal (Ja-b) and basal-to-apical (Jb-a) directions where secretory 
net flux (Jnet) = Jb-a – Ja-b. Data points are means of n = 4 monolayers ± SEM.  
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Figure 4.4. Dose-dependency of prazosin transepithelial flux across confluent 
native and human BCRP-MDCKII monolayers 
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Figure 4.5. Action of bi-directional transport of prazosin across native and 
human BCRP-MDCKII monolayers 
 
(A) Dose-dependency of prazosin net secretory flux (Jnet = Jb-a – Ja-b) across native 
MDCKII and hBCRP-MDCKII in the presence and absence of the BCRP 
inhibitor Ko143 (1µM). MDCKII cells were grown to confluency on 96-well 
Transwell supports.  Data points are means of n = 4 monolayers ± SEM.  
 
(B) Transepithelial flux of prazosin across BCRP-MDCKII grown to confluency 
on permeable 24-well Transwell supports. Donor prazosin concentration was 
10µM. Flux were determined in the presence and absence of the known ABC-
transporter inhibitors Ko143 (10μM) and verapamil (10μM). Data bars are 
means of n = 4 monolayers ± SEM. * P < 0.05, significantly different from 
control.  
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Figure 4.5. Action of bi-directional transport of prazosin across native and 
human BCRP-MDCKII monolayers 
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Figure 4.6. Bi-directional transport of nitrofurantoin across ABC-transfected 
MDCKII cells 
 
Figures (A)-(D) show the transepithelial flux of nitrofurantoin across confluent 
monolayers of (A) native MDCKII, (B) MDR1-MDCKII, (C) human BCRP-MDCKII 
and (D) mouse Bcrp1-MDCKII. Donor nitrofurantoin concentration was 10µM. Flux 
were determined in the apical to basal direction (Ja-b), basal to apical direction (Jb-a) 
and net flux was determined by Jnet = Jb-a - Ja-b. Data bars are means of n = 6 wells, 
data pooled and normalised from 2 independent experiments ± SEM.   
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Figure 4.6. Bi-directional transport of nitrofurantoin across ABC-transfected 
MDCKII cells 
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Figure 4.7. Effect of Ko143 on nitrofurantoin transepithelial flux across 
confluent human BCRP-MDCKII monolayers 
 
BCRP-MDCKII cells were cultured on 24-well Transwell supports. Nitrofurantoin 
donor concentration was 10µM; receiver concentration was measured by HPLC-MS.  
Flux were determined in the presence and absence of the ABC transporter inhibitors 
Ko143 (10μM). Data bars are means of n = 4-6 monolayers ± SEM. * P < 0.05, 
significantly different from control.  
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Figure 4.7. Effect of Ko143 on nitrofurantoin transepithelial flux across 
confluent human BCRP-MDCKII monolayers 
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Table 4.3. Table showing bi-directional flux of selected compounds in Caco-2 
cells 
 
Summary table of bi-directional flux in the apical to basal direction, basal to apical 
direction, net secretion (Jnet = Jb-a - Ja-b), efflux ratio (Jb-a / Ja-b) and partition coefficient 
(LogP) of potential BCRP substrates across Caco-2 monolayers. Cells were grown to 
confluency on 96-well permeable Transwell supports and assays were conducted via 
automation on a Hamilton StarPlus Robot. Compounds were used at a concentration 
of 10µM. Data points are means of n = 4-6 wells, data were pooled and normalised 
from 2 independent experiments ± SEM. 
 
Bidirectional Flux 
(pmol.cm-2.hr-1)
Compound Ja-b Jb-a Jnet Efflux Ratio logP
Cimetidine 67.9 ± 5.1 371.7 ± 8.1 303.7 ± 3.1 5.5 ± 0.3 0.4
Clozapine 232.3 ± 9.2 581.7 ± 41.8 349.5 ± 37.8 2.5 ± 0.1 3.2
Diclofenac 462.5 ± 140 828.2 ± 1.3 365.7 ± 138.7 1.8 ± 0.1 4.5
Flavopiridol 365.4 ± 11.7 1333.3 ± 54.8 967.9 ± 55 3.6 ± 0.2 3.3
Gefitinib 17.3 ± 3.6 135.9 ± 10.7 118.7 ± 7.7 7.9 ± 1.1 4.9
Nitrofurantoin 75.3 ± 9.4 1261.5 ± 199.4 1186.2 ± 197.7 16.8 ± 2.9 0.5
Novobiocin 66.4 ± 3.8 451.2 ± 19.1 384.7 ± 19.2 6.8 ± 0.4 2.5
Prazosin 209.3 ± 10.8 1313.6 ± 57.7 1104.3 ± 50.3 6.3 ± 0.2 1.3
Progesterone 211.8 ± 3.8 566.6 ± 51 354.9 ± 54.1 2.7 ± 0.3 3.9
Quinidine 357.8 ± 15.7 1272.5 ± 23.8 914.6 ± 33.1 3.6 ± 0.2 3.4
Risperidone 495.9 ± 12.1 1270.2 ± 40 774.3 ± 46 2.6 ± 0.1 3.5
Sulphasalazine 0.51 ± 0.1 646.3 ± 53.7 645.8 ± 53.7 1267.3 ± 0.1 3.8
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Figure 4.8. Bi-directional and net flux of flavopiridol across confluent Caco-2 cell 
monolayers 
 
(A) Dose-dependence of flavopiridol flux across Caco-2 cells grown to confluency 
on permeable 96-well Transwell supports. Flux were determined in the apical-
to-basal (Ja-b) and basal-to-apical (Jb-a) directions where secretory net flux (Jnet) 
= Jb-a – Ja-b. Data points are means of n = 4-6 monolayers ± SEM.  
 
(B) Effect of the BCRP inhibitor Ko143 (10µM) on flavopiridol net flux (Jnet) 
across Caco-2 cell monolayers. Control curve is a Michaelis-Menten fit of the 
data, Km = 43.8 ± 2.5 µM and Vmax = 5.12 ± 0.99 nmol.cm
-2
.hr
-1
. Ko143 curve 
is a Michaelis-Menten fit, Km = 9.84 ± 4.34 µM and Vmax = 1.59 ± 0.2 
nmol.cm
-2
.hr
-1
.  Data points are means of n = 4-6 monolayers ± SEM.   
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Figure 4.8. Bi-directional and net flux of flavopiridol across confluent Caco-2 cell 
monolayers 
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Figure 4.9. Bi-directional and net flux of prazosin across confluent Caco-2 cell 
monolayers 
 
(A) Dose-dependence of prazosin flux across Caco-2 cell monolayers. Flux were 
determined in the apical-to-basal (Ja-b) and basal-to-apical (Jb-a) directions 
where secretory net flux (Jnet) = Jb-a – Ja-b. Data points are means of n = 4-6 
monolayers ± SEM.  
 
(B) Effect of the BCRP inhibitor Ko143 (10µM) on prazosin net flux (Jnet) across 
Caco-2 cell monolayers. Control curve is a Michaelis-Menten fit, Km = 22.1 ± 
2.9µM and Vmax = 3.57 ± 0.17 nmol.cm
-2
.hr
-1
. Ko143 curve is a Michaelis-
Menten fit, Km = 46.8 ± 17.2 µM and Vmax = 2.54 ± 0.41 nmol.cm
-2
.hr
-1
. Data 
points are means of n = 4-6 monolayers ± SEM.    
 
(C) Effect of the ABC transporter inhibitors Ko143 (10μM) and verapamil 
(100µM) on prazosin bi-directional flux across Caco-2 cell monolayers 
cultured on 24-well Transwell supports. Prazosin donor concentration was 
10µM. Data are means of n = 4-6 monolayers ± SEM. * P < 0.05, significantly 
different from control.  
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Figure 4.9. Bi-directional and net flux of prazosin across confluent Caco-2 cell 
monolayers 
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Figure 4.10. Bi-directional flux of nitrofurantoin across confluent Caco-2 cell 
monolayers 
 
(A) Dose-dependence of nitrofurantoin flux across Caco-2 cell monolayers grown 
to confluency on permeable 96-well Transwell supports. Flux were determined 
in the apical-to-basal (Ja-b) and basal-to-apical (Jb-a) directions where secretory 
net flux (Jnet) = Jb-a – Ja-b. Data points are means of n = 4-6 monolayers ± SEM.  
 
(B) Effect of the BCRP inhibitor Ko143 (10µM) on nitrofurantoin net flux (Jnet) 
across Caco-2 cell monolayers. Control curve is a Michaelis-Menten fit, Km = 
69.4 ± 22.3 µM and Vmax = 14.03 ± 2.27 nmol.cm
-2
.hr
-1
. Ko143 curve is a 
Michaelis-Menten fit, Km = 34.8 ± 12.4 µM and Vmax = 1.3 ± 0.19 nmol.cm
-
2
.hr
-1
. Data points are means of n = 4-6 monolayers ± SEM.   
 
(C) Nitrofurantoin bi-directional and net flux across Caco-2 cells cultured on 24-
well Transwell supports in the presence and absence of ABC transporter 
inhibitors. Nitrofurantoin donor concentration was 10µM. Flux were 
determined in the presence and absence of the ABC transporter inhibitors 
Ko143 (10μM) and verapamil (100µM). Data bars are means of n = 4-6 
monolayers ± SEM. * P < 0.05, significantly different from control.  
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Figure 4.10. Bi-directional flux of nitrofurantoin across confluent Caco-2 cell 
monolayers 
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Figure 4.11. Correlation between Caco-2 and native MDCKII absorptive 
permeability (Papp) of selected compounds 
 
Caco-2 vs. native MDCKII absorptive permeability of compounds. 1. Cimetidine, 2. 
Clozapine, 3. Diclofenac, 4. Flavopiridol, 5. Gefitinib, 6. Nitrofurantoin, 7. 
Novobiocin, 8. Prazosin, 9. Progesterone, 10. Quinidine, 11. Risperidone.  
Linear regression analysis shows no correlation between the permeability of several 
compounds across MDCKII and Caco-2 monolayers. Data points are means of 4-6 
monolayers of MDCKII and Caco-2 cells, d.f = 9, P > 0.05, R
2 
= 0.47. 
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Figure 4.11. Correlation between Caco-2 and native MDCKII absorptive 
permeability (Papp) of selected compounds 
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Figure 4.12. Correlation between absorptive permeability (Pa-b) and the partition 
coefficient (LogP) for select compounds in (A) native MDCKII and (B) Caco-2 
cells  
 
Pa-b vs. LogP. 1. Cimetidine, 2. Clozapine, 3. Diclofenac, 4. Flavopiridol, 5. Gefitinib, 
6. Nitrofurantoin, 7. Novobiocin, 8. Prazosin, 9. Progesterone, 10. Quinidine, 11. 
Risperidone, 12. Sulphasalazine. Curve shows an approximate sigmoid relationship 
and is plotted by hand. 
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Figure 4.12. Correlation between absorptive permeability (Pa-b) and the partition 
coefficient (LogP) for select compounds in (A) MDCKII and (B) Caco-2 cells
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4.4 Discussion 
Various methods have been utilised to screen for BCRP substrates. In Chapter 3 the 
Hoechst 33342 retention assay was shown to have fundamental limitations. Matsson 
et al. (2009), using Saos-2 transfected cells with BCRP, measured the ratio of 
mitoxantrone accumulation after co-incubation with an inhibitor to the accumulation 
observed with mitoxantrone only (Matsson et al., 2009). Alternatively cytotoxicity 
profiles were correlated with BCRP expression levels in the National Cancer Institute 
anticancer drug screen in 60 cell-lines, positive or negative correlations of enhanced 
sensitivity or protection indicating interactions with BCRP (Deeken et al., 2009). 
Another method uses inside-out membrane vesicles prepared from BCRP transfected 
cell-lines (e.g. HEK 293 cells) which has allowed ATP-dependent substrate 
accumulation to be studied (Ni et al., 2010). Finally a photo-active compound, [
125
I]-
IAAP may be used to label BCRP in isolated membranes with BCRP substrates or 
inhibitors used to show inhibition of binding in a concentration-dependent manner (Ni 
et al., 2010). The data presented in this chapter have used reconstituted parental 
MDCKII epithelial cell monolayers together with their ABC transfected MDCKII 
counterparts to determine selective BCRP substrates. By directly comparing native 
wild-type cell monolayers with their transfected counterparts, transported substrates 
may be readily and unambiguously identified by HPLC/MS. This method provides 
many advantages and it may be scaled to multi-well formats (e.g. 24/96 well assays 
used here). Since HPLC/MS compound identification is used, many substrates may be 
examined directly without the need to prepare radioisotopes or use of indirect 
measures such as inhibition of ligand binding. As a live-cell assay, non-specific 
toxicity may be easily identified (monolayer disruption).   
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Bi-directional flux were determined to calculate net flux (Jnet = Jb-a - Ja-b), 
which in turn was used to compare parental and transfected MDCKII cell lines; 
significantly higher secretory flux values were deemed to indicate that a compound 
was a substrate of either human BCRP, mouse Bcrp or human MDR1. Some studies 
rely on the use of the efflux ratio, whereby the secretory flux is divided by the 
absorptive flux (ER = Jb-a / Ja-b) (Xiao et al., 2006). Net secretory flux rather than ER 
was used to determine ABC substrate specificity. The main reason for this was that a 
small change in the absorptive flux resulting from small leaks/change in paracellular 
permeability in monolayers may result in a large change in ER. Monolayer integrity 
was measured using transepithelial electrical resistance (RT) which allows rejection of 
leaky monolayers. However, the low transepithelial resistance of MDCKII epithelial 
monolayers does not allow for accuracy in this regard so that additional controls such 
as bi-ionic diffusion potentials were used to assess the cation selectivity of the 
paracellular pathway. Inclusion of an intra-assay measure of paracellular permeability 
such as lucifer yellow flux is recommended but not all experiments included such a 
control for passive diffusion during the experiment because of complications with the 
robotic script. The magnitude of net secretion is largely unaffected by paracellular 
leak flux so this was used as the primary comparison between parental and transfected 
MDCKII cell layers.  
Fixed measurement parameters were chosen for the screening studies 
described in this Chapter.  Monolayer assays are very sensitive to factors such as time 
and substrate concentration (Hegedus et al., 2009). Time was fixed at 2 hours which 
allows low permeability compounds to be detected. A fixed concentration of 10μM 
compound was chosen for all compounds in the substrate screen. For a high affinity 
substrate Km < 10μM this concentration may saturate transport via hBCRP/mBcrp or 
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MDR1 but also via the endogenous efflux system. As explained by Hunter et al. 
(1991) this would not necessarily decrease the ability to discriminate between passive 
and active transport providing the passive component was low and the Vmax high 
(Hunter et al., 1991). For a low affinity substrate Km > 10μM the active component 
for a finite Vmax would be lower so that the discrimination ability would be lower. 
 One of the noticeable complications in using the MDCKII cell monolayers is 
the presence of endogenous transporters for the compounds tested. Indeed 
transepithelial secretion of the majority of the compounds is observed across native 
MDCKII cell monolayers, an observation corroborated by the data in Chapter 3 with 
Hoechst 33342 retention. Transepithelial secretion requires both transport across the 
basal membrane with subsequent ABC-dependent extrusion across the apical 
membrane. An inability to access a transport step at the basal membrane would render 
an ABC-substrate to be not secreted. Alternatively the capacity of transport at the 
basal membrane may rate limit overall secretory transport rate (Xiao et al., 2006). 
This endogenous ABC dog transporter expressed in MDCKII cells is likely to be 
MDR1 but additional ABC transporters may exist (Hunter et al., 1991; Pavek et al., 
2005). This could well mask the secretion that would normally be seen with 
BCRP/MDR1 transfected capacity. 
 Therefore compounds such as cimetidine and quinidine maybe preferentially 
transported by the endogenous protein but may well be BCRP and MDR1 substrates. 
Further work is needed to define the nature of secretory flux and their molecular basis 
in MDCKII cells. However it can be certain that as nitrofurantoin is not secreted in 
native MDCKII cells, it has different substrate specificity or dog BCRP is not 
expressed. A final complication may reside in the presence of absorptive transport 
mechanisms in the brush-border of MDCKII epithelial cells; mitoxantrone has been 
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shown to be a substrate for an uptake pathway that increases Ja-b, above Jb-a, so 
obscuring secretion (Pan et al., 2009). In the present data set nitrofurantoin shows 
substantial net absorption in native MDCKII monolayers.  Species differences 
between MDR1 function were shown by Feng et al. (2008) to be minimal between 
human and mouse. Furthermore, Zhou et al. (2009) showed that there was minimal 
difference with respect to human BCRP and mouse Bcrp function. Data on the 
respective dog proteins is however sparse. Out of the 11 compounds screened in this 
study, 5 compounds were secreted by human BCRP, 5 secreted by mouse Bcrp and 4 
of these substrates were shared between human and mouse Bcrp. Human and mouse 
proteins show 81% identity and as 4 out of 5 substrates were shared between human 
and mouse BCRP/Bcrp this strong correlation demonstrates that mouse mBcrp can be 
an important tool in understanding BCRP function in man. The MDCKII substrate 
screens combined with the pharmacological inhibitors provide additional evidence for 
compound identification as BCRP substrates. Flavopiridol, prazosin and 
nitrofurantoin were confirmed as human BCRP substrates in this manner. The 
substrate screen however failed to identify known substrates perhaps due to the 
reasons outlined above.  Cimetidine is a known BCRP and MDR1 substrate yet was 
not identified as a substrate, whilst quinidine is a widely used MDR1 substrate and 
was not identified as an MDR1 substrate.  
 Caco-2 human intestinal epithelial monolayers have been frequently used to 
predict the likely bioavailability of compounds from the lumen (oral route). Artursson 
and Karlsson (1991) have compared the oral bioavailability of 20 compounds with 
absorptive permeability coefficients measured in Caco-2 cells. The data are best-fit by 
a sigmoid with an apparent upper limit of permeability P > 10
-6
 cm/sec. In addition 
these authors correlated Caco-2 permeability with the log octanol/water partition 
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coefficient (LogP) and found a sigmoid relationship with saturation of Caco-2 
permeability at greater than 10
-5 
cm/sec at a log D > 0. However there were 
exceptions to this for both lipophilic and hydrophilic compounds most probably 
related to transport phenomena. Table 4.1 summarises absorptive permeabilities 
measured in both MDCKII and Caco-2 epithelial layers. Figure 4.11 shows the 
relationship between measurements in these 2 systems. As expected, due to the 
differences in membrane protein transporter expression between MDCKII cells and 
Caco-2 cells at the apical and basolateral surfaces (Hilgendorf et al., 2007) there is not 
a strong relationship in absorptive permeabilities between the 2 cell systems.  
 Figure 4.12 displays the relationship between the absorptive permeability in 
Caco-2 cells and the LogP value, as noted by Artursson and Karlsson (1991). 
However with this data set there is not a clear sigmoid relationship showing saturation 
(unlike that shown by Artursson and Karlsson, 1991); there are too many exceptions 
to this, perhaps a larger compound screen would show differently. Prazosin displays 
higher values of absorptive permeability than expected on the basis of its LogP value. 
This may relate to either a specific transport system present in the apical 
membrane/transcellular route or access to the cation-selective paracellular route. 
Transporters of relevance affecting absorptive permeability may include OATPs, 
OCTs, and OATs (Hilgendorf et al., 2007). Gefitinib and sulphasalazine, in contrast 
display markedly reduced absorptive permeabilities on the basis of their LogP values. 
The most likely reason for this is that the operation of efflux mechanisms at the brush-
border limits transcellular transport.  
 A primary aim of this chapter was to confirm the existence of a BCRP 
mediated component of secretion in the Caco-2 cells despite the existence of multiple 
ABC transporters. Flavopiridol, nitrofurantoin and prazosin all showed Ko143 
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sensitive components of transepithelial secretion. The main route of flavopiridol 
secretion appeared to be via another ABC transporter such as MRP2. BCRP was only 
clearly involved at higher concentrations of flavopiridol. Prazosin was shown using 
Ko143 and verapamil, as BCRP and MDR1 selective inhibitors respectively, to be a 
substrate for both BCRP and MDR1 substrate as previously reported (Cerveny et al., 
2006; Feng et al., 2008; Matsson et al., 2009; Muenster et al., 2008; Polli et al., 2001; 
Staud et al., 2006; Zhou et al., 2009). However the majority of the secretion in Caco-2 
epithelia was via BCRP with only a marginal secretion by MDR1. This compound 
and its fluorescent derivatives could therefore be a useful tool in further investigations 
of BCRP function. However nitrofurantoin secretion was shown to be a selective 
BCRP substrate that was verapamil insensitive. MDR1 and MRP2 have been ruled 
out as transporters of nitrofurantoin in vitro (Merino et al., 2005; Wang & Morris, 
2007), with both studies showing BCRP alone mediates nitrofurantoin transport. 
However there is some speculation in the literature about the specificity of 
nitrofurantoin secretion via BCRP. A pharmacogenetic study looking at patients with 
the C421A polymorphism which reduces functional BCRP activity in vitro, showed 
human nitrofurantoin pharmacokinetics not to change in those individuals (Adkison et 
al., 2008). If nitrofurantoin is secreted by only BCRP, this mutation, which is known 
to widely affect transport of many BCRP substrate in vivo (Sparreboom et al., 2004, 
2005; Zhang et al., 2006), should cause the pharmacokinetic profile of nitrofurantoin 
in these patients to be altered. No MRP transfected MDCKII cell lines were used in 
the substrate screen to test for MRP involvement in nitrofurantoin secretion. However 
verapamil at 100μM is known to inhibit both MRP1 and MRP2 (Matsson et al., 
2007), and was found to have no effect on secretion in the Caco-2 cells, suggesting no 
MRP transporter involvement. To further confirm whether the MRP transporters were 
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not involved in nitrofurantoin secretion, CMFDA accumulation assay described by 
(Bogman et al., 2003) was used (CMFDA being a fluorescent dye that is a 
promiscuous MRP substrate). Nitrofurantoin at 1, 10 or 100µM did not affect 
accumulation of CMFDA in native or MRP2 over expressing MDCKII cells 
(unpublished data). The near abolition by Ko143 of nitrofurantoin secretion in Caco-2 
cells is very good evidence that nitrofurantoin may be used as a selective substrate for 
BCRP in conditions where there are multiple ABC transporters expressed as is the 
case for Caco-2 cells. 
 In summary, the BCRP substrate screen using the MDCKII cells serves as a 
convenient and direct method for identification of BCRP substrates in vitro. The use 
of pharmacological inhibitors in Caco-2 cells allowed the characterization of a BCRP 
mediated component in low-passage epithelia. Nitrofurantoin is identified as a 
selective BCRP substrate. 
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5. The mechanism of transepithelial 
ciprofloxacin secretion 
 
5.1 Introduction 
Ciprofloxacin is a widely prescribed fluoroquinolone antibiotic that displays a wide 
spectrum activity against both Gram positive and negative bacteria. Fluoroquinolones 
penetrate well into most body tissues and fluids, having a high volume of distribution 
relative to total body water, making them ideal for treating soft tissue infections.  
Most fluoroquinolone antibiotics are administered orally with high bioavailability. 
However ciprofloxacin bioavailability is between 50-80% (Sorgel et al., 1989). 
Ciprofloxacin is therefore deemed as a low permeability (poor absorption) compound 
(Volpe, 2004; Zakelj et al., 2006) with an octanol/water partition coefficient (LogP) 
value of 1.4, typical of a hydrophilic compound (Zhao et al., 2002). Ciprofloxacin 
undergoes minimal metabolism and is mainly excreted as the parent molecule. 
Clearance is predominantly renal in vivo (Rohwedder et al., 1990; Sorgel et al., 
1989). However, it is also cleared via the intestine (10% of an i.v dose) and into the 
bile (1% of an i.v dose) (Parry et al., 1988; Rohwedder et al., 1990). The exact nature 
of ciprofloxacin efflux across the intestine has been investigated by several 
laboratories and is mediated by ATP-binding cassette (ABC) transporters in common 
with other fluoroquinolones (Alvarez et al., 2008).  
Griffiths et al. (1993, 1994) first confirmed an energy dependent secretion of 
ciprofloxacin in human intestinal Caco-2 cells (Griffiths et al., 1994, 1993). By 
measurements of ciprofloxacin transport across both apical and basolateral 
membranes and cellular accumulation, calculation of the unidirectional flux indicated 
an “active” component at both basolateral and apical membranes (Griffiths et al., 
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1994). These studies suggest the involvement of an ABC transporter-mediated efflux 
of ciprofloxacin but not its exact identity. 
MDR1 involvement in Caco-2 cell mediated secretion appears unlikely since 
Cavet et al. (1996, 1997) showed no effect of ciprofloxacin on secretion of the known 
MDR1 substrate vinblastine (Cavet et al., 1997, 1996). Although the anti-MDR1 
monoclonal antibodies MRK16 and UIC2 reduced vinblastine secretion neither had 
any effect on ciprofloxacin secretion. Further investigation confirmed that MDR1 was 
not involved since with native MDCKII cell monolayers or MDCKII cell monolayers 
over-expressing human MDR1, no ciprofloxacin secretion was seen (Lowes & 
Simmons, 2002). 
Lowes and Simmons (2002) further investigated the nature of ciprofloxacin 
secretion in Caco-2 cells and looked at the potential involvement of MRP2. It was 
shown that MRP2 is unlikely to facilitate ciprofloxacin transport since the MRP 
selective inhibitor, MK571, had only a minor effect on ciprofloxacin secretion. 
Furthermore, over-expressing MRP2-MDCKII cell monolayers showed no net 
secretion of ciprofloxacin (Lowes, 2001).  
MRP1 was shown not to be involved in mediating ciprofloxacin transport 
using J774 macrophages (Michot et al., 2004), although it is suggested that another 
MRP family member was involved in ciprofloxacin transport since the organic anions 
gemfibrozil and probenecid inhibited ciprofloxacin efflux (Michot et al., 2004).  
Grepafloxacin, a fluoroquinolone only differing from ciprofloxacin by 2 
additional methyl groups (Lowes & Simmons, 2002), was shown to be secreted by 
both MDR1 and MRP2. However, grepafloxacin was shown to competitively inhibit 
ciprofloxacin secretion, showing that there is a third route of secretion shared by 
grepafloxacin and ciprofloxacin. This common pathway has yet to be determined. 
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Ciprofloxacin appears to fit the preferential criteria of a BCRP substrate 
outlined by the International Transporter Consortium (Giacomini et al., 2010); 
ciprofloxacin possesses fused heterocyclic rings and amine side groups, characteristic 
for binding to BCRP. Merino et al. (2006) used the MDCKII cell line stably 
transfected with the human and mouse homologues of BCRP/Bcrp to show that 
ciprofloxacin was a substrate for mouse Bcrp, whereas hBCRP mediated secretion 
was, at best, marginal (Merino et al., 2006). 
The same group used Bcrp ko (-/-) null mice to show that mouse Bcrp affects 
ciprofloxacin pharmacokinetics in vivo (Merino et al., 2006). They showed that after 
subcutaneous injection ciprofloxacin plasma concentrations were elevated 2-fold 
compared with wild type animals and further showed that wild type lactating dams 
had a 2-fold higher concentration of ciprofloxacin in their milk compared with Bcrp 
ko (-/-) lactating mice (Merino et al., 2006). Further work demonstrated mBcrp 
involvement in the biliary excretion of ciprofloxacin in mice (Ando et al, 2007). 
Therefore, it seems likely that BCRP is involved in intestinal secretion of 
ciprofloxacin in humans. 
Other ABC transporters may also be involved. Using murine J774 
macrophages (Marquez et al., 2009) selected for resistance to ciprofloxacin, the 
nature of ciprofloxacin secretion was examined; gemfibrozil (non-specific MRP 
inhibitor) inhibited ciprofloxacin excretion but elacridar,  a dual P-glycoprotein and 
BCRP inhibitor was largely ineffective (Marquez et al., 2009). Furthermore 
ciprofloxacin resistant J774 macrophages had an increased expression of both Mrp2 
and Mrp4 family members. Using siRNA knock down it was demonstrated that just 
Mrp4 was responsible for the drug resistant phenotype by preventing cellular 
accumulation of ciprofloxacin. Thus ciprofloxacin is a substrate for mouse Mrp4 and 
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chronic exposure of ciprofloxacin causes an up-regulation of Mrp2 and Mrp4, 
suggesting this may occur in other eukaryotic cell types.   
The main aim of this chapter is to examine the role of hBCRP in mediating 
ciprofloxacin secretion. Ciprofloxacin transport will be determined in human and 
mouse BCRP/Bcrp transfected MDCKII cell-layers. Then the mechanism of 
ciprofloxacin secretion by human intestinal Caco-2 epithelia will be addressed using 
two variant cell lines, low and high passage (PA) Caco-2 cell, in which BCRP 
expression is different. Finally the possible involvement of MRP4 in ciprofloxacin 
transport will be tested.  
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5.2 Methods 
5.2.1 Bi-directional transport across epithelial layers grown on 12-
well filter plates 
Bi-directional [
14
C]-ciprofloxacin transport across cell monolayers was determined by 
scintillation counting in the same way as described in Materials and Methods (Section 
2.2.2.2). [
14
C]-Ciprofloxacin was a gift from Bayer (Wuppertal, Germany). 
5.2.2 Bi-directional transport across epithelial layers grown on 96-
well filter plates  
Bi-directional ciprofloxacin transport across 96-well cell monolayers was determined 
by HPLC-MS in the same way as described in Materials and Methods (Section 
2.2.2.2). 
5.2.3 Cellular ciprofloxacin accumulation in HEK 293 cells 
HEK 293 cells were seeded at a density of 5 x 10
4 
cells into 12-well plates (Corning). 
Cells were grown for 4 days. Media was aspirated and cells were washed 2x with pre-
warmed Krebs‟ buffer. Transport solutions comprised Krebs‟ buffer with [14C]-
ciprofloxacin (0.1µCi.ml
-1
, made up to 10µM with unlabelled ciprofloxacin) plus the 
addition of pharmacological inhibitors. Cells were incubated at 37°C for 1 hour with 
ciprofloxacin solutions and were then washed 2x with ice cold Krebs‟ to remove 
bound isotope from the cell surface. Cells were then treated with 500µl lysis buffer 
(0.05% Triton X-100) for 15-30 minutes. After lysis a 50µl aliquot was dispensed into 
2.5ml of scintillation cocktail and radioactivity was determined by scintillation 
counting, whilst another 50µl of sample was collected for measurement and protein 
correction via a Bradford Assay. Cellular accumulation of [
14
C]-ciprofloxacin (10μM) 
was determined by scintillation counting. Cellular accumulation was determined as 
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shown in Material and Methods section 2.2.2.2. Values were then normalised to 
control values and displayed as arbitrary values. 
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5.3 Results 
5.3.1 Bi-directional ciprofloxacin flux across MDCKII cell 
monolayers 
[
14
C]-Ciprofloxacin transepithelial flux were determined in both the absorptive (Ja-b, 
apical to basal) and secretory (Jb-a, basal to apical) directions in native MDCKII, 
hBCRP-MDCKII and mBcrp1-MDCKII cell monolayers (Figure 5.1). In wild-type 
MDCKII cell monolayers and human BCRP-transfected MDCKII cell monolayers the 
bi-directional flux were similar (0.16 ± 0.03 nmol.cm
-2
.hr
-1
 and 0.12 ± 0.01 nmol.cm
-
2
.hr
-1
, for Ja-b and Jb-a, respectively, and 0.22 ± 0.05 nmol.cm
-2
.hr
-1
 and 0.18 ± 0.02 
nmol.cm
-2
.hr
-1
, Ja-b and Jb-a, respectively) with no significant net secretory flux evident 
(Figure 5.1 A and B).   
However, in contrast to the hBCRP-MDCKII epithelial layers which showed 
no ciprofloxacin secretion, in murine Bcrp1-MDCKII cell monolayers a marked net 
secretion of  ciprofloxacin  was evident (Jnet = -0.03 ± 0.03 nmol.cm
-2
.hr
-1
 for WT and 
0.24 ± 0.02 nmol.cm
-2
.hr
-1
 for mBcrp transfected cell layers, n = 3, P < 0.05, Figure 
5.1 C, D). Over expression of mBcrp increased basal to apical flux to 0.34 ± 0.03 
nmol.cm
-2
.hr
-1
, (n = 3, P < 0.05 vs. control values). Efflux ratios (Jb-a / Ja-b) for 
ciprofloxacin transport were 0.78, 0.81 and 3.4 for WT-MDCKII, hBCRP-MDCKII 
and mBcrp1-MDCKII cells respectively. The findings in this study support the data 
published by Merino et al. (2006) who showed the absorptive ciprofloxacin net flux 
across the native MDCKII cell monolayers to be reversed to a net secretion of 
ciprofloxacin with murine Bcrp transfection (Merino et al., 2006). Merino et al. 
(2006) also found a marginal secretion of ciprofloxacin in the human BCRP-MDCKII 
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cells, but this was only significant after 4 hours of incubation. These authors 
hypothesised that the cell line had only poor expression of BCRP compared to the 
murine variant (Bcrp). In order to discount the possibility that the reduced 
ciprofloxacin secretion was due to a measurement artefact associated with the use of 
radiolabel, ciprofloxacin flux were also determined in the robotic 96-well assay but 
with total ciprofloxacin in receiver wells being determined by HPLC-MS (see 
Methods). Table 5.1 confirms that no net secretion of ciprofloxacin is observed in 
native MDCKII cell layers and that mBcrp transfected cell-layers maintain a 
significant secretory flux and enhanced efflux ratio (Table 5.1). Furthermore, in 
hBCRP-MDCKII epithelial layers a significant but small secretion of ciprofloxacin 
was observed (Table 5.1). 
The kinetics of mBcrp mediated ciprofloxacin secretion is shown in Figure 
5.2. Net ciprofloxacin secretion displays saturation kinetics with a Km of 167 ± 63 µM 
and a Vmax of 10.2 ± 1.3 nmol.cm
-2
.hr
-1
. 
The pharmacological sensitivity of ciprofloxacin secretion by mBcrp1-
MDCKII cells was assessed (Figure 5.3). Ko143, a potent and specific BCRP 
inhibitor (Allen et al., 2002) was shown earlier to have an IC50 of 0.15μM for Hoechst 
33342 accumulation in mBcrp1-MDCKII cells (see Chapter 3) and 1.06μM for 
Hoechst 33342 accumulation in hBCRP-MDCKII cells (see Chapter 3). Used at a 
concentration of 1μM, Ko143 completely abolished net secretory ciprofloxacin flux in 
mBcrp1-MDCKII cells (0.24 ± 0.02 nmol.cm
-2
.hr
-1
 to –0.05 ± 0.03 nmol.cm-2.hr-1, n = 
3, P < 0.05, Figure 5.2A).  
The ratio of ciprofloxacin permeability (Pb-a / Pa-b) was reduced from 2.77 ± 
0.16 in control to 0.65 ± 0.24 in the presence of 1µM Ko143, (n = 3, P < 0.05, Figure 
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5.3B). Furthermore 1µM Ko143 increased cellular accumulation across the 
basolateral membrane from 4.56 ± 0.29 µM to 6.46 ± 0.39 µM (n = 3, P < 0.05, 
Figure 5.3C), although the concentration never exceeds that of the external medium 
(10µM). There was no significant change in accumulation across the apical surface in 
the presence of 1µM Ko143. 
Cyclosporin A (CsA) is now known to inhibit both MDR1 and BCRP, albeit 
with lower affinity (Ejendal & Hrycyna, 2005; Matsson et al., 2009). In the present 
study, application of a high dose of 50μM CsA greatly reduced net secretory 
ciprofloxacin flux in mBcrp1-MDCKII cells (0.24 ± 0.02 nmol.cm
-2
.hr
-1
 to 0.04 ± 
0.02 nmol.cm
-2
.hr
-1
, n = 3, P < 0.05 versus controls). 
It has been previously shown that the anion transport inhibitor 4,4´-
diisothiocyanostilbene-2,2´-disulphonic acid (DIDS) at 0.4mM inhibits ciprofloxacin 
secretion across Caco-2 cell monolayers (Cavet et al., 1997). It was found in this 
study that DIDS only partially inhibits ciprofloxacin secretion in mBcrp1-MDCKII 
cells by ~25% (0.24 ± 0.02 nmol.cm
-2
.hr
-1
 to 0.18 ± 0.02 nmol.cm
-2
.hr
-1
, n = 3, P < 
0.05). DIDS is therefore not a definitive inhibitor with respect to ciprofloxacin 
secretion.   
MK571 is a known MRP selective inhibitor and was included in the study to 
confirm the involvement of MRP family members in ciprofloxacin secretion in 
MDCKII cells. Matsson et al. (2009) report MK571 to be also an inhibitor of BCRP 
(at 50μM), although MK571 has no effect on ciprofloxacin secretion at 10μM or ratio 
of bi-directional permeabilities (Figure 5.2A and B). MK571 had no significant effect 
on ciprofloxacin cellular accumulation across the apical and basolateral membranes. 
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5.3.2 Is ciprofloxacin secretion mediated by BCRP in Caco-2 cell 
monolayers? 
It has already been shown (Chapter 3) that  whereas  low passage Caco-2 cells express 
hBCRP, high passage Caco-2 cells have only limited expression in comparison. Both 
strains of Caco-2 cells used in this study, high passage (111-116 passage) and low 
passage (34-45 passage), secreted ciprofloxacin (Figure 5.4 and 5.5 respectively).  
Ciprofloxacin secretion by Caco-2 cells has been the subject of extensive studies in 
Caco-2 epithelia (Cavet et al., 1997; Griffiths et al., 1993; Lowes & Simmons, 2002). 
The efflux ratios (Jb-a / Ja-b) for ciprofloxacin transport were 3.55 and 1.94 for high and 
low passage Caco-2 cells respectively. Basolateral ciprofloxacin cellular uptake 
(accumulation) was significantly greater than accumulation across the apical 
membrane (p = 0.0314 and p = 0.085 for both high and low passage Caco-2 cells 
respectively), suggesting the existence of a basolateral uptake mechanism. 
Ko143 at 1µM was used to test for a BCRP mediated component of 
ciprofloxacin secretion in Caco-2 cells of high or low passage Caco-2 cell strains. No 
significant effect of 1µM Ko143 on ciprofloxacin secretion was seen in the high 
passage Caco-2 cell monolayers (Figure 5.4) consistent with the low levels of BCRP 
expression. In contrast, in low PA Caco-2 cells 1µM Ko143 reduced, but did not 
abolish net ciprofloxacin secretion from 0.26 ± 0.02 nmol.cm
-2
.hr
-1
 to 0.13 ± 0.02 
nmol.cm
-2
.hr
-1
 (n = 4, P < 0.05, Figure 5.5). The ratio of bi-directional permeabilities 
for ciprofloxacin was reduced from 2.29 ± 0.18 to 1.63 ± 0.07 in the presence of 1µM 
Ko143. No effect upon cellular accumulation across the apical and basolateral 
membranes in either high or low passage Caco-2 cells was seen for 1µM Ko143 
(Figure 5.4C and 5.5C respectively). 
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The effects of a higher concentration of 10µM Ko143 was also tested in the 
low passage Caco-2 cells; net ciprofloxacin secretion was reduced from 0.26 ± 0.02 
nmol.cm
-2
.hr
-1
 to 0.11 ± 0.02 nmol.cm
-2
.hr
-1
 (n = 3, P < 0.05, Figure 5.6). 10µM 
Ko143 also reduced the ratio of bi-directional permeabilities from 2.29 ± 0.18 to 1.36 
± 0.1 P < 0.05, (Figure 5.6). Therefore, a significant component of ciprofloxacin 
secretion remains after inhibition by Ko143. The IC50 of Ko143 on hBCRP was 
previously shown to be 1.06µM (Chapter 3 section 3.3.3.3). 
Ciprofloxacin flux was sensitive to 50μM CsA in both Caco-2 strains, 
reducing net secretion from 0.39 ± 0.06 nmol.cm
-2
.hr
-1
 to 0.14 ± 0.03 nmol.cm
-2
.hr
-1
, 
(n = 3, P < 0.05) and 0.26 ± 0.02 nmol.cm
-2
.hr
-1
 to 0.08 ± 0.00(7) nmol.cm
-2
.hr
-1
 (n = 
3, P < 0.05) in high and low passage Caco-2 cell monolayers respectively (Figures 
5.4B and 5.5B).  
It has been previously shown that the anion transport inhibitor 4,4´-
diisothiocyanostilbene-2,2´-disulphonic acid (DIDS) at 0.4mM inhibits ciprofloxacin 
secretion across Caco-2 cell monolayers (Cavet et al., 1997). Secretory ciprofloxacin 
flux was reduced in both high and low passage Caco-2 cell monolayers from 0.39 ± 
0.06 nmol.cm
-2
.hr
-1
 to 0.14 ± 0.03 nmol.cm
-2
.hr
-1
, n = 3, P < 0.05,  a ~65% reduction,  
and 0.26 ± 0.02 nmol.cm
-2
.hr
-1
 to 0.09 ± 0.02 nmol.cm
-2
.hr
-1
, n = 3, P < 0.05, also a  
~65% reduction, respectively (Figures 5.4B and 5.5B). DIDS also had a profound 
effect on cellular ciprofloxacin accumulation in both Caco-2 cell strains. In high 
passage Caco-2 cell monolayers cellular accumulation across the apical membrane 
rose from 14.91 ± 1.89 µM to 39.1 ± 9.16 µM, whilst accumulation across the 
basolateral membrane also increased from 24.59 ± 2.31 µM to 49.05 ± 12.61 µM. The 
same pattern was seen in the low passage Caco-2 cell-strain with apical accumulation 
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changing from 11.25 ± 0.55 µM to 26.32 ± 1.38 µM, whilst accumulation across the 
basolateral membrane also increased from 19.01 ± 1.51 µM to 60.2 ± 0.63 µM. 
Although DIDS is known to possess diverse pharmacological actions, the contrasting 
actions of DIDS on ciprofloxacin secretion in mouse Bcrp1-MDCKII and Caco-2 
cells of both strains, suggests that DIDS inhibits a component of ciprofloxacin 
secretion that is unrelated to BCRP.   
 
5.3.3 Is MRP4 involved in ciprofloxacin secretion? 
 
Given the identification by Marquez et al. (2009) that MRP4 was involved in active 
efflux of ciprofloxacin from macrophages, a possible involvement of MRP4 in Caco-2 
mediated ciprofloxacin transport was tested. First ciprofloxacin accumulation was 
investigated in WT-HEK 293 and MRP4-transfected HEK 293 epithelial cells. 
Initially qPCR analysis confirmed a significantly greater expression of MRP4 
mRNA in the MRP4-HEK 293 cells compared with the wild type cells (Figure 5.7, n 
= 3 extractions, P < 0.05). Net ciprofloxacin uptake was significantly reduced in the 
MRP4-overexpressing line in relation to the wild-type (Figure 5.8) indicating MRP4-
mediated ciprofloxacin export. To confirm MRP4 involvement the addition of MRP 
inhibitors dipyrimadole (10μM), indomethacin (25μM), quercetin (10μM) and 
importantly MK571 (10μM) all resulted in significant increases in accumulation 
above control levels in both wild-type and transfected cells, with MK571 increasing 
ciprofloxacin accumulation in MRP4-HEK cells to the levels seen in un-transfected 
cells (Figure 5.8). Ko143 at 1μM was without effect on ciprofloxacin accumulation in 
either control or MRP4-HEK cells confirming the relative specificity of this agent. 
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These data therefore indicates that MRP-family members other than MRP4 are 
expressed in HEK cells and that ciprofloxacin is indeed an MRP4 substrate. 
To test for MRP4 involvement in Caco-2 cells firstly qPCR was conducted to 
find the expression of MRP4 mRNA in both Caco-2 cell variants. Figure 5.7 shows 
the low passage Caco-2 cells had a greater expression of MRP4 mRNA in comparison 
to high passage Caco-2 cells (n = 3 extractions, P < 0.05). Low passage Caco-2 cells 
were used in the presence of the MRP inhibitors indomethacin (10μM) and MK571 
(10μM) to confirm MRP4 involvement (Figure 5.6). No significant changes in 
ciprofloxacin flux were seen with any of the MRP4 modulating agents, confirming 
that MRP4 is not involved in Caco-2 cell mediated ciprofloxacin secretion.  
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Figure 5.1. Transepithelial [
14
C]-ciprofloxacin flux across BCRP transfected 
MDCKII cell monolayers 
 
Figures (A)-(C) show the time dependence of [
14
C]-ciprofloxacin flux (0.1µCi.ml
-1
, 
made up to 10µM with unlabelled ciprofloxacin) across confluent monolayers of (A) 
native MDCKII, (B) human BCRP-MDCKII (C) and mouse Bcrp1-MDCKII cells 
grown on 12-well permeable supports. Flux were determined in the apical-to-basal (Ja-
b) and basal-to-apical (Jb-a) directions where secretory net flux (Jnet) = Jb-a - Ja-b. Data 
bars are means of 3 independent experiments (n = 9 monolayers) ± SEM.  
Figure (D) shows transepithelial [
14
C]-ciprofloxacin flux averaged over the 3 hours 
for native MDCKII, human BCRP-MDCKII and mouse Bcrp1-MDCKII. Data bars 
are means of 3 independent experiments (n = 9 monolayers) ± SEM. * P < 0.05 
represent significant difference of transfected MDCKII net flux compared to native 
MDCKII.   
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Figure 5.1. Transepithelial [
14
C]-ciprofloxacin flux across native and BCRP 
transfected MDCKII cell monolayers 
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Table 5.1. Table showing bi-directional flux of ciprofloxacin in epithelial cell 
monolayers measured by HPLC-MS  
 
Summary table of bi-directional flux in the apical to basal direction, basal to apical 
direction, net secretion (Jnet = Jb-a - Ja-b) and efflux ratio (Jb-a / Ja-b) of ciprofloxacin 
across MDCKII and low PA Caco-2 cell monolayers. Cells were grown to confluency 
on 96-well permeable Transwell supports and assays were conducted via automation 
on a Hamilton StarPlus Robot. Ciprofloxacin was used at a concentration of 10µM. 
Data points are means of n = 4-6 wells, data were pooled and normalised from 2 
independent experiments ± SEM. 
 
Bidirectional Flux 
(pmol.cm2.hr-1)
Ja-b Jb-a Jnet Efflux Ratio
MDCKII 22.3 ± 22.3 12.1 ± 12.1 -10.2 ± 10.2 0.5 ± 0.1
hBCRP-MDCKII 11.4 ± 4.9 28.5 ± 8.7 17.1 ± 4 2.5 ± 2.3
mBcrp1-MDCKII 1.2 ± 0.1 77.7 ± 5.8 76.6 ± 5.8 67 ± 2
Caco-2 1.2 ± 0.2 132.9 ± 23.1 131.8 ± 23 110.8 ± 9.4
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Figure 5.2. Concentration dependent curves showing the transepithelial flux of 
ciprofloxacin across confluent mouse Bcrp1-MDCKII monolayers 
 
Concentration dependence of unidirectional (Ja-b, Jb-a) and net ciprofloxacin secretion 
across confluent mouse Bcrp1-MDCKII monolayers. Donor [
14
C]-ciprofloxacin was 
made up to concentrations using unlabelled ciprofloxacin. Curves show a Michaelis-
Menten fit, net ciprofloxacin, Km = 169.9 ± 62.7 µM and Vmax = 10.2 ± 1.3 nmol.cm
-
2
.hr
-1
. Data points are mean of n = 9 monolayers ± SEM from 3 independent 
experiments.  
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Figure 5.2. Concentration dependent curves showing the transepithelial flux of 
ciprofloxacin across confluent mouse Bcrp1-MDCKII monolayers 
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Figure 5.3. Effect of known ABC transporter inhibitors on (A) Bi-directional 
ciprofloxacin flux (B) Ciprofloxacin membrane permeability and (C) 
Intracellular ciprofloxacin levels across mouse Bcrp1-MDCKII monolayers 
 
(A) Sensitivity of net transepithelial [14C]-ciprofloxacin flux (0.1µCi.mL-1 plus 
10µM unlabelled) to pharmacological inhibition across mBcrp1-MDCKII cell 
monolayers. Net flux (Jnet = Jb-a - Ja-b) were determined in the presence and 
absence of Ko143 (1μM) and MK571 (10μM). Data bars are means of 3 
independent experiments (n = 9 monolayers) ± SEM. Significant reductions in 
Jnet compared to control values are denoted by * P < 0.05.  
 
(B) Sensitivity of [14C]-ciprofloxacin permeability (0.1µCi.ml-1, made up to 10µM 
with unlabelled) to pharmacological inhibition across mBcrp1-MDCKII cell 
monolayers. Cellular permeabilities (Pb-a / Pa-b) were determined in the 
presence and absence of Ko143 (1µM) and MK571 (10μM). Data bars are 
means of 3 independent experiments (n = 9 monolayers) ± SEM. Significant 
reductions in permeability compared to control values are denoted by * P < 
0.05.  
 
 
(C) Sensitivity of cellular [14C]-ciprofloxacin uptake (0.1µCi.ml- 1 made up to 
10µM with unlabelled) to pharmacological inhibition across the apical and 
basolateral membranes of mBcrp1-MDCKII cell monolayers. The 
pharmacological inhibitors used were Ko143 (1µM) and MK571 (10μM). 
Data bars are means of 3 independent experiments (n = 9 monolayers) ± SEM. 
Significant reductions in accumulation compared to control values are denoted 
by * P < 0.05.  
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Figure 5.3. Effect of known ABC transporter inhibitors on (A) Bi-directional 
ciprofloxacin flux (B) Ciprofloxacin membrane permeability and (C) 
Intracellular ciprofloxacin levels across mouse Bcrp1-MDCKII monolayers 
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Figure 5.4. Transepithelial [
14
C]-ciprofloxacin flux across high passage Caco-2 
cell monolayers  
 
(A) Time dependence of [14C]-ciprofloxacin unidirectional flux (0.1µCi.ml-1, 
made up to 10µM with unlabelled) across confluent monolayers of high PA 
strain Caco-2 cells (passage 111-116) grown on 12-well permeable supports. 
Flux were determined in the apical-to-basal (Ja-b) and basal-to-apical (Jb-a) 
directions where secretory net flux Jnet = Jb-a – Ja-b. Data points are mean of n = 
9 monolayers ± SEM from 3 independent experiments. 
 
(B) Sensitivity of net transepithelial [14C]-ciprofloxacin flux (0.1µCi.ml-1, made 
up to 10µM with unlabelled) to pharmacological inhibition across high PA 
Caco-2 cell monolayers. Net flux (Jnet = Jb-a - Ja-b) were determined in the 
presence and absence of CsA (50µM), DIDS (0.4mM) and Ko143 (1μM). 
Data bars are means of 3 independent experiments (n = 9 monolayers) ± SEM. 
Significant reductions in Jnet compared to control values are denoted by * P < 
0.05.  
 
(C) Sensitivity of cellular [14C]-ciprofloxacin uptake (0.1µCi.ml-1, made up to 
10µM with unlabelled) to pharmacological inhibition across the apical and 
basolateral membranes of high PA Caco-2 cell monolayers. The 
pharmacological inhibitors used were; CsA (50µM), DIDS (0.4mM) and 
Ko143 (1μM). Data bars are means of 3 independent experiments (n = 9 
monolayers) ± SEM. Significant reductions in Jnet compared to control values 
are denoted by *P < 0.05. 
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Figure 5.4. Transepithelial [
14
C]-ciprofloxacin flux across high passage Caco-2 
cell monolayers  
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Figure 5.5. Transepithelial [
14
C]-ciprofloxacin flux across low passage Caco-2 
cell monolayers  
 
(A) Time dependence of [14C]-ciprofloxacin unidirectinal flux (0.1µCi.ml-1, made 
up to 10µM with unlabelled) across confluent monolayers of low PA strain 
Caco-2 cells (passage 34-45) grown on 12-well permeable supports. Flux were 
determined in the apical-to-basal (Ja-b) and basal-to-apical (Jb-a) directions 
where secretory net flux (Jnet) = Jb-a – Ja-b. Data points are mean of n = 9-12 
monolayers ± SEM from 3-4 independent experiments. 
 
(B) Sensitivity of net transepithelial [14C]-ciprofloxacin flux (0.1µCi.ml-1, made 
up to 10µM with unlabelled) to pharmacological inhibition across low PA 
Caco-2 cell monolayers. Net flux (Jnet = Jb-a - Ja-b) were determined in the 
presence and absence of CsA (50µM), DIDS (0.4mM) and Ko143 (1μM). 
Data bars are means of 3-4 independent experiments (n = 9-12 monolayers) ± 
SEM. Significant reductions in Jnet compared to control values are denoted by 
* P < 0.05.  
 
(C) Sensitivity of cellular [14C]-ciprofloxacin uptake (0.1µCi.ml-1, made up to 
10µM with unlabelled) to pharmacological inhibition across the apical and 
basolateral membranes of low PA Caco-2 cell monolayers. The 
pharmacological inhibitors used were; CsA (50µM), DIDS (0.4mM) and 
Ko143 (1μM). Data bars are means of 3-4 independent experiments (n = 9-12 
monolayers) ± SEM. Significant reductions in Jnet compared to control values 
are denoted by * P < 0.05.  
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Figure 5.5. Transepithelial [
14
C]-ciprofloxacin flux across low passage Caco-2 
cell monolayers  
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Figure 5.6. Effect of BCRP and MRP4 inhibitors on (A) Net ciprofloxacin flux 
(Jnet) (B) Ciprofloxacin membrane permeability and (C) Cellular ciprofloxacin 
uptake across low passage Caco-2 monolayers 
 
(A) Sensitivity of net transepithelial [14C]-ciprofloxacin flux (0.1µCi.ml-1, made 
up to 10µM with unlabelled) to pharmacological inhibition across low PA 
Caco-2 cell monolayers. Net flux (Jnet = Jb-a - Ja-b) were determined in the 
presence and absence of the MRP4 inhibitors indomethacin (25µM) and 
MK571 (10μM), and the BCRP inhibitor Ko143 at  a higher concentration of 
10µM. Data bars are means of 3-4 independent experiments (n = 9-12 
monolayers) ± SEM. Significant reductions in Jnet compared to control values 
are denoted by  * P < 0.05.  
 
(B) Sensitivity of [14C]-ciprofloxacin permeability (0.1µCi.ml-1, made up to 10µM 
with unlabelled) to pharmacological inhibition across low PA Caco-2 cell 
monolayers. Cellular permeabilities (Pb-a / Pa-b) were determined in the 
presence and absence of the MRP4 inhibitors indomethacin (25µM) and 
MK571 (10μM), and the BCRP inhibitor Ko143 at a higher concentration of 
10µM. Data bars are means of 3-4 independent experiments (n = 9-12 
monolayers) ± SEM. Significant reductions in permeability compared to 
control values are denoted by * P < 0.05.   
 
(C) Sensitivity of cellular [14C]-ciprofloxacin uptake (0.1µCi.ml-1, made up to 
10µM with unlabelled) to pharmacological inhibition across the apical and 
basolateral membranes of low PA Caco-2 cell monolayers. The 
pharmacological inhibitors used were the MRP4 inhibitors indomethacin 
(25µM) and MK571 (10μM), and the BCRP inhibitor Ko143 at a higher 
concentration of 10µM. Data bars are means of 3-4 independent experiments 
(n = 9-12 monolayers) ± SEM. Significant reductions in accumulation 
compared to control values are denoted by * P < 0.05.  
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Figure 5.6. Effect of BCRP and MRP4 inhibitors on (A) Net ciprofloxacin flux 
(Jnet) (B) Ciprofloxacin membrane permeability and (C) Cellular ciprofloxacin 
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Figure 5.7. Demonstration of MRP4 mRNA expression in (A) HEPG2, (B) HEK 
293 and (C) Caco-2 cells 
 
(A) An agarose gel image showing PCR products from HepG2 cells. Lane 1 and 2 
are reverse transcriptase negatives showing no bands of MRP4 or GAPDH 
respectively. Lanes 3 shows the expected MRP4 product at 236 base pairs. 
Lane 4 shows the expected housekeeping gene product of GAPDH. PCR 
product of MRP4 was confirmed by nucleotide sequencing by comparing to 
published sequence, giving 98% identity (see Materials and Methods section 
2.2.3.4). 
 
(B) Real time PCR analysis indicating expression of MRP4 mRNA in native HEK 
and human transfected MRP4-HEK cells. Data bars are adjusted relative to 
GAPDH expression. Quantification was done via the Pfaffl method (bars 
represent n = 3 extractions, ± SD). Significant difference in MRP4 mRNA 
between native HEK and MRP4-HEK cells denoted by * P < 0.05.   
 
(C) Real time PCR analysis indicating expression of MRP4 mRNA in Caco-2 
epithelia. Data bars are adjusted relative to GAPDH expression. Quantification 
was done via the Pfaffl method (bars represent n = 3 extractions, ± SD). 
Significant difference in MRP4 mRNA between low and high passage Caco-2 
cells denoted by * P < 0.05.   
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Figure 5.7. Demonstration of MRP4 mRNA expression in (A) HEPG2, (B) HEK 
293 and (C) Caco-2 cells 
198 
 
Figure 5.8. Effect of MRP4 transfection on [
14
C]-ciprofloxacin cellular uptake in 
HEK 293 cells 
 
(A) Sensitivity of cellular [14C]-ciprofloxacin uptake (0.1µCi.ml-1, made up to 
10µM with unlabelled) to pharmacological inhibition across native and MRP4 
transfected HEK cells. Cells were grown to confluency on 12-well plates. 
Uptake was measured in the presence and absence of the MRP inhibitors 
dypyridamole (10μM), indomethacin (25μM), MK571 (10μM) and quercetin 
(10μM). Data bars are means of 3 independent experiments (n = 9 wells) ± 
SEM. Significant reductions in uptake compared to control values are denoted 
by * P < 0.05, whilst significant differences between HEK native cells and 
MRP4-HEK cells are denoted by #.  
 
(B)  Sensitivity of cellular [14C]-ciprofloxacin uptake (0.1µCi.ml-1, made up to 
10µM with unlabelled) to pharmacological inhibition across native and MRP4 
transfected HEK cells. Cells were grown to confluency on 12-well plates. 
Uptake was measured in the presence and absence of the BCRP inhibitor 
Ko143 (1μM). 
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Figure 5.8. Effect of MRP4 transfection on [
14
C]-ciprofloxacin cellular uptake in 
HEK 293 cells 
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Figure 5.9. Summary diagram of ciprofloxacin transport across Caco-2 cells  
 
Ciprofloxacin (shown in red) was shown to be taken up into both low and high 
passage Caco-2 cells via an unknown route, mainly across the basolateral membrane. 
Ciprofloxacin net secretion occurred across the apical membrane and was mediated 
by BCRP and an unknown mechanism across the low passage Caco-2 cells. Whilst in 
high passage Caco-2 cells BCRP is not involved in secretion due to a low cellular 
expression of BCRP. The exit across the apical membrane is energy dependent and 
remains to be elucidated (candidates that remain include OATPs and MATE 
transporters).  
Apical
Basolateral
BCRP*
?
?
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5.4 Discussion 
It has previously been shown that a major route of ciprofloxacin clearance in vivo is 
secretion across the apical membrane of enterocytes into the intestinal lumen (Sorgel 
et al., 1989; Sorgel et al., 1991). The primary route of ciprofloxacin clearance is via 
the kidneys; however the intestinal route of secretion becomes increasingly important 
in patients that have compromised renal function (Rohwedder et al., 1990). Caco-2 
cells have been previously used to investigate the intestinal clearance of ciprofloxacin 
and demonstrate net secretion of ciprofloxacin across reconstituted Caco-2 epithelia 
with evidence for an energy-dependent export across the apical surface (Cavet et al., 
1997; Griffiths et al., 1993; Lowes & Simmons, 2002). Calculated unidirectional flux 
show that accumulation is at the basolateral surface. This accumulation compared to 
the external medium (an observation seen in this study also) likely acts as a driving 
force across the apical membrane. In this study, two strains of Caco-2 cells have 
further shown net secretion of ciprofloxacin across the apical membrane and a similar 
ciprofloxacin accumulation to previous reports (Cavet et al., 1997; Griffiths et al., 
1993), resulting in ciprofloxacin cellular concentrations higher than the external 
medium (Figures 5.5 and 5.6). Differing strains of Caco-2 cells have arisen most 
likely due to the heterogeneous nature of the original culture and to variable cell 
selection pressures arising in different laboratories due to differences in growth 
conditions, seeding densities, and genetic drift from the original cells (Sambuy et al., 
2005). The two Caco-2 cell strains used in the present studies have different 
transporter expression profiles with marked differences in ABC-transporter 
expression, most notably with respect to BCRP and MRP4. Importantly, despite such 
differences, both Caco-2 cell strains display net ciprofloxacin secretion across the 
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apical surface with a similar basolateral accumulation in these cells (summary 
diagram of ciprofloxacin across Caco-2 cells is shown in Figure 5.9). 
This study confirms that mouse Bcrp transports ciprofloxacin across the apical 
surface of mBcrp1-MDCKII cells, previously shown by Merino et al. (2006). 
Ciprofloxacin exit mediated by mBcrp maintains a low concentration inside the cell. 
Furthermore it shows that ciprofloxacin accumulation was much lower compared with 
the Caco-2 cells.  
Ko143, a selective BCRP inhibitor, completely abolished net secretion of 
ciprofloxacin and increased basolateral accumulation in the mBcrp1-MDCKII cells. 
Conversely ciprofloxacin transport by human BCRP gave mixed results. Human 
BCRP transfected MDCKII cells did not show secretion of radiolabelled [
14
C]-
ciprofloxacin. Ciprofloxacin measured by the more sensitive approach of HPLC-MS 
showed a significant net secretion in the hBCRP-MDCKII cells but this was low 
compared with mBcrp1-MDCKII cells. It may be concluded that human BCRP may 
transport ciprofloxacin, but that its affinity may be reduced compared to that of the 
mouse Bcrp protein. In Chapter 3 it has been demonstrated that the hBCRP-MDCKII 
and mBcrp1-MDCKII cell lines both express BCRP mRNA and protein consistent 
with functional activity. Therefore it is unlikely that a difference in expression level 
may explain the difference in ciprofloxacin transport observed between the mBcrp 
and hBCRP transfected cell lines as suggested by Merino at el (2006). One notable 
difference between the two proteins expressed in MDCK cells is the difference in 
glycosylation on human BCRP and mouse Bcrp. This difference may result in subtle 
differences in substrate binding. Further investigation on this aspect is warranted. 
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The fact that low and high passage Caco-2 cell layers secrete ciprofloxacin 
suggests that a substantial fraction of such secretion occurs via a BCRP-independent 
route. A different approach in investigating the nature of Caco-2 cell mediated 
ciprofloxacin secretion was the use of selective pharmacological inhibitors. Whereas 
Ko143 was ineffective in reducing ciprofloxacin secretion in the high passage Caco-2 
cells, due to the very low expression of BCRP expression in this Caco-2 cell strain 
(see Chapter 3), in the low passage Caco-2 cell line, which has a greater expression of 
BCRP, a reduction in net secretion of ~65% was observed with 1µM Ko143. These 
data show that BCRP may play a significant role in ciprofloxacin secretion across the 
human intestine, but that additional mechanism(s) of ciprofloxacin secretion are 
important.  
Marquez et al. (2009) showed that murine Mrp4 was responsible for 
ciprofloxacin transport in J774 macrophages.  DIDS has been shown both in this 
study and previously to be effective in reducing net secretion and increasing cellular 
ciprofloxacin accumulation in Caco-2 cells. DIDS inhibits the exit pathway at both 
the apical and basolateral membranes whilst active uptake causes the ciprofloxacin 
concentration to reach levels far greater than the external medium. DIDS is also 
known to be effective at inhibiting transport by the MRP family members. With this 
reasoning human MRP4 was investigated as a transport mechanism of ciprofloxacin 
in this study. MRP4 over-expressing HEK 293 cells (Wielinga et al., 2002) were 
shown to accumulate less ciprofloxacin compared with native HEK cells. Known 
MRP inhibiting agents such as MK571 (Reid et al., 2003a; van Aubel et al., 2002; 
Wu et al., 2005) increased ciprofloxacin accumulation in these HEK cells. Taken 
together these data confirm ciprofloxacin as a substrate for MRP4 in the over-
expressing cell lines. The efficacy of agents such as MK571 in both native and 
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transfected models suggest endogenous expression of MRP family members besides 
MRP4 in HEK 293 cells. Ko143 was without effect on MRP4.  
MRP4 mRNA was analysed in both Caco-2 cell strains; high passage Caco-2 
cells showed poor expression whilst the lower passage Caco-2 cells had a greater 
expression of MRP4 mRNA. It was found the MRP4 inhibiting agents had no to little 
effect on net ciprofloxacin secretion across Caco-2 cells and so the involvement of 
MRP4 in Caco-2 mediated ciprofloxacin efflux can be excluded. 
Over-expression of ABC transporters (BCRP, MRP4) in heterologous systems 
has confirmed ciprofloxacin as a substrate and highlights the complex transport nature 
of this zwitterion. As already noted ciprofloxacin has a high-volume of distribution 
suggesting ready access to the intracellular compartment of many cells, thus ABC-
mediated efflux must exist with specific influx pathways. In macrophages it is 
hypothesised that MRP4 up-regulation may render intracellular antibiotic 
concentrations to be negligible, so providing a bacterial niche inaccessible to therapy 
(Marquez et al., 2009). It is apparent the major route of secretion from Caco-2 cells is 
neither via BCRP nor MRP4, even though BCRP may be involved depending on the 
expression level of BCRP in the Caco-2 cells. The alternative transport pathway still 
needs to be elucidated and several candidates remain. The alternative role of OATPs 
(Kalliokoski & Niemi, 2009) and other energy dependent efflux transporters such as 
MATE1 (Meyer zu Schwabedissen et al., 2010) require further investigation. Human 
intestinal tissue also needs to be investigated to see if BCRP plays a greater role in 
ciprofloxacin efflux in vivo compared with the human intestinal Caco-2 cells. 
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6. Regulation of functional BCRP in Caco-2 cells 
 
6.1 Introduction 
The previous chapters have shown that a diverse range of substrates may be 
transported by BCRP. Additionally since BCRP is highly expressed in gastro-
intestinal mucosae, BCRP-mediated excretion will affect the absorption and 
subsequent disposition of substrates within the body. Data in Chapter 5 show that 
BCRP expression varies between 2 strains of human intestinal Caco-2 cells resulting 
in altered transepithelial flux of substrates such as ciprofloxacin. Therefore, factors 
affecting the expression and amount of BCRP present in its physiological location at 
the brush-border membrane of enterocytes will impact on substrate absorption from 
the intestinal lumen.  
Many studies on other ABC transporters such as MDR1 have shown that 
transcription is directly regulated by nuclear receptors (PXR/RXR) that act as 
„xenosensors‟. MDR1 substrates are invariably regulators of MDR1 expression 
mediated by nuclear receptor transcriptional activation (Haslam et al., 2008). 
A well characterised endogenous mechanism of BCRP transcriptional 
regulation is mediated via nuclear receptors of sex steroid hormones. Sex hormone 
(e.g. estrogen, progesterone) regulation of human BCRP would result in sex 
differences in BCRP expression in the intestine which has not been seen in previous 
studies (Gutmann et al., 2005). However Merino et al. (2005) have shown changes in 
human liver BCRP expression and there are reports of significantly higher plasma 
clearance in males than females for the BCRP substrate methotrexate and topotecan 
(Gallo et al., 2000; Godfrey et al., 1998; Loos et al., 2000; Wall et al., 2000). 
Furthermore BCRP expression is known to be highest in the placenta and the 
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expression varies considerably during the different stages of foetal development. 
Wang et al. (2008) have investigated the molecular mechanism underlying this 
regulation in human placental BeWo cells and have shown that progesterone PRA and 
PRB receptor isoforms differentially regulate BCRP transcription; PRB regulating 
transcription in a positive manner whilst PRA having limited effect, but when co-
expressed with PRB it suppresses PRB-mediated activation (Wang et al., 2008a). 
BCRP has been shown to be a survival factor during the formation of the placental 
syncytium (Evseenko et al., 2007). 
Ee et al. (2004) have identified an estrogen response element in the promoter 
region of BCRP that when stimulated causes an increase in BCRP mRNA (Ee et al., 
2004). Vore et al. (2008) further show that stimulation via 17β-estradiol and 
progesterone causes a modulation of BCRP expression through this nuclear response 
element. Several studies report negative regulation of BCRP protein expression by 
oestrogen; in oestrogen receptor alpha positive MCF cells 17β-estradiol reduces 
BCRP protein by a post-translational mechanism (Imai et al., 2005). Furthermore 
17β-estradiol reduces BCRP mRNA and protein via the oestrogen receptor beta in rat 
brain capillaries (Mahringer & Fricker, 2010). A potential role for sex hormone 
regulation of BCRP expression in the intestine can therefore be postulated.  
Another mechanism of induction noted for human BCRP and mouse Bcrp is 
mediated through hypoxia-inducible factor 1/2α (HIF-1/2α) that is activated in 
hypoxic conditions (Krishnamurthy & Schuetz, 2005). In cardiac stem cells hypoxia-
inducible factor (HIF-2α) binds to a conserved HIF-2α response element in the murine 
Abcg2 promoter to increase Bcrp expression (Martin et al., 2008). Transcriptional 
assays reveal a dose-dependent activation of Abcg2 expression by HIF-2α. Caco-2 
cells arose from a colonic tumour and this cell line is likely to be associated with 
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hypoxia, however enterocytes are well perfused with blood and therefore unlikely to 
be subjected to hypoxia under normal physiological conditions. As there were limited 
facilities to culture Caco-2 cells under hypoxic conditions the HIF-1α pathway was 
not investigated. 
Since enterocytes are exposed to a wide variety of xenobiotics via diet it 
seems highly likely that dietary components will act to regulate the expression of 
BCRP along the gastro-intestinal tract. The variability of BCRP expression seen in 
human intestinal tissue (Zamber et al., 2003) may be down to inter-individual 
variation in diet and intestinal microflora. Flavonoids are plant secondary metabolites, 
primarily natural in origin, which are present in most diets. They are found in 
chocolate, citrus fruits, liquorice, red wine, tea and vegetables to name but a few and 
an average intake of flavonoids have been approximated to be 1g per day (Formica & 
Regelson, 1995). They are heavily metabolised by the gut flora and thus active 
concentrations will be reduced considerably. However these compounds have been 
recognised to have beneficial health effects with anti-carcinogenic effects (Havsteen, 
2002). Thus foods with high flavonoid content are becoming more popular and even 
flavonoid supplements, such as quercetin and genistein are available, which are often 
taken over long periods of time. Many studies link the modulating effects of these 
flavonoids with the ABC-efflux proteins, they have diverse structures and are known 
to be substrates, inhibitors and inducers of the ABC-efflux proteins (Alvarez et al., 
2009; Ebert et al., 2007; Wang, 2007), thus flavonoids may be implicated with drug 
interactions. Recently the aryl hydrocarbon receptor has been shown to be a 
transcriptional activator of BCRP expression via a proximal dioxin response element 
within the BCRP promoter region (Tan et al., 2010). The effects of several flavonoids 
and aryl hydrocarbon receptor (AhR) agonists on BCRP regulation in Caco-2 cells; β-
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naphthoflavone (BNF), chrysin, dibenzoylmethane (DBM), quercetin and tert-
butylhydroquinone (TBHQ) have therefore been tested.  
Other exogenous factors of BCRP regulation are pharmaceuticals. To date few 
drugs have been shown to be BCRP regulators but there are one group of compounds 
that do have an effect in vitro. The thiazolidinediones (glitazones) are used to treat 
type II diabetes by reducing blood glucose and increasing insulin sensitivity, however 
they seem to have an alternative role in up-regulating BCRP expression and function 
in vitro (Szatmari et al., 2006). The thiazolidinediones are PPARγ agonists and thus 
this pathway was investigated in Caco-2 cells using the thiazolidinedione 
rosiglitazone. 
Dynamic regulation of BCRP transcription in the human gastrointestinal tract 
is therefore likely, several transcriptional activators (sex steroid nuclear receptors, 
HIF, AhR, PPARγ) have been identified in various tissues. In this chapter 
mechanisms of BCRP induction identified in the literature have been investigated in 
low PA human intestinal Caco-2 cells which both express normal polarised BCRP 
expression and which may be easily subjected to prolonged exposure to inducing 
agents by inclusion in the culture medium. Functional activity has been assessed using 
the BCRP substrates identified in Chapter 3, namely, flavopiridol, prazosin and 
nitrofurantoin.  
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6.2 Methods 
6.2.1 Induction pre-treatments of Caco-2 cell monolayers for qPCR, 
immunoblotting and bi-directional transport assays. 
 
Cell monolayers were incubated between 24-72 hours with different agents, the 
DMSO concentration never exceeding 0.1%. All inducing agents were made up in 
DMSO and then diluted to the required final concentration using phenol red free 
Dulbecco‟s Minimum Essential Media. For measuring changes in mRNA cells were 
grown in 6-well plates then incubated between 24-72 hours depending on the 
experiment. 
For measuring changes in protein expression, Caco-2 cells were grown in 
75cm
2
 flasks and were incubated in the presence of inducing agents for 72 hours. 
Whilst for measuring changes in protein function cells were grown on 96-well 
Transwell plates until confluency and were incubated between 24-72 hours, again 
depending on the experiment.  
When measuring changes in Caco-2 cell mRNA and protein expression the 
cells were washed twice with 1% Phosphate Buffered Saline (PBS) and protocols for 
RNA extraction and protein extraction were followed (shown in Materials and 
Methods, sections 2.2.3.1 and 2.2.4 respectively). 
For measuring changes in protein function cell monolayers had an initial 
washout period consisting of 2 initial washes with pre-warmed media at 37°C and 
followed by incubation for 60 minutes. 60 minutes washout being long enough to 
ensure any inducing agent has had adequate dilution and transit time from the cell. 
The washout duration was not too long as to prevent a reversal of the induction. The 
protocol was then followed as described in sections 2.2.2.3. 
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6.3 Results 
 
6.3.1 The effect of induction agents on BCRP mRNA expression in 
Caco-2 cells  
 
Since phenol red, or lipophilic impurities in phenol red, possess weak estrogenic 
activity (Kd 10-20µM on the estrogen receptor in MCF-7 cells) and phenol red 
concentrations in culture media are 15-45µM (Berthois et al., 1986; Bindal et al., 
1988) the effects of BCRP modulating/inducing agents has been determined in 
custom phenol red free media. Concentrations of inducing agents used had previously 
been reported to increase BCRP mRNA, protein or function (Ebert et al., 2007; 
Szatmari et al., 2006). Initially levels of BCRP mRNA were measured using real time 
PCR analysis after 24 hours of incubation with inducing agents; however limited 
effects were shown after this time period (data not shown). A longer incubation time 
of 72 hours was then chosen for BCRP induction (Figure 6.1). Several 
phytochemicals were used to modulate BCRP expression. β-naphthoflavone (BNF) at 
10µM gave a significant increase in BCRP mRNA expression (n = 3 extractions, P < 
0.05, Figure 6.1). The AhR-agonists chrysin (at 10µM), dibenzoylmethane (DBM at 
50µM) and quercetin (at 20µM) showed a non-significant increase in BCRP mRNA, 
in contrast to increases reported by Ebert et al. (2006). However the synthetic 
antioxidant tert-butylhydroquinone (TBHQ at 50µM) which is also an AhR agonist 
(Gharavi & El-Kadi, 2005) caused a significant increase in BCRP mRNA similar to 
that shown by Ebert et al. (2006). The estrogen, 17-β-estradiol had no effect on BCRP 
mRNA expression (Figure 6.1) unlike previous findings in different cell types (Vore 
& Leggas, 2008). The greatest induction of BCRP mRNA was seen with pre-
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incubation with the thiazolidinedione rosiglitazone (n = 3 extractions, P < 0.05, Figure 
6.1).  
6.3.2 The effect of induction agents on the mRNA expression of 
nuclear receptors AhR and PPARγ 
 
The agents with the greatest effect on BCRP mRNA were the AhR agonists β-
naphthoflavone (BNF) and TBHQ, and the PPARγ agonist rosiglitazone. In order to 
confirm expression of the AhR and PPARγ nuclear receptors, RT-PCR and real time 
PCR analysis were conducted. Figure 6.2A confirms expression of AhR mRNA. AhR 
mRNA expression levels showed no significant differences with pre-incubation with 
the phytochemicals BNF, chrysin, DBM and quercetin. Only TBHQ had a significant 
effect on increasing AhR mRNA (n = 3 extractions, P < 0.05, Figure 6.2). Figure 6.3A 
confirms expression of PPARγ. No significant change in PPARγ mRNA expression 
was seen in the presence of any of the inducing agents, including the PPARγ agonist 
rosiglitazone (Figure 6.3B). 
 
6.3.3 The effect of induction agents on BCRP protein expression in 
Caco-2 cells 
 
Since significant increases in BCRP mRNA were observed, especially with BNF and 
rosiglitazone pre-incubation, BCRP protein expression was measured by 
immunoblotting with the mouse anti-human BCRP antibody BXP-21. A faint band 
for BCRP at ~72kDa was observed in the control low passage Caco-2 cells (Figure 
6.4). BCRP-transfected MDCKII cell protein is included as a positive control and a 
similar band at ~72kDa is observed (Figure 6.4). Caco-2 cells incubated for 72 hours 
in the presence of BNF and rosiglitazone showed an increase in density of the ~72kDa 
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BCRP band. Note that  protein loading for each sample was at a similar  high level as 
shown by  re-probing the blot with an anti-tubulin antibody giving a band at ~50kDa 
(Figure 6.4).  
6.3.4 Testing the inhibitory effects of induction agents on the bi-
directional transport of flavopiridol 
 
Flavopiridol was previously shown in this study to be a human BCRP substrate using 
BCRP-MDCKII transfected layers (Chapter 4); however we have to note that there 
was a significant endogenous secretion of flavopiridol in native MDCKII epithelial 
layers indicating that there is more than one component of secretion in hBCRP-
MDCKII cells. In order to test inducing agents as potential substrate inhibitors of 
hBCRP, their effect on the bi-directional transport of flavopiridol in the hBCRP-
MDCKII cells was tested (Figure 6.5). Chrysin (10µM) is a potent inhibitor of 
flavopiridol secretion (donor concentration 10µM), reducing net flavopiridol secretion 
from 3.3 ± 0.16 nmol.cm
-1
.hr
-1
 in the control to 1.28 ± 0.03 nmol.cm
-1
.hr
-1
 (P < 0.05), 
with a similar inhibitory action compared to Ko143 (Figure 6.5). Chrysin acts as a 
potent BCRP transporter inhibitor (Alvarez et al., 2009; Wang, 2007; Zhang et al., 
2005). Other phytochemicals, quercetin and naringenin, both had a significant effect 
on reducing flavopiridol net secretion at 10µM (P < 0.05, Figure 6.5). Quercetin is a 
known inhibitor of BCRP and MDR1 (Hsiu et al., 2002; Sesink et al., 2005) and 
naringenin inhibits both BCRP and MDR1 also (Ahmed-Belkacem et al., 2005; de 
Castro et al., 2007). BNF did not inhibit flavopiridol secretion at the concentration 
used (10µM). The hormones 17β-estradiol and hydrocortisone had dissimilar effects, 
with 17β-estradiol showing no effect whilst hydrocortisone (both 10µM) gave 
significant inhibition of flavopiridol secretion. Rosiglitazone at 10µM gave slight 
inhibition of flavopiridol transport and has been shown previously to be an inhibitor 
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of both BCRP and MDR1 (Weiss et al., 2009). It should be noted that these inhibitory 
actions do not discriminate between hBCRP and the endogenous secretory capacity of 
MDCKII epithelial cells.   
This data set shows that inducing agents, if present, will act as potential 
inhibitors of BCRP/endogenous secretion. Removal of the external medium and a 
short period of incubation in drug-free medium are required prior to measurement of 
secretory capacity. 
 
6.3.5 The effect of induction agents on the bi-directional transport of 
BCRP substrates in low passage Caco-2 epithelia 
 
6.3.5.1 Flavopiridol 
Inducing agents were incubated in the presence of low passage Caco-2 cells for 48 
and 72 hours (only 72 hour data are shown). Table 6.1 shows the effect of the 
inducing agents on the bi-directional transport of flavopiridol in a 96-well format 
assay. It was found that all 7 inducing agents used increased flavopiridol net secretion 
from control values, including BNF, chrysin, DBM, estradiol, quercetin, rosiglitazone 
and TBHQ. The increased net secretion resulted from a reduction in apical to basal 
transport of flavopiridol and an increase in the basal to apical transport of flavopiridol. 
Rosiglitazone pre-incubation increased net flavopiridol transport by the greatest 
magnitude by 1.46 fold from 1.14 ± 0.06 nmol.cm
-1
.hr
-1
 in the control DMSO treated 
cells to 1.68 ± 0.05 nmol.cm
-1
.hr
-1
 (Table 6.1).  
In order to assess whether the increased flavopiridol flux resulted from an 
increased BCRP component, BNF and rosiglitazone induction was performed in the 
24-well format. Figure 6.6 shows the effect of selective pharmacological inhibitors, 
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Ko143 and verapamil, on flavopiridol flux (donor concentration 10µM) after 
induction. In control layers neither Ko143 nor verapamil reduced flavopiridol 
secretion showing that at the donor concentration used the non-BCRP and non-MDR1 
component of secretion predominated (see also Chapter 4 Figure 4.9B).  BNF and 
rosiglitazone pre-incubation increased the net secretion of flavopiridol significantly 
by 1.44 and 1.41 fold respectively (P < 0.05, Figure 6.6); this increased net secretion 
was sensitive to Ko143. Ko143 reduced secretion from 10.24 ± 0.26 nmol.cm
-1
.hr
-1 
in 
the control BNF treated cell monolayers to 6.42 ± 0.19 nmol.cm
-1
.hr
-1
, and from 10.03 
± 0.35 nmol.cm
-1
.hr
-1 
in the control rosiglitazone treated cell monolayers to 6.7 ± 0.16 
nmol.cm
-1
.hr
-1
. The increase in the Ko143 sensitive flux component between non-
induced and induced monolayers is consistent with BCRP induction. However it 
should be noted that verapamil also reduces the increased flavopiridol flux, indicating 
that a MDR1-mediated route for secretion for flavopiridol may have also increased. 
That flavopiridol may be secreted by BCRP, MDR1 and an additional route in Caco-2 
cells, suggests that flavopiridol is not an ideal choice of substrate for investigation of 
BCRP induction. 
 
6.3.5.2 Prazosin 
The affect of inducing agents were also tested upon prazosin secretion in low-passage 
Caco-2 cells for 48 and 72 hours in the 96-well format assay. At 48 hours of treatment 
only DBM and rosiglitazone increased the net flux of prazosin significantly. When 
incubation time was increased to 72 hours DBM, 17-β-estradiol, rosiglitazone and 
TBHQ all increased prazosin net transport compared to the DMSO treated control 
layers (Table 6.2). Increased prazosin transport occurred by a reduction in apical to 
basal transport and increased basal to apical transport of prazosin. As for flavopiridol, 
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the largest induction was seen with rosiglitazone which increased net secretion of the 
control from 1.11 ± 0.04 nmol.cm
-1
.hr
-1
 to 1.68 ± 0.05 nmol.cm
-1
.hr
-1 
(a 1.51 fold 
increase).  
Figure 6.7 shows the effect of 17-β-estradiol and rosiglitazone pre-incubation 
for 72 hours on prazosin transport across low passage Caco-2 cells grown in the 24-
well format in the presence of ABC transport inhibitors. In the untreated Caco-2 cells 
prazosin net secretion was reduced significantly in the presence of 10µM Ko143 (P < 
0.05, Figure 6.7). Verapamil was ineffective on its own on the net secretion of 
prazosin, however when combined with Ko143, it reduced net secretion significantly. 
These data imply a large BCRP component for prazosin secretion in Caco-2 cells with 
a smaller MDR1 route of secretion in these cells. When the Caco-2 cells were treated 
for 72 hours, 17-β-estradiol had no effect on net secretion of prazosin (unlike the data 
seen in the 96-well format). However, rosiglitazone increased net secretion by 1.77 
fold. The significant increase in prazosin secretion by rosiglitazone was significantly 
reduced from 2.16 ± 0.08 nmol.cm
-1
.hr
-1
 to 0.49 ± 0.04 nmol.cm
-1
.hr
-1
 in the presence 
of 10µM Ko143 (P < 0.05, Figure 6.7). This inhibition reduced net flux levels to that 
seen in untreated Caco-2 cells. Verapamil had no effect on reducing the net secretion 
of prazosin after treatment with rosiglitazone, which at 100µM is known to inhibit 
both MDR1 and MRP2 (Matsson et al., 2007). These data show that the increase in 
prazosin secretion seen with rosiglitazone is due to an increase in BCRP function.  
 
6.3.5.3 Nitrofurantoin 
The data presented in Chapter 4 indicate that nitrofurantoin is a selective BCRP 
substrate in Caco-2 cells. The affect of inducing agents were also tested upon 
nitrofurantoin secretion in low-passage Caco-2 cells for 48 and 72 hours in the 96-
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well format assay. At 48 hours of treatment BNF, DBM, naringenin and TBHQ 
increased the net secretion of nitrofurantoin significantly. However, after 72 hours of 
treatment only BNF and rosiglitazone had an effect of increasing net secretion of 
nitrofurantoin (P < 0.05, Table 6.3). Both compounds increased nitrofurantoin 
secretion by a significant reduction in the apical to basal transport whilst increasing 
the basal to apical transport.  
Figure 6.8 shows the effects of the pharmacological inhibitors Ko143 and 
verapamil on the net flux of nitrofurantoin after treatment with BNF and 
rosiglitazone. In control layers, Ko143 significantly inhibited the bulk of 
nitrofurantoin secretion, whilst verapamil was ineffective alone or in combination 
with Ko143. These data confirm nitrofurantoin as a selective BCRP substrate in the 
low PA Caco-2 cells (as previously described in Chapter 4). BNF increased 
nitrofurantoin net flux from the control value of 2.28 ± 0.08 nmol.cm
-1
.hr
-1
 to 3.91 ± 
0.36 nmol.cm
-1
.hr
-1
, a 1.71 fold increase in secretion (P < 0.05, Figure 6.8). This 
secretion was inhibited in the presence of 10µM Ko143 from 3.91 ± 0.36 nmol.cm
-
1
.hr
-1
 to 0.24 ± 0.03 nmol.cm
-1
.hr
-1 
(P < 0.05). Verapamil had no effect on reducing 
secretion in the BNF treated Caco-2 cells. Rosiglitazone treatment increased 
nitrofurantoin net flux from 2.28 ± 0.08 nmol.cm
-1
.hr
-1
 to 2.95 ± 0.11 nmol.cm
-1
.hr
-1
, a 
1.29 fold increase in secretion (P < 0.05, Figure 6.8). This secretion was inhibited in 
the presence of 10µM Ko143 from 2.95 ± 0.11 nmol.cm
-1
.hr
-1
 to 0.24 ± 0.03 nmol.cm
-
1
.hr
-1 
(P < 0.05). Verapamil again had no significant effect at reducing the net 
secretion of nitrofurantoin. BNF and rosiglitazone pre-incubation therefore increased 
functional BCRP activity in conjunction with increased BCRP mRNA and protein.  
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Figure 6.1. qPCR analysis of BCRP mRNA after 72-hour pre-treatments in low 
passage Caco-2 cells 
 
Caco-2 cells were cultured on 6-well plates for 11 days without inducing treatments 
then treated for a further 3 days (72h) in the presence of the inducing treatments. 
BNF, chrysin, estradiol and rosiglitazone treatments were used at 10µM, quercetin at 
20µM, DBM and TBHQ at 50µM concentrations (diluted in DMSO). Control cells 
were treated with equal volumes of DMSO. Data bars are means of n = 3 wells ± SD 
and are corrected relative to GAPDH expression. * P < 0.05, significantly different 
from control.  
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Figure 6.2. Expression of Ah receptor mRNA in low passage Caco-2 cells  
 
(A) An agarose gel image showing PCR product of Ah receptor from low passage 
Caco-2 cells, displaying the expected product size of 204 base pairs (see 
Materials and Methods section 2.2.3.4). 
 
(B) Real time PCR analysis indicating expression of Ah receptor in low passage 
Caco-2 cells. Caco-2 cells were cultured on 6-well plates for 11 days without 
inducing treatments then treated for a further 3 days (72hrs) in the presence of 
the inducing treatments. BNF, chrysin, estradiol and rosiglitazone treatments 
were used at 10µM, quercetin at 20µM, DBM and TBHQ at 50µM 
concentrations (diluted in DMSO). Control cells were treated with equal 
volumes of DMSO. Data bars are means of n = 3 wells ± SD and are corrected 
relative to GAPDH expression. * P < 0.05, significantly different from control.  
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Figure 6.2. Expression of Ah receptor mRNA in low passage Caco-2 cells  
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Figure 6.3. Expression of PPAR-gamma receptor mRNA in low passage Caco-2 
cells 
  
(A) An agarose gel image showing PCR products of PPAR-gamma from low 
passage Caco-2 cells, displaying the expected product size of 257 base pairs 
(see Materials and Methods section 2.2.3.4). 
 
(B) Real time PCR analysis indicating expression of PPAR-gamma receptor in 
low passage Caco-2 cells. Caco-2 cells were cultured on 6 well plates for 11 
days without inducing treatments then treated for a further 3 days (72hrs) in 
the presence of the inducing treatments. BNF, chrysin, estradiol and 
rosiglitazone treatments were used at 10µM, quercetin at 20µM, DBM and 
TBHQ at 50µM concentrations (diluted in DMSO). Control cells were treated 
with equal volumes of DMSO. Data bars are means of n = 3 wells ± SD and 
are corrected relative to GAPDH expression.  
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Figure 6.3. Expression of PPAR-gamma receptor mRNA in low passage Caco-2 
cells  
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Figure 6.4. Western Blot analysis of BCRP protein expression in low passage 
Caco-2 cells after 72-hour pre-treatments 
 
Images (A) and (B) show BCRP protein and α-tubulin expression respectively. Lane 1 
is DMSO treated low PA Caco-2 control cells (40µg protein loaded), lane 2 is 10µM 
BNF treated low PA Caco-2 cells (40µg protein loaded), lane 3 is 10µM rosiglitazone 
treated low PA Caco-2 cells (40 µg protein loaded) and lane 4 is untreated hBCRP-
MDCKII positive control (10µg protein loaded). Low PA Caco-2 cells (shown in 
lanes 1-3) were grown in 75cm
2 
flasks in the presence of the agents indicated for 72 
hours then protein was extracted. 
 
(A) Membrane was probed initially with mouse-monoclonal anti-human BCRP 
antibody BXP-21 (Santa Cruz) at a dilution of 1 in 100. This image is 
representative of one gel. BCRP yields bands at approximately 72kDa. 
 
(B)  Image shows the membrane from part A stripped and re-probed with a cross 
species polyclonal anti-α-tubulin antibody (Abcam). The α-tubulin band was 
visible at approximately 50kDa.  
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Figure 6.4. Western Blot analysis of BCRP protein expression in low passage 
Caco-2 cells after 72-hour pre-treatments 
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Figure 6.5. Effect of flavopiridol net flux in the presence and absence of potential 
inhibitors across human BCRP-MDCKII monolayers 
 
Human BCRP-MDCKII cells were cultured on 24-well permeable supports until 
confluency. Data bars represent net flux (Jb-a – Ja-b) and show flavopiridol net flux in 
the presence and absence of potential inhibitors. All treatment compounds were used 
at 10µM, aside from quercetin which was used at 20µM. Control cells were treated 
with equal volumes of DMSO. Flavopiridol donor concentration was 10µM, receiver 
concentration was measured by HPLC-MS. Data bars are means of n = 4 monolayers 
± SEM. * P < 0.05, significantly different from control.  
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Figure 6.5. Effect of flavopiridol net flux in the presence and absence of potential 
inhibitors across human BCRP-MDCKII monolayers 
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Table 6.1. Effect of potential BCRP inducing agents after 72-hours pre-treatment 
on flavopiridol transepithelial flux across confluent Caco-2 cell monolayers 
 
Caco-2 cells were cultured on 96-well Transwell supports for 11 days without 
inducing treatments then treated for a further 3 days (72h) in the presence or absence 
of induction treatments. BNF, chrysin, estradiol and rosiglitazone treatments were 
used at 10µM, quercetin at 20µM, DBM and TBHQ at 50µM concentrations (diluted 
in DMSO). Control cells were treated with equal volumes of DMSO. Flavopiridol 
donor concentration was 10µM, receiver concentration was measured by HPLC-MS. 
Data bars are means of n = 4-6 monolayers ± SEM. * P < 0.05, significantly different 
from control.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Transepithelial Flavopiridol Flux (pmol.cm-2.hr-1)
Treatment Ja-b Jb-a Jnet Δ net flux 
Control 397.5 ± 14.3 1542.1 ± 50.4 1144.6 ± 57.4 NA
BNF 340.4 ± 13.4 1874.9 ± 44.2 1570.7 ± 53.4 1.37*
Chrysin 314.6 ± 18.4 1755.1 ± 58 1440.5 ± 47.6 1.26*
DBM 269.8 ± 28.5 1716.8 ± 88.9 1447± 110.7 1.26*
Estradiol 329.5 ± 9.7 1915.5 ± 35.6 1586 ± 40.4 1.39*
Quercetin 272.5 ± 35.9 1724.4 ± 15.6 1451.9 ± 46 1.27*
Rosiglitazone 244.8 ± 25.6 1921.7 ± 67.8 1676.4 ± 46.2 1.46*
TBHQ 253.5 ± 49.6 1802.6 ± 32.9 1549.1 ± 44.8 1.35*
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Figure 6.6. Effect of pre-treatments on flavopiridol transepithelial flux across 
confluent Caco-2 cell monolayers ± known ABC transporter inhibitors 
 
Caco-2 cells were cultured on 24-well Transwell supports for 11 days without 
inducing treatments then treated for a further 3 days (72h) in the presence of induction 
treatments. BNF and rosiglitazone were used at 10µM concentrations (diluted in 
DMSO). Control cells were treated with equal volumes of DMSO. Flavopiridol donor 
concentration was 10µM, receiver concentration was measured by HPLC-MS. Flux 
were determined in the presence and absence of the ABC transporter inhibitors Ko143 
(10μM) and verapamil (100µM). Data bars are means of n = 8 monolayers ± SEM. * 
P < 0.05, significantly different from control values. # P<0.05, significantly different 
from DMSO value.  
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Table 6.2. Effect of potential BCRP inducing agents after 72-hours pre-treatment 
on prazosin transepithelial flux across confluent Caco-2 cell monolayers 
 
Caco-2 cells were cultured on 96-well Transwell supports for 11 days without 
inducing treatments then treated for a further 3 days (72h) in the presence or absence 
of induction treatments. BNF, chrysin, estradiol and rosiglitazone treatments were 
used at 10µM, quercetin at 20µM, DBM and TBHQ at 50µM concentrations (diluted 
in DMSO). Control cells were treated with equal volumes of DMSO. Prazosin donor 
concentration was 10µM, receiver concentration was measured by HPLC-MS. Data 
bars are means of n = 4-6 monolayers ± SEM. * P < 0.05, significantly different from 
control.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Transepithelial Prazosin Flux (pmol.cm-2.hr-1)
Treatment Ja-b Jb-a Jnet Δ net flux 
Control 200.5 ± 8 1308.1 ± 39.6 1114.9 ± 39.2 NA
BNF 105.3 ± 4.1 1347.2 ± 77 1231.6 ± 81.6 1.1
Chrysin 157.4 ± 4.6 1482.5 ± 42.5 1302.3 ± 46.2 1.17
DBM 152.9 ± 7.2 1598.7 ± 66.2 1455.3 ± 83.5 1.31**
Estradiol 169.4 ± 4.7 1812.4 ± 72 1619.7 ± 82.7 1.45**
Quercetin 166.2 ± 3.7 1462.3 ± 33.6 1315 ± 26.8 1.18
Rosiglitazone 163.7 ± 11.9 1793.3 ± 50.2 1682.3 ± 48.8 1.51**
TBHQ 157.3 ± 9.5 1521.8 ± 44.1 1401.2 ± 31.2 1.26*
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Figure 6.7. Effect of pre-treatments on prazosin transepithelial flux across 
confluent Caco-2 cell monolayers ± known ABC transporter inhibitors 
 
Caco-2 cells were cultured on 24-well Transwell supports for 11 days without 
inducing treatments then treated for a further 3 days (72h) in the presence of induction 
treatments. Estradiol and rosiglitazone were used at 10µM concentrations (diluted in 
DMSO). Control cells were treated with equal volumes of DMSO. Prazosin donor 
concentration was 10µM, receiver concentration was measured by HPLC-MS. Flux 
were determined in the presence and absence of the ABC transporter inhibitors Ko143 
(10μM) and verapamil (100µM). Data bars are means of n = 8 monolayers ± SEM. * 
P < 0.05, significantly different from control values. # P < 0.05, significantly different 
from DMSO values. Ko143 and Verapamil vs. Ko143 value ** P < 0.05, significantly 
different.  
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Figure 6.7. Effect of pre-treatments on prazosin transepithelial flux across 
confluent Caco-2 cell monolayers ± known ABC transporter inhibitors 
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Table 6.3. Effect of potential BCRP inducing agents after 72-hours pre-treatment 
on nitrofurantoin transepithelial flux across confluent Caco-2 cell monolayers 
 
Caco-2 cells were cultured on 96-well Transwell supports for 11 days without 
inducing treatments then treated for a further 3 days (72h) in the presence or absence 
of induction treatments. BNF, chrysin, estradiol and rosiglitazone treatments were 
used at 10µM, quercetin at 20µM, DBM and TBHQ at 50µM concentrations (diluted 
in DMSO). Control cells were treated with equal volumes of DMSO. Nitrofurantoin 
donor concentration was 10µM, receiver concentration was measured by HPLC-MS. 
Data bars are means of n = 4-6 monolayers ± SEM. * P < 0.05, significantly different 
from control.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Transepithelial Nitrofurantoin Flux (pmol.cm-2.hr-1)
Treatment Ja-b Jb-a Jnet Δ net flux 
Control 63.5 ± 4.7 1345.6 ± 38.3 1283.5 ± 37 NA
BNF 48.1 ± 5.4 1628.3 ± 115.2 1580.2 ± 112.9 1.23*
Chrysin 49.7 ± 4.0 1385.6 ± 70.6 1335.9 ± 67 1.04
DBM 39.9 ± 6.0 1437.9 ± 58.5 1397.9 ± 56.8 1.09
Estradiol 47.7 ± 7.4 1439.4 ± 56.4 1391.7 ± 50.5 1.08
Quercetin 37.9 ± 0.8 1354.4 ± 50.1 1316.5 ± 50.7 1.03
Rosiglitazone 22.5 ± 1.7 1685.7 ± 45.1 1663.2 ± 45 1.30** 
TBHQ 36.6 ± 6.8 1491.0 ± 62.8 1454.5 ± 58.3 1.13
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Figure 6.8. Effect of pre-treatments on nitrofurantoin transepithelial flux across 
confluent Caco-2 cell monolayers ± known ABC transporter inhibitors 
 
Caco-2 cells were cultured on 24-well Transwell supports for 11 days without 
inducing treatments then treated for a further 3 days (72h) in the presence of induction 
treatments. BNF and rosiglitazone were used at 10µM concentrations (diluted in 
DMSO). Control cells were treated with equal volumes of DMSO. Nitrofurantoin 
donor concentration was 10µM, receiver concentration was measured by HPLC-MS. 
Flux were determined in the presence and absence of the ABC transporter inhibitors 
Ko143 (10μM) and verapamil (100µM). Data bars are means of n = 8 monolayers ± 
SEM. * P < 0.05, significantly different from control values. # P < 0.05, significantly 
different from DMSO value.  
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Figure 6.8. Effect of pre-treatments on nitrofurantoin transepithelial flux across 
confluent Caco-2 cell monolayers ± known ABC transporter inhibitors 
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6.4 Discussion 
The dynamic regulation of BCRP present in its physiological location at the brush-
border of enterocytes is associated with ATP-dependent recycling of absorbed 
substrates back into the lumen. This mode of operation will therefore impact on 
absorption and bioavailability from the intestinal lumen. Low PA Caco-2 cells have 
been used as a model of the human intestinal mucosae and pre-treatments with a 
variety of phytochemicals, sex hormones, AhR agonists BNF and TBHQ (Gharavi & 
El-Kadi, 2005; Wattenberg et al., 1968) and the PPARγ agonist rosiglitazone were 
tested for their ability to modulate BCRP expression at the molecular mRNA and 
protein level, and at the functional level by measurement of BCRP substrate flux. Of 
the treatments used BNF and rosiglitazone pre-incubation showed the most noticeable 
up-regulation of BCRP transcription whilst immunoblotting confirmed an increase in 
protein expression with these agents. These data suggest that the Caco-2 cell system is 
an appropriate model system to test how the complex lumenal environment and 
periodic stimuli arising from diet or drug exposure may later affect the barrier 
function through up-regulation of ABC transporters such as BCRP.  
After confirming changes of BCRP expression at the molecular level, the 
effect of induction agents upon substrate transport was determined. Data in Chapter 4 
have established that flavopiridol, prazosin and nitrofurantoin were BCRP substrates 
of variable specificity. Of the 3 compounds measured flavopiridol is thought to be the 
least selective, the data in Chapter 4 showing that it is likely secreted by multiple 
transporters across Caco-2 cell layers. Substrate flux values were measured in both 
absorptive and secretory directions across the low PA Caco-2 cells. Although all 
compounds tested in this study were shown to increase flavopiridol net transport, the 
promiscuous nature of flavopiridol secretion across Caco-2 cells renders it likely that 
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more than one transporter is being up-regulated, resulting in the increase in 
flavopiridol secretion. For example, quercetin is a known inducing agent of BCRP, 
but equally an inducer of the MDR1 and MRP2 transporters. Therefore, the increase 
in secretion could be the result of the induction of any of these transporters. For this 
reason selective inhibitors, such as Ko143, described previously in Chapter 3, were 
tested to elucidate which transporter pathway was being up-regulated. The pre-
incubation agents BNF and rosiglitazone increased flavopiridol secretion across Caco-
2 cells grown in 24-well plate assays. Ko143 had little effect on the flavopiridol 
secretion in the control cells, however after pre-treating with BNF and rosiglitazone 
the increase of flavopiridol secretion was inhibited by 10µM Ko143 but not by 
100µM verapamil, which are BCRP and MDR1 selective respectively. Therefore at 
least BNF and rosiglitazone are responsible for the increase in BCRP mediated 
flavopiridol secretion in Caco-2 cells. In all cases where there was an increased net 
transepithelial secretion of flavopiridol, there was a reduction in the apical to basal 
absorptive flux (and hence permeability) of flavopiridol. This finding links increased 
functional BCRP activity with a limitation of absorptive permeability. 
Prazosin is a known bi-substrate for BCRP and MDR1 (Feng et al., 2008; 
Matsson et al., 2009; Polli et al., 2001). However, in the low PA Caco-2 cells 
prazosin was shown to be secreted by BCRP in preference to MDR1, and for this 
reason served as a useful tool to measure BCRP induction in these cells. Unlike 
flavopiridol secretion, BNF was ineffective at increasing prazosin secretory transport, 
but the other AhR agonists DBM and TBHQ were effective in increasing prazosin 
secretion. Rosiglitazone, as with flavopiridol, increased prazosin secretion and this 
secretory component was reduced significantly with Ko143. These data increase the 
evidence that AhR and PPARγ mediated pathways contribute to BCRP regulation in 
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the intestinal cell line Caco-2. As was the case for flavopiridol, in all cases where 
there was an increased net transepithelial secretion of prazosin, there was a reduction 
in the apical to basal absorptive flux (and hence permeability) of prazosin. 
Nitrofurantoin proved to be the most useful BCRP substrate for measuring a 
change in BCRP mediated secretion. Unlike the bi-substrates flavopiridol and 
prazosin, nitrofurantoin was shown to be secreted only by BCRP across Caco-2 cell 
layers. For this reason, interpretations of nitrofurantoin flux are without ambiguity. 
Only pre-incubations with BNF and rosiglitazone increased the nitrofurantoin 
secretion across the apical membrane, unlike the many compounds that increased 
secretion of flavopiridol and prazosin. Furthermore this up-regulation in 
nitrofurantoin secretion by the agents BNF and rosiglitazone was Ko143 sensitive and 
verapamil insensitive. The increased net transepithelial secretion of nitrofurantoin 
seen on pre-incubation with rosiglitazone, was associated with a ~60% reduction in 
the apical to basal absorptive flux (and hence permeability) of nitrofurantoin, 
emphasising that increased secretory function directly modulates the absorptive 
permeability. 
Taking the transport data as a whole the only agent that consistently increased 
the net secretion of all 3 compounds was the PPARγ agonist rosiglitazone. The 
enhancement of secretion with rosiglitazone was also consistently Ko143 sensitive. 
Therefore this increase in function taken together with the increase in mRNA and 
protein expression shows rosiglitazone is an effective agent at inducing the BCRP 
pathway in Caco-2 cells. Svatmari et al. (2006) were the first group to link PPARγ 
with BCRP expression (Szatmari et al., 2006). This group showed PPARγ agonists, 
such as rosiglitazone to increase mRNA, protein and function of BCRP in human 
myeloid dendritic cells and monocyclic/macrophage leukaemia cells (MM6), similar 
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to the findings in Caco-2 cells in this study. The authors further describe that PPARγ 
binds with RXR to form a heterodimer which in turn binds to a PPAR response 
element (PPARE) upstream of the BCRP gene to cause increased transcription. In 
order to confirm that PPARγ regulates BCRP in Caco-2 cells the PPARγ antagonist 
GW9662 could be incubated with rosiglitazone, or a marker gene known to be 
regulated by PPARγ (such as the fatty acid-binding protein, FABP4) could be 
monitored to see if it is co-induced alongside BCRP. Furthermore RNA interference 
to reduce PPARγ expression could be undertaken; PPARγ specific siRNA (Kelly et 
al., 2004) has previously been shown to be effective (Szatmari et al., 2006). To 
further establish whether PPARγ partners RXR to induce BCRP in Caco-2 cells, RXR 
agonists such as LG268 could be used in the presence and absence of rosiglitazone to 
see if there is an additive effect of induction. 
Interestingly PPARγ ligands have been reported to induce the expression of 
retinoic acid β-receptors in cancer cells (James et al., 2003) and recently a study in 
Caco-2 cells showed that the non-specific RAR/RXR ligand all-trans retinoic acid 
induces BCRP expression. Therefore multiple pathways exist which may act 
synergistically to up-regulate BCRP if the appropriate ligands are present 
intracellularly. 
Aside from PPARγ activation there is likely another different mechanism of 
BCRP induction that is activated by the flavonoids. This study supports the existing 
evidence that flavonoids can inhibit and also induce BCRP expression. There are 
some inconsistencies in the flavonoid induction work seen in this study and the 
literature for Caco-2 cells. Chrysin and quercetin, for example, are known to induce 
BCRP mRNA and increase the efflux of the BCRP substrate benzo[a]pyrene-3-
sulphate (Ebert et al., 2007), yet in this study these compounds were ineffective at 
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increasing expression and function of BCRP under the conditions chosen. It is likely 
this discrepancy is due to the flavonoid concentrations used between studies- 10µM 
chrysin and 20µM quercetin concentrations used in this study may have been 
insufficient to elicit an affect. Other flavonoids had a profound effect on mRNA 
expression in this study, DBM and TBHQ were highly effective and have been shown 
previously to modulate BCRP expression and function (Ebert et al., 2007). BNF is 
less well characterised as a BCRP inducer compared with other flavonoids and is 
often used as an archetype inducer of the AhR (Miller, 1999). BNF at 10µM was an 
effective inducer of functional BCRP activity. The present flavonoid data shows that 
BCRP is likely to be up-regulated via the AhR pathway in Caco-2 cells. 
Recently the AhR pathway has been proven to regulate BCRP expression and 
function in a Caco-2 cell sub-type; the C2bbe1 cells (Tan et al., 2010). In brief, the 
mechanism of AhR induction involves; the exogenous ligand binding to the inactive 
AhR residing in the cell cytosol; AhR exists as a multimer bound to two chaperone 
proteins hsp90 (heat shock protein dimer of 90-kDa) and hepatitis B virus X-
associated protein 2 (Denison & Nagy, 2003; Tan et al., 2010). This complex 
undergoes a conformational change and migrates into the nucleus. Within the nucleus 
the AhR separates from the protein complex and in turn binds to form a heterodimer 
complex with Arnt. This dimer (AhR-Arnt) has a high affinity to specific DNA 
recognition sites (DREs) that result in activation of downstream gene expression. 
Human BCRP was revealed to have 9 putative core DREs (Tan et al., 2010) and of 
these 4 putative DREs are located in a proximal region within ~200bp from the 
transcriptional start site and 5´-untranslated region. Interestingly this „proximal 
region‟ covers a region in which HIF1α, ERα and PgR (progesterone receptor) are 
known to bind (Ee et al., 2004; Krishnamurthy & Schuetz, 2005; Wang et al., 2008a). 
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As these regions are so close and associated to BCRP induction there may be cross 
talk between activated DREs resulting in potential for both synergistic and inhibitory 
actions on BCRP regulation (Tan et al., 2010), especially as the AhR-ARNT 
heterodimer and ER are known to competitively bind at certain sites (Klinge et al., 
2000; Ohtake et al., 2003).  
Tan et al. (2010) go on to show that one particular DRE activated alone by the 
AhR agonist TCDD results in an up-regulation of function and expression of BCRP 
(position -194/-190 of the core DRE in the 5´-flanking region of the BCRP gene). 
Thus BNF action described in this chapter is likely to be mediated via the AhR 
pathway. 
To further confirm BCRP induction of flavonoids through the AhR receptor 
the cellular cascade through AhR activation could be investigated. For example, one 
of the gene targets of the AhR-Arnt dimer is a DRE that induces CYP1A1. CYP1A1 
is a classic product of AhR regulation and could be quantified to see if this enzyme is 
being up-regulated alongside BCRP (Denison & Nagy, 2003). An AhR antagonist 3´-
methoxy-4´-nitroflavone could be used in the pre-incubations alongside the flavonoids 
to see if this effects BCRP expression (Ebert et al., 2007).  
Hormonal regulation of BCRP via 17β-estradiol seems to be a cell dependent 
effect; it has been shown to increase BCRP transcription in ER-positive T47D:A18 
breast cancer cells (Ee et al., 2004) but reduce its expression in the ER-positive MCF-
7 breast cancer cells (Ee et al., 2004; Imai et al., 2005). In this study levels of BCRP 
mRNA did not change in the presence of the ERα agonist 17β-estradiol, nitrofurantoin 
transport was unaffected, but it did increase the secretion of the bi-substrates 
flavopiridol and prazosin across Caco-2 cell monolayers. How 17β-estradiol increases 
secretion of flavopiridol and prazosin secretion remains to be precisely identified. 
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However, the lack of affect on the BCRP selective nitrofurantoin suggests that 17β-
estradiol action in Caco-2 cells is not mediated by increased BCRP activity. The 
specific ER expressed in Caco-2 cells needs to be identified and further investigation 
with other estrogenic compounds and progesterone would confirm any BCRP 
regulation.     
In summary this chapter has shown that various dietary agents and hormones 
acting through differing signalling targets, particularly AhR and PPARγ, may regulate 
BCRP expression in Caco-2 cells. Whether these pathways allow cross talk to 
synergistically regulate BCRP is unknown. However given that the expression of 
BCRP in the intestine has been shown to vary between individuals (Honjo et al., 
2002; Zamber et al., 2003) and that many agents seem to affect its expression, it 
appears reasonable to suppose that more than one regulatory pathway affects 
expression of this transporter, and in vivo a combination of endogenous and 
exogenous ligands act to regulate BCRP dynamically, resulting in a varied expression 
of BCRP on the apical surface of enterocytes between individuals.  
 
 
 
 
 
 
 
 
 
 
 
243 
 
7.  Summary and concluding remarks  
 
The main objective of this thesis was to explore the function and regulation of the less 
characterised of the three main efflux transporters, BCRP, in the context of epithelial 
expression with a particular focus on the human intestinal epithelial cell line Caco-2.  
BCRP expressed at the apical brush-border membrane mediates active extrusion of its 
substrates either from cytosol or directly from the membrane phase, so contributing to 
the barrier function against xenobiotics from the intestinal lumen.  
 The data set out in Chapter 3 characterised available cell model systems such 
as MDCKII cells transfected with hBCRP/mBcrp or Caco-2 cells by assessing the 
extent of BCRP mRNA and protein expression, with measurements of function being 
assessed using the cellular extrusion of the MDR1/BCRP bi-substrate, Hoechst 33342. 
MDCKII cells transfected with hBCRP/mBcrp1 cDNA, as well as the low PA Caco-2 
cells expressed BCRP at the apical surface of these epithelial cells. BCRP acts to 
reduce Hoechst 33342 intercalation into DNA; decreased Hoechst 33342 being 
observed in BCRP-transfected cell-lines. Since retention of Hoechst 33342 is 
increased upon BCRP inhibition, this may be used as a convenient assay to screen for 
BCRP/MDR1 substrates. However, given the existence of endogenous ABC-transport 
activity in native MDCKII cells or multiple ABC transporters in Caco-2 cells, 
unambiguous identification of neither novel substrates nor BCRP regulation was 
possible, though BCRP-selective inhibitors such as Ko143 increased Hoechst 33342 
cellular retention. 
 In Chapter 4, BCRP substrates were screened using transepithelial transport 
across reconstituted epithelial monolayers of MDCKII cells. Bi-directional transport 
combined with substrate identification by HPLC-MS provided an unambiguous 
measurement when wild-type cells were compared to mBcrp or hBCRP MDCKII 
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epithelia, identifying 5 compounds as hBCRP substrates: diclofenac, flavopiridol, 
nitrofurantoin, prazosin and risperidone. It further identified 5 mouse Bcrp substrates: 
diclofenac, flavopiridol, gefitinib, nitrofurantoin and prazosin. Using MDR1-MDCKII 
epithelia 3 compounds were also identified as MDR1 substrates: clozapine, diclofenac 
and prazosin.  
 Flavopiridol and nitrofurantoin were identified as substrates for both human 
BCRP and mouse Bcrp using the MDCKII cell models and looked the most likely 
candidates for isolating the BCRP-component of transport in Caco-2 cells. Even 
though prazosin is an MDR1 substrate it was selected for further study also, on the 
basis that it was both an hBCRP and mBcrp substrate and is well documented as a 
BCRP substrate. Further investigation looking at pharmacological inhibition in both 
MDCKII and Caco-2 cells showed that out of flavopiridol, nitrofurantoin and 
prazosin, only nitrofurantoin was a selective BCRP substrate.  
 Chapter 5 sought to test the hypothesis that ciprofloxacin transport in Caco-2 
cells was mediated by BCRP. Bi-directional ciprofloxacin transport was initially 
measured via a Transwell based assay across native and hBCRP/mBcrp cDNA 
transfected MDCKII cells and it was found that ciprofloxacin net secretion was 
substantially increased across the mouse transfected cells but only marginally in the 
human BCRP-transfected cells. These data matched with the findings of Merino et al. 
(2006). 
 In two Caco-2 cell types, low PA and high PA cells with and without BCRP 
expression respectively, ciprofloxacin secretion was observed. The low PA Caco-2 
cells which express BCRP saw a significant reduction in secretion in the presence of 
the BCRP inhibitor Ko143. Thus a significant fraction of ciprofloxacin secretion is 
mediated by BCRP; however the fact that both Caco-2 cell-strains secrete 
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ciprofloxacin suggests the existence of a BCRP-independent route that remains 
undefined. In conclusion human BCRP may transport ciprofloxacin depending on its 
expression; however its affinity may be reduced compared to that of the mouse Bcrp 
protein.  
 The final results chapter looked at the effect of pre-incubating different agents 
on the expression and function of BCRP in Caco-2 cells. Induction of BCRP mRNA 
expression and protein expression was correlated with functional measurements using 
the BCRP selective substrate, nitrofurantoin. Several agents with diverse structures 
and different cellular targets affect BCRP expression in Caco-2 cells, particularly 
AhR and PPARγ agonists. Given that the expression of BCRP in the intestine has 
been shown to vary between individuals (Honjo et al., 2002; Zamber et al., 2003) and 
that many agents seem to affect its expression, it looks reasonable that more than one 
regulatory site affects expression of this transporter, and in vivo it is likely a 
combination of endogenous and exogenous ligands act to regulate BCRP 
dynamically, resulting in a varied expression of BCRP on the apical surface of 
enterocytes, resulting in both within and between individual variation.  
 A detailed understanding of such BCRP function may lead, ultimately, to 
improvements to oral drug delivery regimes and to avoidance of unwanted drug-drug 
and herb-drug interactions. For example leflunomide, a disease modifying anti-
rheumatic drug and its metabolite A771726 are known BCRP substrates (Kim et al., 
2010; Kis et al., 2009). In the clinic these agents could lead to liver damage when 
administered with other commonly prescribed BCRP substrates and inhibitors such as 
nitrofurantoin, methotrexate, proton pump inhibitors (pantoprazole) and statins 
(pravastatin). Having a detailed understanding of what compounds are substrates and 
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inhibitors of the main efflux transporters such as MDR1 and BCRP in vitro may 
circumvent such interactions in the clinic.  
 Alternatively some agents can increase BCRP expression and function as 
shown in this study and previous studies (Ebert et al., 2007; Szatmari et al., 2006; Tan 
et al., 2010). For MDR1 it is known that pre-exposure of Caco-2 cells with rifampicin 
can lead to an up-regulation of MDR1 expression and function. Rifampicin in the 
clinical setting could potentially have grave consequences when it is administered 
over time alongside a drug with a narrow therapeutic index such as digoxin. Where 
both impaired absorption or elimination of digoxin could lead to failure of therapy or 
toxicity respectively (Greiner et al., 1999). In a similar manner to MDR1 induction by 
rifampicin, BCRP induction by agents such as dietary flavonoids could lead to failure 
in the absorption of substrates such as methotrexate given orally. The large inter-
individual variability in oral absorption of methotrexate (Balis et al., 1983) may in 
part result from variable BCRP expression. Understanding which agents can cause 
induction of BCRP/MDR1 even in vitro could be used as a flag that such induction is 
occurring in the clinic and maybe a useful screen in the development of new chemical 
entities to prevent drug-drug interactions. 
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Appendix 
 
Appendix table 1. Table showing bi-directional flux of potential BCRP substrates 
in native MDCKII cells 
 
Summary table of bi-directional flux in the apical to basal direction, basal to apical 
direction, net secretion (Jnet = Jb-a - Ja-b), efflux ratio (Jb-a / Ja-b) and permeability 
coefficient (LogP) of potential BCRP substrates across native MDCKII cell 
monolayers. Cells were grown to confluency on 96-well permeable Transwell 
supports and assays were conducted via automation on a Hamilton StarPlus Robot. 
Compounds were used at a concentration of 10µM. Data points are means of n = 4-6 
wells, data were pooled and normalised from 2 independent experiments ± SEM. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Bidirectional Flux 
(pmol.cm-2.hr-1)
Compound Ja-b Jb-a Jnet Efflux Ratio logP
Cimetidine 13.1 ± 0.7 141.9 ± 21.6 128.8 ± 21.3 10.8 ± 1.4 0.4
Clozapine 74.9 ± 7.1 251.3 ± 29.4 176.3 ± 29.5 3.4 ± 0.5 3.2
Diclofenac 332.3 ± 197.2 464 ± 276.4 131.7 ± 137.7 1.4 ± 0.3 4.5
Flavopiridol 296.6 ± 10.1 1168.7 ± 58.6 872.1 ± 50.2 3.9 ± 0.1 3.3
Gefitinib 1.4 ± 0.9 83 ± 30.1 81.6 ± 29.4 59.3 ± 11.9 4.9
Nitrofurantoin 172.6 ± 35.4 91.3 ± 15 -81.3 ± 25.4 0.5 ± 0.1 0.5
Novobiocin 17.4 ± 5.4 206.1 ± 26.8 188.8 ± 24.7 11.9 ± 3.9 2.5
Prazosin 242 ± 22.7 1281.6 ± 112 1039.5 ± 92.1 5.3 ± 0.2 1.3
Progesterone 390 ± 10.6 845.4 ± 29.7 455.4 ± 21.5 2.2 ± 0.1 3.9
Quinidine 112.2 ± 9.3 1961.2 ± 24.9 1849 ± 25.2 17.5 ± 1.4 3.4
Risperidone 307.7 ± 18.4 964.2 ± 32.7 656.4 ± 19.3 3.1 ± 0.1 3.5
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Appendix table 2. Table showing bi-directional flux of potential BCRP substrates 
in hBCRP-MDCKII cells 
 
Summary table of bi-directional flux in the apical to basal direction, basal to apical 
direction, net secretion (Jnet = Jb-a - Ja-b), efflux ratio (Jb-a / Ja-b) and permeability 
coefficient (LogP) of potential BCRP substrates across human BCRP transfected 
MDCKII cell monolayers. Cells were grown to confluency on 96-well permeable 
Transwell supports and assays were conducted via automation on a Hamilton StarPlus 
Robot. Compounds were used at a concentration of 10µM. Data points are means of n 
= 4-6 wells, data were pooled and normalised from 2 independent experiments ± 
SEM. 
 
Bidirectional Flux 
(pmol.cm-2.hr-1)
Compound Ja-b Jb-a Jnet Efflux Ratio logP
Cimetidine 72.1 ± 29 242.9 ± 141 187.4 ± 48.1 3.4 ± 1 0.4
Clozapine 103.8 ± 34.3 341.7 ± 88.5 237.9 ± 51 3.3 ± 0.5 3.2
Diclofenac 411.4 ± 35.4 1090.2 ± 64.4 678.8 ± 57 2.6 ± 0.2 4.5
Flavopiridol 165.7 ± 43.2 2134.9 ± 357.4 1969.2 ± 315.1 12.9 ± 1.1 3.3
Gefitinib 7.3 ± 5.3 273.1 ± 49.6 265.8 ± 45 37.6 ± 15.9 4.9
Nitrofurantoin 1.2 ± 0.2 270.9 ± 31 269.7 ± 31 217.3 ± 30.1 0.5
Novobiocin 10.9 ± 0.7 247 ± 18.5 236.1 ± 18 22.6 ± 3.4 2.5
Prazosin 110.1 ± 17.1 1763.8 ± 190.8 1653.7 ± 117 16 ± 2.6 1.3
Progesterone 333.2 ± 48.8 802 ± 94.3 468.9 ± 131.1 2.4 ± 0.5 3.9
Quinidine 68.9 ± 13.7 2492 ± 643.8 2423.1 ± 640 36.2 ± 8.8 3.4
Risperidone 282.4 ± 19.3 1392.9 ± 211 1110.6 ± 218.1 4.9 ± 0.9 3.5
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Appendix table 3. Tables showing bi-directional flux of potential BCRP 
substrates in mBcrp1-MDCKII cells 
 
Summary table of bi-directional flux in the apical to basal direction, basal to apical 
direction, net secretion (Jnet = Jb-a - Ja-b), efflux ratio (Jb-a / Ja-b) and permeability 
coefficient (LogP) of potential BCRP substrates across mouse Bcrp transfected 
MDCKII cell monolayers. Cells were grown to confluency on 96-well permeable 
Transwell supports and assays were conducted via automation on a Hamilton StarPlus 
Robot. Compounds were used at a concentration of 10µM. Data points are means of n 
= 4-6 wells, data were pooled and normalised from 2 independent experiments ± 
SEM. 
 
Bidirectional Flux 
(pmol.cm-2.hr-1)
Compound Ja-b Jb-a Jnet Efflux Ratio logP
Cimetidine 1.4 ± 0.5 222.1 ± 48.1 220.8 ± 93.1 161.1 ± 25.1 0.4
Clozapine 60 ± 6.8 286.7 ± 20.4 226.7 ± 14.1 4.8 ± 0.5 3.2
Diclofenac 356.6 ± 23 1021.7 ± 27.5 665.1 ± 37.2 2.9 ± 0.2 4.5
Flavopiridol 0.5 ± 0.1 1625.7 ± 87.7 1625.2 ± 87.7 3078.2 ± 203.9 3.3
Gefitinib 6.4 ± 3.9 1202.8 ± 622.5 1196.4 ± 418.6 187.5 ± 16.3 4.9
Nitrofurantoin 1.5 ± 0.1 234.4 ± 93.7 232.9 ± 93.7 156.4 ± 21.1 0.5
Novobiocin 0.6 ± 0.1 163.3 ± 23 162.7 ± 23.1 258.2 ± 30.8 2.5
Prazosin 1.8 ± 0.5 1428.4 ± 49.7 1426.5 ± 50.2 792.2 ± 64.2 1.3
Progesterone 52.4 ± 8.6 189.7 ± 56.8 137.3 ± 52.6 3.6 ± 0.5 3.9
Quinidine 1440 ± 115.4 3830 ± 306 2390 ± 421.4 2.6 ± 0.2 3.4
Risperidone 247.7 ± 28.2 654.8 ± 53.6 407.1 ± 75.5 2.6 ± 0.2 3.5
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Appendix table 4. Tables showing bi-directional flux of potential BCRP 
substrates in MDR1-MDCKII cells 
 
Summary table of bi-directional flux in the apical to basal direction, basal to apical 
direction, net secretion (Jnet = Jb-a - Ja-b), efflux ratio (Jb-a / Ja-b) and permeability 
coefficient (LogP) of potential BCRP substrates across human MDR1 transfected 
MDCKII cell monolayers. Cells were grown to confluency on 96-well permeable 
Transwell supports and assays were conducted via automation on a Hamilton StarPlus 
Robot. Compounds were used at a concentration of 10µM. Data points are means of n 
= 4-6 wells, data were pooled and normalised from 2 independent experiments ± 
SEM. 
 
 
 
 
 
 
 
 
 
Bidirectional Flux 
(pmol.cm-2.hr-1)
Compound Ja-b Jb-a Jnet Efflux Ratio logP
Cimetidine 62.3 ± 7.9 204 ± 49.4 141.1 ± 71.7 3.3 ± 0.4 0.4
Clozapine 225.2 ± 5.7 546.8 ± 28.8 321.5 ± 26.4 2.4 ± 0.1 3.2
Diclofenac 809 ± 80.4 1434.5 ± 193.2 625.6 ± 133.7 1.8 ± 0.2 4.5
Flavopiridol 408.2 ± 48.1 1468.3 ± 148.9 1060.1 ± 145.3 3.6 ± 0.5 3.3
Gefitinib 22.2 ± 10 290.8 ± 18.1 268.6 ± 17.5 13.1 ± 7 4.9
Nitrofurantoin 162.6 ± 12.8 61.3 ± 2.89 -101.3 ± 2.98 0.38 ± 0.1 0.5
Novobiocin 28.5 ± 6 98.5 ± 3.5 69.9 ± 8.3 3.4 ± 0.8 2.5
Prazosin 291.4 ± 8.8 1830 ± 37.3 1538.6 ± 30.9 6.3 ± 0.1 1.3
Progesterone 243.3 ± 28.5 788.5 ± 38.7 545.2 ± 45.3 3.2 ± 0.3 3.9
Quinidine 99.3 ± 4.7 2164.1 ± 34.8 2064.9 ± 38.9 21.8 ± 1.2 3.4
Risperidone 524 ± 68.6 1430.2 ± 91.1 906.1 ± 27.7 2.7 ± 0.2 3.5
